Combination therapy of anti-CD19 agents and B-cell targeted agents for treating B-cell malignancies
Patent Information
- Application Number
- JP2023526881
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-02-09
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-11-04
AI Technical Summary
Current treatments for B-cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are limited by the severity of cytokine release syndrome (CRS) associated with anti-CD19 agents and the need for more effective therapeutic options, especially for relapsed and refractory cases.
Combining anti-CD19 agents with B cell targeting agents, such as B cell depleting agents, to alleviate CRS and enhance therapeutic efficacy by depleting normal B cells before administering anti-CD19 agents.
This combination therapy reduces the severity of CRS and improves treatment outcomes for B-cell malignancies, including relapsed and refractory cases, by targeting both malignant and normal B cells effectively.
Smart Images

Figure 00000072_0000 
Figure 00000075_0000 
Figure 00000127_0000
Abstract
Description
Technical field
[0001] 1. Cross-reference of related applications This application is based on U.S. Provisional Patent Application No. 63 / 110,501 filed on November 6, 2020, U.S. Provisional Patent Application No. 63 / 114,370 filed on November 16, 2020, 2020 U.S. Provisional Patent Application No. 63 / 114,371 filed on November 16, U.S. Provisional Patent Application No. 63 / 147,488 filed on February 9, 2021, filed on February 9, 2021 It claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 147,501, filed on November 6, 2020, and U.S. Provisional Patent Application No. 63 / 110,490, filed on November 6, 2020. The contents of each of the patent applications are incorporated herein by reference in their entirety.
[0002] 2.Sequence list This application contains a sequence listing submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy was created on November 4, 2021, is named NOV-013WO_SL.txt, and is 704,029 bytes in size.
[0003] The present disclosure generally relates to combinations of anti-CD19 agents and B cell targeting agents and their use to treat B cell malignancies. [Background technology]
[0004] B cells express a wide range of cell surface molecules during their differentiation and proliferation. CD19 is a pan-B cell membrane glycoprotein expressed from early stages of pre-B cell development to terminal differentiation, and regulates B lymphocyte development and function. Expression of CD19 has been identified in the majority of non-Hodgkin's lymphomas (NHL) and leukemias, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and Waldenström's macroglobulinemia (WM). has been done.
[0005] For the treatment of B-cell malignancies, several anti-CD19 agents are available, such as blinatumomab, a CD19-CD3 bispecific T-cell engager approved for the treatment of ALL (marketed as BLINCYTO® by Amgen). ), tisagenlecleucel (marketed as KYMRIAH® by Novartis), a chimeric antigen receptor (CAR) T cell composition approved for the treatment of ALL, and diffuse large cell B axicabtagene ciloleucel (marketed as YESCARTA® by Gilead), a CAR T cell composition approved for cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). An approved CAR T cell composition, brexcabutagene autoleucel (marketed by Gilead as TECARTUS®), has been approved. However, some patients treated with blinatumomab and CD19-specific CAR T therapy develop cytokine release syndrome (CRS). Teachey et al.,2013,Blood,121(26):5154-5157;Park et al.,2018,Clin Infect Dis.2018 Aug 15;67(4):533-540. CRS is a systemic inflammatory response that can result in symptoms ranging from mild influenza-like symptoms to severe, life-threatening inflammatory responses. Shimabukuro-Vornhagen et al.,2018,J Immunother Cancer.6:56.
[0006] Despite major improvements in cancer therapy, B-cell malignancies such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia remain major contributors to cancer-related deaths. Therefore, there remains a need for additional therapeutic agents and methods for the treatment of B-cell malignancies and the management of CRS associated with anti-CD19 agents. [Summary of the invention]
[0007] The present disclosure provides combinations of anti-CD19 agents and B cell targeting agents and methods of using such combinations to treat B cell malignancies. Without wishing to be bound by theory, it is believed that CRS associated with anti-CD19 agents can be alleviated by depleting normal B cells with B cell targeting agents. Without wishing to be bound by theory, it is also believed that the therapeutic efficacy of anti-CD19 agents may be enhanced when administered in combination with B cell targeting agents.
[0008] Accordingly, in one aspect, the present disclosure provides a method of treating a subject with a B cell malignancy by administering to the subject an anti-CD19 agent and a B cell targeting agent. In some embodiments, the B cell targeting agent is administered prior to administration of the anti-CD19 agent. Without wishing to be bound by theory, it is believed that cytokine release by normal B cells is an important driver in CRS, and normal B cells in a subject are treated with B cell targeting agents prior to administration of anti-CD19 agents to the subject. It is believed that depletion of CRS may reduce the severity of CRS experienced by a subject.
[0009] In another aspect, the disclosure provides a combination of an anti-CD19 agent and a B cell targeting agent. Such combinations can be used, for example, in methods of treating a subject with a B-cell malignancy (eg, NHL, such as DLBCL or MCL). In some embodiments, the subject has NHL, e.g., DLBCL or MCL, and has received (i) at least one prior (and optionally up to five prior) standard treatments, such as rituximab. have failed anti-CD20 therapy, and / or (ii) are intolerant or ineligible for one or more other approved therapies, such as autologous stem cell transplantation (ASCT), and / or (iii) Non-responder to chimeric antigen receptor (CAR) T cell therapy. NHL can be relapsed and / or refractory.
[0010] In a further aspect, the present disclosure provides anti-CD19 for use in combination with a B-cell targeting agent, e.g., for use in the treatment of a subject with a B-cell malignancy (e.g., NHL, such as DLBCL or MCL). B cell targeting agents for use in combination with anti-CD19 agents and anti-CD19 agents are provided. In some embodiments, the subject has NHL, e.g., DLBCL or MCL, and has received (i) at least one prior (and optionally up to five prior) standard treatments, such as rituximab. have failed anti-CD20 therapy, and / or (ii) are intolerant or ineligible for one or more other approved therapies, such as autologous stem cell transplantation (ASCT), and / or (iii) Non-responder to chimeric antigen receptor (CAR) T cell therapy. NHL can be relapsed and / or refractory.
[0011] Anti-CD19 agents used in the methods and combinations of the present disclosure can be CD19-binding molecules that specifically bind human CD19, such as antibodies that specifically bind human CD19, antigen-binding fragments thereof, and multispecific molecules. . Alternatively, the anti-CD19 agent can be a population of cells that express chimeric antigen receptor ("CAR") molecules that bind CD19.
[0012] In some embodiments, the CD19 binding molecule is a monospecific CD19 binding molecule (eg, an antibody and antigen binding fragment thereof) that includes a CD19 antigen binding domain or antigen binding module (“ABM”). Exemplary CD19 binding molecules that can be monospecific are described in Section 7.2 and Specific Embodiments 2-39 below.
[0013] In other embodiments, the CD19 binding molecule is a multispecific binding molecule (“MBM”) that includes a CD19 ABM. In certain embodiments, the MBM is a bispecific binding molecule (“BBM”). The BBM includes a first ABM that specifically binds human CD19 (“ABM1” or “CD19 ABM”) and a second antigen, such as human CD3 or other components of the T-cell receptor (TCR) complex. A specifically binding second ABM (“ABM2”) (sometimes referred to herein as a “TCR ABM”). The terms ABM1, ABM2, CD19 ABM and TCR ABM are used for convenience only and are not intended to convey any particular configuration of the BBM. In some embodiments, the TCR ABM binds CD3 (referred to herein as "CD3 ABM" or the like). Therefore, the disclosures regarding ABM2 and TCR ABM are also applicable to CD3 ABM. Such multispecific molecules can be used to direct CD3+ effector T cells to CD19+ sites, thereby allowing them to attack and lyse CD19+ cells and tumors.
[0014] In other embodiments, the MBM associates CD19, CD3 or other components of the TCR complex on the T cell and either CD2 or a human tumor-associated antigen (“TAA”), e.g., a B cell antigen other than CD19. It is a trispecific binding molecule (“TBM”) that allows TBM consists of at least three antigen-binding modules (i) capable of binding to (i) CD19 (ABM1), (ii) a component of the TCR complex (ABM2), and (iii) either CD2 or TAA (ABM3). "ABM"). TBMs that bind (1) human CD19, (2) CD3 or other components of the TCR complex, and (3) CD2 are conveniently referred to herein as "type 1 TBMs." TBMs that bind (1) human CD19, (2) CD3 or other components of the TCR complex, and (3) TAAs are conveniently referred to herein as "type 2 TBMs."
[0015] Without wishing to be bound by theory, the inventors believe that the combination of CD2 and TCR complex association in type 1 TBM may result in T cell-mediated tumor cell lysis (e.g., by TCR clustering). ) and a second costimulatory pathway that induces T cell proliferation and potentially overcomes anergy. Without wishing to be bound by theory, it is believed that in type 2 TBM, the association of TAA in addition to CD19 and TCR complex components results in a bispecific aggregate that targets only CD19 and TCR complex components. It is also conceivable that the clinical outcome of RTCC therapy for B-cell malignancies would be improved by targeting more cancerous B cells than with the use of B-cell malignancies.
[0016] Thus, in some embodiments, the CD19 binding molecules used in the methods and combinations of the present disclosure include (1) human CD19, (2) CD3 or other components of the TCR complex, and (3) CD2. It is a type 1 TBM that combines.
[0017] In other embodiments, the CD19 binding molecules used in the methods and combinations of the present disclosure include (1) human CD19, (2) CD3 or other components of the TCR complex, and (3) 2 It is a type TBM.
[0018] Unless explicitly stated otherwise or the context indicates otherwise, TBM in this disclosure applies to both Type 1 and Type 2 TBMs.
[0019] Exemplary MBM features are described in Section 7.2 below and in specific embodiments 40-605.
[0020] Additionally, exemplary CD19 binding molecules that can be used in the methods and combinations of the present disclosure are described in Section 7.2 and Specific Embodiments 614-626 below.
[0021] In some embodiments, the anti-CD19 agent used in the methods and combinations of the present disclosure is a population of cells that express a CAR molecule that binds CD19. Characteristics of exemplary CARs and populations of cells expressing CAR molecules are described in Section 7.3 below and in specific embodiments 627-700.
[0022] In some embodiments, the B cell targeting agent is a B cell activating factor receptor (BAFFR) binding molecule, a CD20 binding molecule, a CD22 binding molecule or a B cell activating factor (BAFF) binding molecule. Exemplary features of B cell targeting agents are described in Section 7.4 and specific embodiments 701-741 below.
[0023] Exemplary B cell malignancies and patient populations suitable for treatment using the methods and compositions described herein are described in Section 7.6 and Specific Embodiments 760-807 below.
[0024] The anti-CD19 agents described throughout can be administered to a subject as a combination therapy. For example, a combination can include an anti-CD19 agent and a B cell targeting agent. An anti-CD19 agent, in some embodiments, can be a CD19 binding molecule.
[0025] In some embodiments (e.g., when used in combination), the CD19 binding molecules include CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; It may include CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences of SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16. In other embodiments, the CD19 binding molecules include CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 and SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19. CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequence of. The CD19 binding molecules include CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, and CDR-H3 having the amino acid sequences of SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22. -L1, CDR-L2 and CDR-L3 may also be included. In certain embodiments, CD19 binding comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12 and SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 25. It may include CDR-L1, CDR-L2 and CDR-L3 having amino acid sequences.
[0026] The CD19 binding molecule can include a VH having the amino acid sequence of SEQ ID NO:13. A CD19 binding molecule may also include a VL having the amino acid sequence of SEQ ID NO:26. A CD19 binding molecule may also include both a VH having the amino acid sequence of SEQ ID NO: 13 and a VL having the amino acid sequence of SEQ ID NO: 26.
[0027] A CD19 binding molecule can also be a multispecific binding molecule (MBM). For example, a CD19-binding molecule may include (a) antigen binding module 1 (ABM1), which specifically binds CD19; and (b) a different target molecule (e.g., a component of the human T-cell receptor (TCR) complex (CD3); etc.)). The CD19 binding molecule can be a trispecific binding molecule (TBM) that includes antigen binding module 3 (ABM3) that specifically binds target molecules other than CD19. For example, if the CD19 binding molecule is TBM, in some instances ABM2 may specifically bind to a component of the human T cell receptor (TCR) complex, and ABM3 may specifically bind to human CD2. Can be combined.
[0028] A CD19 binding molecule can be trivalent in some embodiments. A CD19 binding molecule can be designed in one of several ways, for example, in any one of the configurations depicted in FIGS. 2A-2P. For example, a CD19 binding molecule can have a configuration as depicted in Figure 2I. CD19 binding molecules may also have the configuration referred to in Section 7.2.4.1 as T2.
[0029] The CD19 binding molecule may have ABM3 that specifically binds human CD2. In some embodiments, ABM3 is an ABM based on a non-immunoglobulin scaffold. In some embodiments, ABM3 may include a receptor binding domain for CD2 ligand. In some embodiments, ABM3 is a CD58 moiety. The CD58 portion used may include the amino acid sequence of CD58-6 set forth in Table 12.
[0030] A CD19 binding molecule may also include a unique Fc domain. For example, a CD19 binding molecule can include a first variant Fc region and a second variant Fc region forming an Fc domain. The first variant Fc region and the second variant Fc region can together form an Fc heterodimer. In some embodiments, the first variant Fc region and the second variant Fc region can include the amino acid substitution T366W:T366S / L368A / Y407V. In some embodiments, the Fc domain is an Fc heterodimer that includes a knob-in-hole (“KIH”) modification. In some embodiments, the Fc domain has altered effector function. In some embodiments, an Fc domain may have altered binding to one or more Fc receptors. Some mutations in the Fc domain can be silencing mutations. For example, one or more mutations may result in silent IgG1. In some embodiments, the mutation may include the D265A mutation. In other embodiments, mutations may include the D265A and P329A mutations. In some embodiments, the Fc domain of the CD19 binding molecule comprises (a) a first CH3 domain comprising a modified T366W; and (b) a second CH3 domain that forms a heterodimer with the first CH3 domain. and includes modifications T366S, L368A and Y407V. In some embodiments, the Fc domain of the CD19 binding molecule comprises an aspartate residue at position 265 with an alanine residue, an asparagine residue at position 297 with an alanine residue, and a proline residue at position 329 with an alanine residue. Contains a human IgG1 Fc domain modified by substituting groups (D265A / N297A / P329A).
[0031] In some particular embodiments, the CD19 binding molecules include (a) CDR-H1, CDR-H2, and Antigen binding module 1 (ABM1) comprising CDR-H3 and CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences of SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19; (TCR) antigen binding module 2 (ABM2) that specifically binds to a component of the complex; and (c) trispecific binding molecule (TBM) that includes antigen binding module 3 (ABM3) that specifically binds human CD2. It is. The CD19 binding molecule may be trivalent. ABM1 can be Fab. The CD19 binding molecule may also have an ABM1 comprising a VH having the amino acid sequence of SEQ ID NO: 13 and a VL having the amino acid sequence of SEQ ID NO: 26.
[0032] A CD19 binding molecule may have a component of a TCR complex that binds CD3. The CD19 binding molecule ABM2 can be an anti-CD3 antibody or its antigen binding domain. For example, ABM2 may contain CDR sequences of CD3hi. The heavy chain sequence of CD3hi can be as listed in Table 9A. In some embodiments, the anti-CD3 antibody or antigen binding domain thereof is in the form of a scFv. For example, ABM2 can include the amino acid sequence of the scFv designated as CD3hi in Table 9A. The CD19 binding molecule may include the CD58 moiety, ABM3. By way of example, the CD58 portion can be the amino acid sequence of CD58-6 set forth in Table 12. CD19 binding molecules used in combination and / or disclosed throughout may also include an Fc domain. A first variant Fc region and a second variant Fc region in an Fc domain can together form an Fc heterodimer.
[0033] In certain embodiments, the CD19 binding molecules include (a) CDR-H1, CDR-H2, and CDR-H3 that specifically bind CD19 and have the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; and antigen binding module 1 (ABM1), which is a Fab containing CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19; (b) specifically binds to CD3 and (c) the amino acid sequence of CD58-6 that specifically binds human CD2 and is set forth in Table 12. an antigen binding module 3 (ABM3) comprising; and (d) a trispecific binding molecule (TBM) comprising an Fc domain.
[0034] In certain embodiments, the CD19 binding molecules include (a) CDR-H1, CDR-H2, and CDR-H3 that specifically binds CD19 and have the amino acid sequences of SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32; and antigen binding module 1 (ABM1), which is a Fab containing CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45; (b) specifically binds to CD3 and (c) the amino acid sequence of CD58-6 that specifically binds human CD2 and is set forth in Table 12. an antigen binding module 3 (ABM3) comprising; and (d) a trispecific binding molecule (TBM) comprising an Fc domain.
[0035] In another specific embodiment, the CD19 binding molecule (a) specifically binds CD19, and (i) has a CDR-H1, CDR- Antigen binding module 1 (ABM1), a Fab comprising H2 and CDR-H3 and CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences of SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19; (b) CD3 (c) an antigen binding module 2 (ABM2) comprising the amino acid sequence of an scFv that specifically binds to human CD2 and is designated as CD3hi in Table 9A; (c) CD58 that specifically binds to human CD2 and is listed in Table 12; Antigen Binding Module 3 (ABM3) comprising an amino acid sequence of -6; and (d) a trispecific binding molecule (TBM) comprising an Fc domain. ABM1, a CD19 binding molecule, has CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and the amino acid sequences of SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19. CDR-L1, CDR-L2 and CDR-L3. In some embodiments, ABM1 may include a VH having the amino acid sequence of SEQ ID NO: 13 and a VL having the amino acid sequence of SEQ ID NO: 26.
[0036] In another specific embodiment, the CD19 binding molecule is (a) antigen binding module 1 (ABM1) that specifically binds CD19; (b) antigen binding module 2 that specifically binds CD3 and comprises an scFv. (ABM2); (c) a first half antibody comprising an Fc region; and an antigen binding module 3 (ABM3) that specifically binds human CD2 and comprising a CD58 IgV domain; and (d) a second half antibody comprising an Fc region. The Fc region in the first half antibody and the Fc region in the second half antibody form an Fc heterodimer. The CD19 binding molecule comprises a first half antibody comprising a heavy chain comprising an amino acid sequence of SEQ ID NO: 63; and a light chain comprising an amino acid sequence of SEQ ID NO: 64; and a second half antibody comprising an amino acid sequence of SEQ ID NO: 65. may be included. The CD19 binding molecules used in combination and / or disclosed throughout include a heavy chain comprising the amino acid sequence of SEQ ID NO: 74; and a first half antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 64; A second half-antibody comprising the amino acid sequence of No. 75 or SEQ ID No. 86 may be included. In some embodiments, the CD19 binding molecules used in combination and / or disclosed throughout include a heavy chain comprising the amino acid sequence of SEQ ID NO: 74; and a light chain comprising the amino acid sequence of SEQ ID NO: 64. one half-antibody; as well as a second half-antibody comprising the amino acid sequence of SEQ ID NO:86.
[0037] In one embodiment, the CD19 binding molecule is (a) a first half-antibody heavy chain, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 63 and an Fc sequence; b) a first half-antibody light chain, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 64; (c) a second half-antibody light chain, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 64; comprises a second half-antibody comprising the amino acid sequence of SEQ ID NO: 65 and an Fc sequence.
[0038] In another embodiment, the CD19 binding molecule is (a) a first polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 74; (b) a second polypeptide; a second polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 64; and (c) a third polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 75 or SEQ ID NO: 86. a third polypeptide comprising the amino acid sequence of
[0039] In some embodiments, the CD19 binding molecule is (a) a first polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 74; (b) a second polypeptide; (c) a second polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 64; and (c) a third polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 86. A third polypeptide may be included.
[0040] As described throughout, the combination may include an anti-CD19 agent and a B cell targeting agent. In some embodiments, the B cell targeting agent is a B cell depleting agent. In some embodiments, the B cell targeting agent is a BAFF receptor (BAFFR) binding molecule. For example, a BAFFR binding molecule is an antibody or an antigen binding domain thereof. In this embodiment, the BAFFR binding molecules include CDR-H1, CDR-H2, CDR-H3 having the amino acid sequence of ianalumab set forth in Table 18 and CDR-L1 having the amino acid sequence of ianalumab set forth in Table 18, May include CDR-L2 and CDR-L3. The BAFFR binding molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the VH and VL sequences of ianalumab as set forth in Table 18. (VL). In a specific example, the BAFFR binding molecule is ianalumab.
[0041] The anti-CD19 agent and B cell targeting agent can be separate molecules. In some embodiments, an anti-CD19 agent and a B cell targeting agent may be formulated in separate pharmaceutical compositions.
[0042] Also provided herein are combinations comprising an anti-CD19 agent described herein and a B cell targeting agent described herein for use in the treatment of a subject having a B cell malignancy. The combinations described throughout can be used in methods for treating subjects with B cell malignancies. The method can include administering an anti-CD19 agent and a B cell targeting agent as described throughout. With respect to timing of administration, the B cell targeting agent can be administered to the subject one or more times prior to the first administration of the anti-CD19 agent to the subject. The method of administration can also include administering the anti-CD19 agent and the B cell targeting agent simultaneously. In some embodiments, the B cell malignancy is diffuse large B cell lymphoma (DLBCL). For example, the B-cell malignancy can be relapsed and / or refractory diffuse large B-cell lymphoma (DLBCL). In some embodiments, the B cell malignancy can be acute lymphoblastic leukemia (ALL). For example, the B cell malignancy can be relapsed and / or refractory ALL. The combination of anti-CD19 agent and B cell targeting agent may further include a therapeutic agent as described herein. [Brief explanation of drawings]
[0043] [Figure 1A] Exemplary BBM morphology. 1A-1AH illustrate components of the exemplary BBM configuration shown in FIGS. 1B-1AH. Not all regions connecting the different domains of each chain are shown (e.g., the linker connecting the VH and VL domains of the scFv, the hinge connecting the CH2 and CH3 domains of the Fc domain, etc. are omitted). ). 1B to 1F show divalent BBM; FIGS. 1G to 1Z show trivalent BBM; and FIGS. 1AA to 1AH show quadrivalent BBM. [Figure 1B] (As mentioned above.) [Figure 1C] (As mentioned above.) [Figure 1D] (As mentioned above.) [Figure 1E](As mentioned above.) [Figure 1F] (As mentioned above.) [Figure 1G] (As mentioned above.) [Figure 1H] (As mentioned above.) [Figure 1I] (As mentioned above.) [Figure 1J] (As mentioned above.) [Figure 1K] (As mentioned above.) [Figure 1L] (As mentioned above.) [Figure 1M] (As mentioned above.) [Figure 1N] (As mentioned above.) [Figure 1O] (As mentioned above.) [Figure 1P] (As mentioned above.) [Figure 1Q] (As mentioned above.) [Figure 1R] (As mentioned above.) [Figure 1S] (As mentioned above.) [Figure 1T] (As mentioned above.) [Figure 1U] (As mentioned above.) [Figure 1V] (As mentioned above.) [Figure 1W] (As mentioned above.) [Figure 1X] (As mentioned above.) [Figure 1Y] (As mentioned above.) [Figure 1Z] (As mentioned above.) [Figure 1AA] (As mentioned above.) [Figure 1AB] (As mentioned above.) [Figure 1AC] (As mentioned above.) [Figure 1AD] (As mentioned above.) [Figure 1AE] (As mentioned above.) [Figure 1AF] (As mentioned above.) [Figure 1AG] (As mentioned above.) [Figure 1AH] (As mentioned above.) [Figure 2A] Exemplary TBM morphology. FIG. 2A shows components of the exemplary TBM configuration shown in FIGS. 2B-2V. Not all regions connecting the different domains of each chain are shown (e.g., linkers connecting the VH and VL domains of scFv, hinges connecting CH2 and CH3 domains of Fc, etc. are omitted) . 2B to 2P show trivalent TBM; FIGS. 2Q to 2S show quadrivalent TBM; FIG. 2T shows pentavalent TBM, and FIGS. 2U to 2V show hexavalent TBM. [Figure 2B] (As mentioned above.) [Figure 2C] (As mentioned above.) [Figure 2D] (As mentioned above.) [Figure 2E] (As mentioned above.) [Figure 2F] (As mentioned above.) [Figure 2G] (As mentioned above.) [Figure 2H] (As mentioned above.) [Figure 2I] (As mentioned above.) [Figure 2J] (As mentioned above.) [Figure 2K] (As mentioned above.) [Figure 2L] (As mentioned above.) [Figure 2M] (As mentioned above.) [Figure 2N] (As mentioned above.) [Figure 2O] (As mentioned above.) [Figure 2P] (As mentioned above.) [Figure 2Q] (As mentioned above.) [Figure 2R] (As mentioned above.) [Figure 2S] (As mentioned above.) [Figure 2T] (As mentioned above.) [Figure 2U] (As mentioned above.) [Figure 2V] (As mentioned above.) [Figure 3A] Schematic representation of the bispecific (FIG. 3A and FIG. 3C) and trispecific (FIG. 3B) constructs of Example 1. [Figure 3B] (As mentioned above.) [Figure 3C] (As mentioned above.) [Figure 4A] Ability of CD19 BBM to induce redirected T cytotoxicity (RTCC) against CD19+ target cells. Both NEG258-based BBM and NEG218-based BBM mediated RTCC activity against CD19+ target cell lines. Nalm6-luc (Figure 4A) and Karpas422-luc (Figure 4B) cells were co-cultured with expanded T cells at a 3:1 effector:target cell (E:T) ratio in the presence of serially diluted BBM. did. After 24 hours of incubation, the luminescent signal was measured. [Figure 4B] (As mentioned above.) [Figure 5A] Ability of CD19 BBM to induce T cell proliferation. Both NEG258-based BBM and NEG218-based BBM induced T cell proliferation. Karpas422-luc (Figure 5A) and Nalm6-luc (Figure 5B) cells were co-cultured with expanded T cells at a 1:1 E:T ratio in the presence of serially diluted BBM. After 96 hours of incubation, the luminescent signal was measured. [Figure 5B] (As mentioned above.) [Figure 6A] Ability of CD19 TBM to induce CD2-dependent T cell activation. Knockout of CD2 attenuated the advantage of the trispecific construct. Figures 6A-6B show representative flow cytometry analysis of CD2 expression on JNL CD2 WT (Figure 6A) and KO (Figure 6B) cells. Staining with anti-CD2 mAb (histogram shaded with dots) is overlaid with staining with mIgG1 isotype control (histogram shaded with diagonal lines) or unstained (histogram with open spaces). Figures 6C-6F show JNL CD2+ (Figures 6C-6D) and CD2- (Figures 6E-6D) co-cultured with CD19+ target cells at a 3:1 E:T ratio in the presence of serially diluted BBM and TBM. 6F) Shows cell data. After 24 hours of incubation, the luminescent signal was measured. [Figure 6B] (As mentioned above.) [Figure 6C] (As mentioned above.) [Figure 6D] (As mentioned above.) [Figure 6E] (As mentioned above.) [Figure 6F] (As mentioned above.) [Figure 7A] Binding of CD19 TBM to cyno B cells. Figure 7A shows data for TBMs with NEG218-based CD19 binding arms and Figure 7B shows data for TBMs with NEG258-based CD19 binding arms. [Figure 7B] (As mentioned above.) [Figure 8A] Ability of CD19 TBM to induce T cell activation upon cyno B cell depletion in PBMCs. In Figure 8A, PBMCs were isolated from cynomolgus monkey whole blood using Ficoll density gradient centrifugation and incubated with bi- or trispecific constructs overnight. Samples were collected and stained simultaneously for CD3 and CD20 to identify B and T cells in the PBMC population. B cell depletion rates were calculated as described in Section 8.6.1. Figures 8B to 8H show the results of determining single positive cells (CD69+CD25- or CD69-CD25+) or double positive cells (CD69+CD25+) by FACS analysis of CD69 and CD25 expression on CD3+ T cells. Figure 8B: Untreated (medium only); Figures 8C to 8E: CD3hi TSP1L; Figures 8F to 8H: CD3hi TSP1. [Figure 8B] (As mentioned above.) [Figure 8C] (As mentioned above.) [Figure 8D] (As mentioned above.) [Figure 8E] (As mentioned above.) [Figure 8F] (As mentioned above.) [Figure 8G] (As mentioned above.) [Figure 8H] (As mentioned above.) [Figure 9A] Ability of NEG258-based and NEG218-based TBM to induce redirected T cytotoxicity by human donor cells against Nalm6 (FIGS. 9A-9H) and Karpas422 (FIGS. 9I-9P) target cells. [Figure 9B] (As mentioned above.) [Figure 9C] (As mentioned above.) [Figure 9D] (As mentioned above.) [Figure 9E] (As mentioned above.) [Figure 9F] (As mentioned above.) [Figure 9G] (As mentioned above.) [Figure 9H] (As mentioned above.) [Figure 9I] (As mentioned above.) [Figure 9J] (As mentioned above.) [Figure 9K] (As mentioned above.) [Figure 9L] (As mentioned above.) [Figure 9M] (As mentioned above.) [Figure 9N] (As mentioned above.) [Figure 9O] (As mentioned above.) [Figure 9P] (As mentioned above.) [Figure 10A] Ability of NEG258- and NEG218-based TBMs with different CD3 affinities to induce redirected T cytotoxicity by human donor cells against Nalm6 (FIGS. 10A-10H) and Karpas422 (FIGS. 10I-10P) target cells. [Figure 10B] (As mentioned above.) [Figure 10C] (As mentioned above.) [Figure 10D] (As mentioned above.) [Figure 10E] (As mentioned above.) [Figure 10F] (As mentioned above.) [Figure 10G] (As mentioned above.) [Figure 10H] (As mentioned above.) [Figure 10I] (As mentioned above.) [Figure 10J] (As mentioned above.) [Figure 10K] (As mentioned above.) [Figure 10L] (As mentioned above.) [Figure 10M] (As mentioned above.) [Figure 10N] (As mentioned above.) [Figure 10O] (As mentioned above.) [Figure 10P] (As mentioned above.) [Figure 11A] Ability of NEG258-based TBMs with CD2-binding arms and those with control lysozyme-binding arms to induce redirected T cytotoxicity by human donor cells against Nalm6 (Figures 11A-11H) and Karpas422 (Figures 11I-11L) target cells. . [Figure 11B] (As mentioned above.) [Figure 11C] (As mentioned above.) [Figure 11D] (As mentioned above.) [Figure 11E] (As mentioned above.) [Figure 11F] (As mentioned above.) [Figure 11G] (As mentioned above.) [Figure 11H] (As mentioned above.) [Figure 11I] (As mentioned above.) [Figure 11J] (As mentioned above.) [Figure 11K] (As mentioned above.) [Figure 11L] (As mentioned above.) [Figure 12A] Induction of T cell cytokine release by NEG258-based and NEG218-based TBM. Figure 12A: IFN-γ; Figure 12B: TNF-α; Figure 12C: IL2. [Figure 12B] (As mentioned above.) [Figure 12C] (As mentioned above.) [Figure 13A] Binding of NEG258- and NEG218-based TBMs to mouse 300.19 cell lines overexpressing human CD19 (Figure 13A) or cyno CD19 (Figure 13B). TBM shows only negligible binding to the wild type 300.19 cell line (Figure 13C). [Figure 13B] (As mentioned above.) [Figure 13C] (As mentioned above.) [Figure 14] Schematic representation of CD58. [Figure 15] Redirected T cytotoxicity by TBM containing CD58 mutant sequences. [Figure 16] Antigen-independent T cell activation by TBM containing CD58 variant sequences. Data are expressed as relative luminescence units (RLU). [Figure 17A] CD19 and CD58 expression in various cell lines: Figures 17A-17B: CD19 and CD58 expression, respectively, in OCI-LY-19 cells; Figures 17C-17D: CD19 and CD58 expression, respectively, in Karpas-422 cells; Figure 17E ~Figure 17F: CD19 and CD58 expression, respectively, on Toledo cells; Figure 17G~Figure 17H: CD19 and CD58 expression, respectively, on Nalm-6 cells. [Figure 17B] (As mentioned above.) [Figure 17C] (As mentioned above.) [Figure 17D] (As mentioned above.) [Figure 17E] (As mentioned above.) [Figure 17F] (As mentioned above.) [Figure 17G] (As mentioned above.) [Figure 17H] (As mentioned above.) [Figure 18A] Ability of NEG258-based TBM and BBM to induce redirected T cytotoxicity by human donor cells against Karpas422 target cells. Figures 18A and 18B show data using T cells from two different donors. [Figure 18B] (As mentioned above.) [Figure 19A] Induction of T cell cytokine release by NEG258-based TBM and BBM. Figures 19A to 19B: IFN-γ (donor 1 and donor 2, respectively); Figures 19C to 19D: IL-2 (donor 1 and donor 2, respectively); Figures 19E to 19F: TNF-α (donor 1 and donor 2, respectively); Donor 2). Triangles on the X-axis indicate decreasing concentrations of the construct from left to right of the figure. [Figure 19B] (As mentioned above.) [Figure 19C] (As mentioned above.) [Figure 19D] (As mentioned above.) [Figure 19E] (As mentioned above.) [Figure 19F] (As mentioned above.) [Figure 20] Binding of NEG258-based TBM and BBM to T cells. [Figure 21A] NEG258-based TBM and BBM-mediated T cell proliferation. Figure 21A: T cell proliferation under OC-LY-19 co-culture; Figure 21B: T cell proliferation under Karpas422 co-culture; Figure 21C: T cell proliferation under Toledo co-culture. [Figure 21B] (As mentioned above.) [Figure 21C] (As mentioned above.) [Figure 22A] Ability of NEG258-based TBM and BBM to induce redirected T cytotoxicity by human donor cells against Karpas422 target cells. Figures 22A and 22B show data using T cells from two different donors. [Figure 22B] (As mentioned above.) [Figure 23A] Ability of NEG258-based TBM and BBM to induce redirected T cytotoxicity by human donor cells against various target cells. Figure 23A~Figure 23B: OC-LY-19 (Donor 1 and Donor 2, respectively); Figure 23C~Figure 23D: Toledo (Donor 1 and Donor 2, respectively); Figure 23E~Figure 23F: Nalm6 (Donor 1 and Donor 2, respectively) ); Figures 23G to 23H: Nalm6 KO (donor 1 and donor 2, respectively); Figures 23I to 23J: K562 (donor 1 and donor 2, respectively). [Figure 23B] (As mentioned above.) [Figure 23C] (As mentioned above.) [Figure 23D] (As mentioned above.) [Figure 23E] (As mentioned above.) [Figure 23F] (As mentioned above.) [Figure 23G] (As mentioned above.) [Figure 23H] (As mentioned above.) [Figure 23I] (As mentioned above.) [Figure 23J] (As mentioned above.) [Figure 24A] Induction of T cell cytokine release by NEG258-based TBM and BBM in various target cells. Figures 24A~24B: TNF-α from OC-LY-19 (donor 1 and donor 2, respectively); Figures 24C~24D: TNF-α from Toledo (donor 1 and donor 2, respectively); Figure 24E~ 24F: TNF-α from Nalm6 (donor 1 and donor 2, respectively); Figures 24G to 24H: TNF-α from Nalm6 KO (donor 1 and donor 2, respectively); Figures 24I to 24J: TNF- from K562 α (Donor 1 and Donor 2, respectively). [Figure 24B] (As mentioned above.) [Figure 24C] (As mentioned above.) [Figure 24D] (As mentioned above.) [Figure 24E] (As mentioned above.) [Figure 24F] (As mentioned above.) [Figure 24G] (As mentioned above.) [Figure 24H] (As mentioned above.) [Figure 24I] (As mentioned above.) [Figure 24J] (As mentioned above.) [Figure 25A]Rechallenge RTCC assay with Karpas 422 and OCI-LY-19 cell lines. Figure 25A: Assay setup. Figure 25B~Figure 25D: Karpas 422 (after the first challenge, after the second challenge, and after the third challenge, respectively);Figure 25E~Figure 25H: OCI-LY-19 (after the first challenge, after the second challenge, respectively) after the challenge, after the third challenge, and after the fourth challenge). [Figure 25B] (As mentioned above.) [Figure 25C] (As mentioned above.) [Figure 25D] (As mentioned above.) [Figure 25E] (As mentioned above.) [Figure 25F] (As mentioned above.) [Figure 25G] (As mentioned above.) [Figure 25H] (As mentioned above.) [Figure 26A] Rechallenge T cell phenotyping with Karpas 422 and OCI-LY-19 cell lines. Figures 26A to 26H: Karpas 422 phenotyping; Figures 26I to 26P: OCI-LY-19 phenotyping. Figures 26A and 26I: %IL-2+ CD4 T cells; Figures 26B and 26J: %IFNγ+ CD4 T cells; Figures 26C and 26K: %IL-2+ CD8 T cells; Figures 26D and 26L: % IFNγ+ CD8 T cells; Figures 26E and 26M: CD3 young; Figures 26F and 26N: CD4 old; Figures 26G and 26O: CD8 young; Figures 26H and 26P: CD8 old. Lines in the figure represent different T cell donors. [Figure 26B] (As mentioned above.) [Figure 26C] (As mentioned above.) [Figure 26D] (As mentioned above.) [Figure 26E] (As mentioned above.) [Figure 26F] (As mentioned above.) [Figure 26G] (As mentioned above.) [Figure 26H] (As mentioned above.) [Figure 26I] (As mentioned above.) [Figure 26J] (As mentioned above.) [Figure 26K] (As mentioned above.) [Figure 26L] (As mentioned above.) [Figure 26M] (As mentioned above.) [Figure 26N] (As mentioned above.) [Figure 26O] (As mentioned above.) [Figure 26P] (As mentioned above.) [Figure 27A] Ability of CD3hi TSP1 to induce T cell proliferation in the presence of CD19+ target cells compared to CD3hi BSP1. In the presence of 1 nM (Figures 27A-27B) or 0.1 nM (Figures 27C-27D) of CD3hi TSP1 or CD3hi BSP1 and in the presence of irradiated autologous PBMC (T cell depleted) (Figures 27A and 27C) or in the absence (FIGS. 27B and 27D), Nalm6-luc cells were sorted and co-cultured with CD28+ or CD28-CD8 T cells at an E:T ratio of 1:3 for 72 hours. Proliferation was measured as the percentage of CFSE-diluted cells among live cells. [Figure 27B] (As mentioned above.) [Figure 27C] (As mentioned above.) [Figure 27D] (As mentioned above.) [Figure 28A] Ability of CD3hi TSP1 and CD3hi BSP1 to induce T cell cytokine production in the presence of Nalm6 CD19+ target cells (E:T 1:3). Figures 28A-28B: CD28- and CD28+CD8 T cells producing GzB (Figure 28A) and IFN-γ (Figure 28B) when co-cultured with 1nM CD3hi TSP1 or 1nM CD3hi BSP1 in the presence of irradiated PBMCs. median fluorescence intensity (MFI). Figures 28C-28D: CD28- and CD28+CD8 T producing GzB (Figure 28C) and IFN-γ (Figure 28D) when co-cultured with 1nM CD3hi TSP1 or 1nM CD3hi BSP1 in the absence of irradiated PBMCs. MFI of cells. Figures 28E-28F: CD28- and CD28+CD8 producing GzB (Figure 28E) and IFN-γ (Figure 28F) when co-cultured with 0.1 nM CD3hi TSP1 or 0.1 nM CD3hi BSP1 in the presence of irradiated PBMCs. MFI of T cells. Figures 28G-28H: CD28- and CD28+ producing GzB (Figure 28G) and IFN-γ (Figure 28H) when co-cultured with 0.1 nM CD3hi TSP1 or 0.1 nM CD3hi BSP1 in the absence of irradiated PBMCs. MFI of CD8 T cells. Figures 28I-28L: CD3hi at 1 nM (Figures 28I and 28J) or 0.1 nM (Figures 28K and 28L) in the presence (Figures 28I and 28K) or absence (Figures 28J and 28L) of irradiated PBMCs. Proportion of viable T cells when co-cultured with TSP1 or CD3hi BSP1. [Figure 28B] (As mentioned above.) [Figure 28C] (As mentioned above.) [Figure 28D] (As mentioned above.) [Figure 28E] (As mentioned above.) [Figure 28F] (As mentioned above.) [Figure 28G] (As mentioned above.) [Figure 28H] (As mentioned above.) [Figure 28I] (As mentioned above.) [Figure 28J] (As mentioned above.) [Figure 28K] (As mentioned above.) [Figure 28L] (As mentioned above.) [Figure 29A] Ability of CD3hi TSP1 to induce changes in T cell phenotype compared to CD3hi BSP1. Figure 29A: Representative examples of CD28- and CD28+ T cells sorted for CCR7 and CD45RO expression. Figures 29B to 29I: In the presence (Figures 29B to 29E) or absence (Figures 29F to 29I) of PBMC and 1 nM (Figures 29B to 29C and Figures 29F to 29G) or 0.1 nM (Figures 29D to 29G). Combined expression of the two surface markers CD45RO and CCR7 (naive, CD45RO Distribution of different T cell populations defined based on -CCR7+; central memory (CM), CD45RO+CCR7+; effector memory (EM), CD45RO+CCR7-; and terminally differentiated type (TEMRA), CD45RO-CCR7-). Data for proliferating cells (CFSE-) are shown in Figures 29B, 29D, 29F and 29H. Data for non-proliferating cells (CSFE+) are shown in Figures 29C, 29E, 29G and 29I. Data for CD28- cells is shown on the left side of each figure, and data for CD28+ cells is shown on the right side of the figures. [Figure 29B] (As mentioned above.) [Figure 29C] (As mentioned above.) [Figure 29D] (As mentioned above.) [Figure 29E] (As mentioned above.) [Figure 29F] (As mentioned above.) [Figure 29G] (As mentioned above.) [Figure 29H] (As mentioned above.) [Figure 29I] (As mentioned above.) [Figure 30A] Ability of CD3hi TSP1 to induce redirected T cytotoxicity (RTCC) against CD19+ target cells compared to CD3hi BSP1. In the presence of 1 nM (Figures 30A and 30C) or 0.1 nM (Figures 30B and 30D) of CD3hi BSP1, CD3hi TSP1 or CD3hi TSP1C and in the presence of irradiated autologous PBMC (T cell depleted) (Figures 30A and 30C). RTCC results from Nalm6-luc cells co-cultured with post-sorted CD28+ or CD28-CD8 T cells at an E:T ratio of 1:3 for 72 hours in the presence (Figure 30B) or absence (Figures 30C and 30D). (n=3) Luminescent signals were measured at the end of co-culture incubation. Results are expressed as fold increase over the untreated condition, where no antibody was added to assess the background signal provided by the control antibody. [Figure 30B] (As mentioned above.) [Figure 30C] (As mentioned above.) [Figure 30D] (As mentioned above.) [Figure 31A] Antitumor activity of CD3hi TSP1 (Figure 31A) and CD3med TSP1 (Figure 31B) in human PBMC adoptive transfer adaptation of OCI-LY-19 subcutaneous tumor model. [Figure 31B] (As mentioned above.) [Figure 32A] Weight change after treatment with CD3hi TSP1 (Figure 32A) and CD3med TSP1 (Figure 32B) in human PBMC adoptive transfer adaptation of OCI-LY-19 subcutaneous tumor model. [Figure 32B] (As mentioned above.) [Figure 33] Schematic diagram of the humanization process of NSG mice. [Figure 34A]Antitumor activity of CD3 TSP1, CD3hi BSP1 and CD3med TSP1 in the DLBCL subcutaneous tumor model of huCD34+ NSG mice (Figure 34A) and body weight change after treatment with CD3 TSP1, CD3hi BSP1 and CD3med TSP1 in the DLBCL subcutaneous tumor model of huCD34+ NSG mice (Figure 34A). Figure 34B). [Figure 34B] (As mentioned above.) [Figure 35A] Antitumor activity (Figures 35A and 35C) and body weight after antibody treatment with CD3hi TSP1 (Figures 35A and 35B) and CD3med TSP1 (Figures 35C and 35D) in OCI-LY-19 DLBCL subcutaneous tumor model of huCD34+ NSG mice Reaction (Figure 35B and Figure 35D). [Figure 35B] (As mentioned above.) [Figure 35C] (As mentioned above.) [Figure 35D] (As mentioned above.) [Figure 36A] Antitumor activity of CD3hi BSP1 (Figure 36A), CD3hi TSP1 (Figure 36B) and CD3med TSP1 (Figure 36C) in human PBMC adoptive transfer adaptation of Daudi-Luc subcutaneous tumor model. [Figure 36B] (As mentioned above.) [Figure 36C] (As mentioned above.) [Figure 37A] Weight changes after antibody treatment with CD3hi BSP1 (Figure 37A), CD3hi TSP1 (Figure 37B) or CD3med TSP1 (Figure 37C) in human PBMC adoptive transfer adaptation of Daudi-Luc subcutaneous tumor model. [Figure 37B] (As mentioned above.) [Figure 37C] (As mentioned above.) [Figure 38A] A schematic diagram of the Biacore measurement cycle is shown. [Figure 38B] (As mentioned above.) [Figure 39A-1] Representative sensorgrams and response and concentration plots are shown. Figure 39A.1 to Figure 39A.11 (collectively "Figure 39A") are WTIgG1, LALAPA-IgG1, LALAGA-IgG1, LALAPG-IgG1, DAPA-IgG1, LALASKPA-IgG1, DAPASK-IgG1, GADAPA-IgG1, GADAPASK Representative sensorgrams and response plots of -IgG1 and DANAPA-IgG1 (concentration range: 0.2nM to 100nM for human FcγR1A) are shown; Figures 39B.1 to 39B.11 (collectively "Figure 39B") are WT, LALAPA-IgG1, LALAGA-IgG1, LALAPG-IgG1, DAPA-IgG1, LALASKPA-IgG1, DAPASK-IgG1, GADAPA-IgG1, GADAPASK-IgG1 and DANAPA-IgG1 against FcγR3A V158 (concentration range: 1.95nM to 1000nM) and binding kinetics. Figures 39C.1 to 39C.11 (“Collectively, Figure 39C”) show WT, LALAPA-IgG1, LALAGA-IgG1, LALAPG-IgG1, DAPA-IgG1, LALASKPA-IgG1, DAPASK-IgG1, GADAPA- The sensorgram and binding kinetics of IgG1, GADAPASK-IgG1 and DANAPA-IgG1 (concentration range: 0.49nM to 250nM for human C1q) are shown. [Figure 39A-2] (As mentioned above.) [Figure 39A-3] (As mentioned above.) [Figure 39A-4] (As mentioned above.) [Figure 39A-5] (As mentioned above.) [Figure 39A-6] (As mentioned above.) [Figure 39A-7] (As mentioned above.) [Figure 39A-8] (As mentioned above.) [Figure 39A-9] (As mentioned above.) [Figure 39A-10] (As mentioned above.) [Figure 39A-11] (As mentioned above.) [Figure 39B-1] (As mentioned above.) [Figure 39B-2] (As mentioned above.) [Figure 39B-3] (As mentioned above.) [Figure 39B-4] (As mentioned above.) [Figure 39B-5] (As mentioned above.) [Figure 39B-6] (As mentioned above.) [Figure 39B-7] (As mentioned above.) [Figure 39B-8] (As mentioned above.) [Figure 39B-9] (As mentioned above.) [Figure 39B-10] (As mentioned above.) [Figure 39B-11] (As mentioned above.) [Figure 39C-1] (As mentioned above.) [Figure 39C-2] (As mentioned above.) [Figure 39C-3] (As mentioned above.) [Figure 39C-4] (As mentioned above.) [Figure 39C-5] (As mentioned above.) [Figure 39C-6] (As mentioned above.) [Figure 39C-7] (As mentioned above.) [Figure 39C-8] (As mentioned above.) [Figure 39C-9] (As mentioned above.) [Figure 39C-10] (As mentioned above.) [Figure 39C-11] (As mentioned above.) [Figure 40A] Figure 40: Figure 40A shows nuclear factor of activated T cells (NFAT) pathway activity of wild type and mutant antibodies. FIG. 40B shows NFAT pathway activity in cells sensitized by addition of wild type and mutant antibody, INFγ. [Figure 40B] (As mentioned above.) [Figure 41A] Representative sensorgrams and response plots of WT, DANAPA, GADAPASK, LALA and LALASKPA mutants (concentration range: 0.2 nM to 25 nM for human FcγR1A) are shown. [Figure 41B] (As mentioned above.) [Figure 41C] (As mentioned above.) [Figure 41D] (As mentioned above.) [Figure 41E] (As mentioned above.) [Figure 42] Nuclear factor of activated T cells (NFAT) pathway activity of wild type and mutant antibodies is shown. [Figure 43A] Secretion of IL-6 (Figure 43A) and TNF-α (Figure 43B) from B cell depleted PBMC-Karpas 422 and T cell Karpas 422 co-cultures in the presence of CD3hi TSP1 and added B cells. [Figure 43B] (As mentioned above.) [Figure 44A-1] Expression of BAFF-R and CD19 in luciferized B-cell lymphoma cell lines as determined by flow cytometry. Figure 44A.1~44A.2: DOHH-2 Luc; Figure 44B.1~44B.2: Karpas 422 Luc; Figure 44C.1~44C.2: OCILY-19 Luc; Figure 44D.1~44D.2: SU-DHL-4 Luc; Figure 44E.1~44E.2: Toledo Luc. [Figure 44A-2] (As mentioned above.) [Figure 44B-1] (As mentioned above.) [Figure 44B-2] (As mentioned above.) [Figure 44C-1] (As mentioned above.) [Figure 44C-2] (As mentioned above.) [Figure 44D-1] (As mentioned above.) [Figure 44D-2] (As mentioned above.) [Figure 44E-1] (As mentioned above.) [Figure 44E-2] (As mentioned above.) [Figure 45A] Combined target cell killing from the combination of anti-BAFFR antibody VAY736 and CD3hi TSP1 TBM in B cell-depleted PBMC-Karpas 422 cell co-cultures from two donors (Figures 45A-45B and Figure 45C, respectively). The dotted line in each of Figures 45A-45C indicates target cell killing induced by selected concentrations of CD3hi TSP1 in the absence of any VAY736 or isotype Afuc antibodies. [Figure 45B] (As mentioned above.) [Figure 45C] (As mentioned above.) [Figure 46A] Tumor growth in an in vivo model of DLBCL in animals treated with vehicle (Figure 46A), 5 mg / kg VAY736 (Figure 46B), 50 mg / kg VAY736 (Figure 46C) or rituximab (Figure 46D). [Figure 46B] (As mentioned above.) [Figure 46C] (As mentioned above.) [Figure 46D] (As mentioned above.) [Form for carrying out the invention]
[0044] 7.1.Definition As used herein, the following terms are intended to have the following meanings.
[0045] ABM chains: Individual ABMs may exist as one polypeptide chain (eg, in the case of scFvs) or may be formed by the association of two or more polypeptide chains (eg, in the case of Fabs). As used herein, the term "ABM chain" refers to all or a portion of an ABM present on a single polypeptide chain. Use of the term "ABM chain" is intended for convenience and illustrative purposes only, and does not imply any particular form or method of production.
[0046] ADCC: As used herein, “ADCC” or “antibody-dependent cell-mediated cytotoxicity” refers to the ability of non-specific cytotoxic cells expressing FcγRs to recognize bound antibodies on target cells. , refers to a cell-mediated reaction that subsequently causes lysis of the target cell. ADCC is correlated with binding to FcγRIIIa; increased binding to FcγRIIIa results in increased ADCC activity.
[0047] ADCP: "ADCP" or antibody-dependent cell-mediated phagocytosis as used herein refers to non-specific phagocytes expressing FcγRs that recognize bound antibodies on target cells and then refers to the cell-mediated reaction that causes phagocytosis of
[0048] Antibody: As used herein, the term "antibody" refers to a polypeptide (or polypeptide of the immunoglobulin family) that is capable of non-covalently, reversibly and specifically binding to an antigen. set). For example, natural "antibodies" of the IgG type are tetramers containing at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain (abbreviated herein as CL). The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDR), interspersed with more conserved regions called framework regions (FR). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of heavy and light chains contain binding domains that interact with antigen. The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component of the classical complement system (Clq). The term "antibody" includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, bispecific or multispecific antibodies, and anti-idiotypic (anti-Id) antibodies (e.g., (including anti-Id antibodies to antibodies of the present disclosure). Antibodies can be of any isotype / class (eg IgG, IgE, IgM, IgD, IgA and IgY) or subclass (eg IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
[0049] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used functionally. In this regard, it will be appreciated that the variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and heavy chains (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, and complement fixation. By convention, the numbering of constant region domains increases as they become more distal from the antigen-binding site or amino terminus of the antibody. In wild-type antibodies, the N-terminus is the variable region and the C-terminus is the constant region; the CH3 and CL domains actually contain the carboxy terminus of the heavy and light chains, respectively.
[0050] Antibody fragment: As used herein, the term "antibody fragment" of an antibody refers to one or more portions of an antibody. In certain embodiments, these portions are part of the contact domain of the antibody. In certain other embodiments, these moieties are non-covalently, reversibly bonded, sometimes referred to herein as "antigen-binding fragments", "antigen-binding fragments thereof", "antigen-binding portions", etc. and antigen-binding fragments that retain the ability to specifically bind antigen. Examples of binding fragments include, but are not limited to, single chain Fv (scFv), Fab fragments, monovalent fragments consisting of VL, VH, CL and CH1 domains; F(ab)2 fragments, by disulfide bridges in the hinge region; Bivalent fragments comprising two Fab fragments linked; Fd fragments consisting of VH and CH1 domains; Fv fragments consisting of VL and VH domains of a single arm of the antibody; dAb fragments consisting of VH domains (Ward et al., 1989 , Nature 341:544-546); and isolated complementarity determining regions (CDRs). Accordingly, the term "antibody fragment" encompasses proteolytic fragments of antibodies (eg, Fab and F(ab)2 fragments) as well as modified proteins that include one or more portions of an antibody (eg, scFv).
[0051] Antibody fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, intrabodies, bispecific antibodies, trispecific antibodies, tetraspecific antibodies, v-NARs and bis-scFvs ( See, e.g., Hollinger and Hudson, 2005, Nature Biotechnology 23:1126-1136). Antibody fragments can be grafted into scaffolds based on polypeptides such as fibronectin type III (Fn3) (see US Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies).
[0052] Antibody fragments include pairs of tandem Fv segments (e.g., VH-CH1-VH-CH1) that together with complementary light chain polypeptides (e.g., VL-VC-VL-VC) form a pair of antigen-binding regions. ) (Zapata et al., 1995, Protein Eng. 8:1057-1062; and US Pat. No. 5,641,870).
[0053] Antibody numbering system: References herein to numbered amino acid residues in antibody domains are based on the EU numbering system (eg, in Table 1), unless otherwise specified. This method was first devised by Edelman et al., 1969, Proc. Nat'l Acad. Sci. USA 63:78-85 and Kabat et al., 1991, in Sequences of Proteins of Immunological Interest, US Department of Described in detail in Health and Human Services, NIH, USA.
[0054] Antigen binding module: The term "antigen binding module" or "ABM" as used herein refers to a portion of an MBM that has the ability to non-covalently, reversibly, and specifically bind an antigen. Point. ABMs can be immunoglobulin-based or non-immunoglobulin-based. As used herein, the terms "ABM1" and "CD19 ABM" (etc.) refer to an ABM that specifically binds to CD19, and the terms "ABM2" and "TCR ABM" (etc.) refer to an ABM that specifically binds to CD19, and the terms "ABM2" and "TCR ABM" (etc.) The term "ABM3" refers to an ABM that specifically binds to a body component; the term "ABM3" refers to an ABM that specifically binds to CD2 or TAA (depending on the context); the term "CD2 ABM" (and others) refers to an ABM that specifically binds to CD2 or TAA (depending on the context); refers to an ABM that specifically binds, and the term "TAA ABM" (and the like) refers to an ABM that specifically binds to TAA. The terms ABM1, ABM2 and ABM3 are used for convenience only and are not intended to convey any particular form of MBM. In some embodiments, ABM2 binds CD3 (referred to herein as "CD3 ABM", etc.). Therefore, disclosures regarding one or more ABM2 are also applicable to CD3 ABM.
[0055] Antigen-binding fragment: The term "antigen-binding fragment" of an antibody refers to the portion of an antibody that has the ability to bind antigen non-covalently, reversibly and specifically.
[0056] Antigen-binding molecule: The term "antigen-binding molecule" refers to a molecule, such as an antibody, that includes one or more antigen-binding domains. Antigen binding molecules can include one or more polypeptide chains, such as one, two, three, four or more polypeptide chains. The polypeptide chains in an antigen-binding molecule can be associated with each other directly or indirectly (e.g., a first polypeptide chain can be associated with a second polypeptide chain, which in turn can be associated with a third polypeptide chain. to form an antigen-binding molecule, in which the first and second polypeptide chains are directly associated with each other, or the second and third polypeptide chains are directly associated with each other, and the first and third (the polypeptide chains are indirectly associated with each other via a second polypeptide chain).
[0057] Associated: The term "associated" in the context of antigen binding molecules refers to a functional relationship between two or more polypeptide chains and / or between two or more portions of a single polypeptide chain. In particular, the term "associated" means that two or more polypeptides (or portions of a single polypeptide) are associated with each other non-covalently, e.g. through molecular interactions, and / or through one or more disulfide bridges. or covalently associated through chemical cross-linking, thereby producing a functional antigen-binding molecule, eg, a BBM or TBM, in which the antigen-binding domain is capable of binding to its respective target. Examples of associations that may exist in MBM include (but are not limited to) between Fc regions of Fc domains (homodimers or heterodimers as described in Section 7.2.2.1.5). , between the VH and VL regions of Fab or Fv, and between CH1 and CL of Fab.
[0058] BAFF: The term "BAFF" refers to B cell activating factor protein. BAFF is also known as tumor necrosis factor ligand superfamily member 13B and B lymphocyte stimulating factor (BLyS). Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human BAFF can be found under UniProt / Swiss-Prot accession number Q9Y275, and the nucleotide sequence encoding human BAFF can be found under accession number NM_006573.5. BAFF is a ligand for BAFFR and plays a role in B cell proliferation and differentiation.
[0059] BAFFR: The term "BAFFR" refers to B cell activating factor receptor protein. BAFFR is also known as TNF receptor superfamily member 13C (TNFRSF13C). Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human BAFFR can be found under UniProt / Swiss-Prot accession number Q96RJ3, and the nucleotide sequence encoding human BAFFR can be found under accession number NM_052945.4. It is primarily expressed on B lymphocytes and a subset of T cells.
[0060] B cell: As used herein, the term "B cell" refers to a cell of the B cell lineage, a type of white blood cell of the lymphocyte subtype. Examples of B cells include plasmablasts, plasma cells, lymphoplasmacytoid cells, memory B cells, follicular B cells, marginal zone B cells, B-1 cells, B-2 cells, and regulatory B cells. It will be done.
[0061] B cell targeting agent: As used herein, the term "B cell targeting agent" refers to an agent that binds to a cell surface molecule of a B cell (e.g., via an antigen binding domain of an antibody) and / or Refers to an agent (eg, a therapeutic agent) that depletes human B cells in vitro and / or in vivo. B cell targeting agents that deplete B cells are referred to herein as "B cell depleting agents." A B cell depleting agent, e.g. a B cell depleting antibody, depletes B cells in vitro, preferably with an EC50 of 10 nM or less, preferably with an EC50 of 1 nM or less, as measured in a human B cell depletion assay. , depletes B cells with an EC50 below 100 pM. For example, in mouse models, B cell depleting agents that deplete B cells in vivo preferably reduce the percentage of B cells in vivo by up to 70%, as measured by fluorescence-activated cell sorting (FACS) of B cells. Preferably by 80%, more preferably by 90% or more. B cell depletion assays for measuring B cell depletion in vitro and in vivo are described in WO 2010 / 007082, the contents of which are incorporated herein by reference in their entirety.
[0062] B cell malignancy: As used herein, B cell malignancy refers to the uncontrolled proliferation of B cells. Examples of B-cell malignancies include non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, leukemia, and myeloma. For example, B-cell malignancies include, but are not limited to, multiple myeloma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), follicular lymphoma, mantle cell lymphoma (MCL), diffuse large cell type B-cell lymphoma (DLBCL), marginal zone lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), hairy cell leukemia, splenic marginal zone B-cell lymphoma, extranodal margins May be marginal zone lymphoma (EMZL), nodal marginal zone B-cell lymphoma (NZML) and primary effusion lymphoma.
[0063] Binding Sequence: With reference to Tables 1, 9, 10, 11, 14, 15, 18 or 19 (including subparts thereof), the term "binding sequence" refers to the set of CDRs, VH - means ABM with VL pair or scFv.
[0064] Bispecific binding molecule: The term "bispecific binding molecule" or "BBM" refers to a molecule that specifically binds two antigens and contains two or more ABMs. The BBM of the present disclosure comprises at least one antigen binding domain specific for CD19 and at least one antigen binding domain specific for a different antigen, eg, a component of a TCR complex. Representative BBMs are shown in Figures 1B-1AH. A BBM may contain one, two, three, four or even more polypeptide chains.
[0065] Bivalent: The term "bivalent" as used herein in relation to an antigen binding molecule refers to an antigen binding molecule having two antigen binding domains. The domains can be the same or different. Thus, a bivalent antigen binding molecule can be monospecific or bispecific. A bivalent BBM can include an ABM that specifically binds CD19 and another ABM that binds another antigen, such as a component of a TCR complex.
[0066] Cancer: The term "cancer" refers to a disease characterized by the uncontrolled (often rapid) growth of abnormal cells. Cancer cells can spread locally or to other parts of the body via the bloodstream and lymphatic system. Examples of cancer include the B cell malignancies described herein. The term "cancerous B cell" refers to a B cell that is undergoing or has undergone uncontrolled proliferation.
[0067] CD3: The term "CD3" or "complex 3" refers to a group of three differentiated co-receptors of T cell receptors. CD3 promotes the activation of both cytotoxic T cells (e.g. CD8+ naive T cells) and T helper cells (e.g. CD4+ naive T cells) and has four different chains: one CD3γ chain (e.g. Genbank accession numbers NM_000073 and MP_000064 (human)), one CD3δ chain (e.g., Genbank accession numbers NM_000732, NM_001040651, NP_00732 and NP_001035741 (human)) and two CD3ε chains (e.g., Genbank accession numbers NM_000733 and NP_00724 (human)). configured. The CD3 chain is a highly related cell surface protein of the immunoglobulin superfamily that contains a single extracellular immunoglobulin domain. The CD3 molecule associates with the T cell receptor (TCR) and the ζ-chain to form the T cell receptor (TCR) complex, which functions in generating activation signals in T lymphocytes. Unless explicitly indicated, references in this application to CD3 may refer to a CD3 co-receptor, a CD3 co-receptor complex or any polypeptide chain of a CD3 co-receptor complex.
[0068] CD19:: The term "CD19" or "cluster of differentiation 19" refers to cluster of differentiation 19 protein, which is a detectable antigenic determinant on leukemia progenitor cells. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human CD19 can be found as UniProt / Swiss-Prot accession number P15391, and the nucleotide sequence encoding human CD19 can be found under accession number NM_001178098. CD19 is expressed in most B-cell lineage cancers, including, for example, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), and non-Hodgkin's lymphoma. It is also an early marker of B cell progenitor cells. See, eg, Nicholson et al., 1997, Mol. Immun. 34(16-17):1157-1165.
[0069] Anti-CD19 agent: The term "anti-CD19 agent" refers to an agent (eg, a therapeutic agent) that targets CD19. Examples of anti-CD19 agents include CD19 binding molecules (including monospecific and multispecific antigen binding molecules) such as blinatumomab, NEG218-based monospecific and multispecific binding molecules described herein, Included are NEG258-based monospecific and multispecific binding molecules and CAR T compositions such as tisagene lecleucel, axicabtagene ciloleucel, and brexcabutagene autoleucel, as described herein.
[0070] Chimeric antibody: The term "chimeric antibody" (or antigen-binding fragment thereof) refers to antibodies of a class, effector function and / or species in which (a) the constant region or portion thereof has a different or modified antigen-binding site (variable region); or (b) the constant region of the chimeric antibody or its An antibody molecule (or antigen-binding fragment thereof) in which portions have been modified, substituted or replaced by variable regions with different or altered antigen specificities. For example, murine antibodies can be modified by replacing their constant regions with constant regions from human immunoglobulins. Substitution with human constant regions allows the chimeric antibody to retain its specificity in recognizing antigen while having reduced antigenicity in humans compared to the original murine antibody.
[0071] Chimeric antigen receptor: The term "chimeric antigen receptor" or alternatively "CAR" refers to a set of polypeptides, typically two in the simplest embodiment, that, when located within an immune effector cell, Cells are provided that have specificity for target cells, typically cancer cells, and that involve intracellular signal generation. In some embodiments, the CAR comprises a cytoplasmic signaling domain that includes at least an extracellular antigen binding domain, a transmembrane domain, and a functional signaling domain derived from a stimulatory molecule and / or costimulatory molecule defined below. (also referred to herein as the "intracellular signaling domain"). A set of polypeptides may or may not be contiguous with each other. When the polypeptides are not contiguous with each other, the set of polypeptides is such that the presence of a dimerization molecule allows the polypeptides to bind to each other, e.g., to bind an antigen-binding domain to an intracellular signaling domain. Contains a dimerization switch that can be used. CAR molecules are typically administered to a subject by administration of immune effector cells (eg, T cells, which are preferably the subject's autologous cells) that have been engineered to express the CAR molecule.
[0072] In combination: Administered "in combination" as used herein means two (or more) different treatments are delivered to a subject while the subject is suffering from a disorder. However, for example, the two or more treatments are delivered after the subject is diagnosed with the disorder and before the disorder is cured or disappears or before the treatment is discontinued for other reasons. The terms "combination" and "in combination" are not limited to the precise and simultaneous administration of two or more treatments, but rather the use of drugs in conjunction with additional therapies to be administered in a separate manner. It refers to administering to a subject a pharmaceutical composition containing an agent (eg, an anti-CD19 agent or a B cell targeting agent) in an order and time interval that provides a greater benefit than otherwise would be the case.
[0073] Complementarity Determining Region: As used herein, the term "complementarity determining region" or "CDR" refers to the sequence of amino acids within an antibody variable region that confers antigen specificity and binding affinity. For example, there are generally three CDRs in each heavy chain variable region (e.g., CDR-H1, CDR-H2, and CDR-H3) and three CDRs in each light chain variable region (e.g., CDR-L1, CDR-L2, and CDR -L3). The exact amino acid sequence boundaries of a given CDR are determined by Kabat et al., 1991, “Sequences of Proteins of Immunological Interest”, 5th Ed. ), Al-Lazikani et al., 1997, JMB 273, 927-948 (“Chothia” numbering scheme) and ImMunoGenTics (IMGT) numbering (Lefranc, 1999, the Immunologist 7:132-136; Lefranc, et al., 2003 ,Dev.Comp.Immunol.27:55-77 (the "IMGT" numbering scheme). For example, the classical format According to Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (CDR-H1), 50-65 (CDR-H2) and 95-102 (CDR-H3). ;CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (CDR-L1), 50-56 (CDR-L2) and 89-97 (CDR-L3). , CDR amino acids in VH are numbered 26-32 (CDR-H1), 52-56 (CDR-H2) and 95-102 (CDR-H3); amino acid residues in VL are numbered 26-32 (CDR-H3); (CDR-L1), 50~52 (CDR-L2) and 91~96 (CDR-L3). By combining both Kabat and Chothia's CDR definitions, CDRs are Amino acid residues 26-35 (CDR-H1), 50-65 (CDR-H2) and 95-102 (CDR-H3) and amino acid residues 24-34 (CDR-L1), 50-56 ( CDR-L2) and 89 to 97 (CDR-L3). According to IMGT, the CDR amino acid residues in VH are approximately 26 to 35 (CDR-H1), 51 to 57 (CDR-H2), and 93 to 102 (CDR-H3) and the CDR amino acid residues in VL are approximately 27-32 (CDR-L1), 50-52 (CDR-L2) and 89-97 (CDR-L3) (“Kabat” numbering). With IMGT, the CDR regions of an antibody can be determined using the program IMGT / Domain Gap Align.
[0074] Conservative sequence modification: The term "conservative sequence modification" refers to an amino acid modification that does not substantially affect or alter the binding properties of a CD19 binding molecule or a component thereof (e.g., CD19 binding domain or Fc region). Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the binding molecule by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain.Families of amino acid residues having similar side chains have been defined in the art. The family includes amino acids with basic side chains (e.g. lysine, arginine, histidine), amino acids with acidic side chains (e.g. aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with β-branched side chains (e.g. , threonine, valine, isoleucine) and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).Thus, one or more amino acid residues within the binding molecule are from the same side chain family. can be substituted with other amino acid residues and the modified binding molecules can be tested, for example, for binding to a target molecule and / or effective heterodimerization and / or effector function.
[0075] Bispecific antibody: As used herein, the term "bispecific antibody" typically refers to a small antibody with two antigen-binding sites formed by the pairing of scFv chains. Refers to antibody fragments. Each scFv comprises a heavy chain variable domain (VH) linked to a light chain variable domain (VL) in the same polypeptide chain (VH-VL, where VH is either N-terminal or C-terminal to the VL). ). Unlike typical scFvs, where the VH and VL are separated by a linker that allows the VH and VL on the same polypeptide chain to pair to form an antigen-binding domain, bispecific antibodies typically contains a linker that is too short to allow pairing between the VH and VL domains on the same chain, whereby the VH and VL domains are paired with complementary domains on another chain and the two antigen-binding A region is formed. Bispecific antibodies are further described in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al., 1993, Proc. Natl. Acad. Sci. USA 90:6444-6448. Well described.
[0076] dsFv: The term "dsFv" refers to a disulfide-stabilized Fv fragment. In dsFv, VH and VL are linked by interdomain disulfide bonds. To generate such molecules, one amino acid in the framework regions of VH and VL is each mutated to cysteine, which in turn forms a stable interchain disulfide bond. Typically, position 44 in the VH and position 100 in the VL are mutated to cysteine. See Brinkmann, 2010, Antibody Engineering 181-189, DOI:10.1007 / 978-3-642-01147-4_14. The term dsFv refers to what is known as dsFv (a molecule in which VH and VL are connected by an interchain disulfide bond rather than a linker peptide) or scdsFv (a molecule in which VH and VL are connected by a linker and an interchain disulfide bond). It includes both.
[0077] Effector function: The term "effector function" refers to the activity of an antibody molecule, usually mediated by binding of an effector molecule through a domain of the antibody other than the antigen-binding domain. Effector functions include, for example, complement-mediated effector functions mediated by the binding of the C1 component of complement to antibodies. Activation of complement is important in the opsonization and lysis of cellular pathogens. Activation of complement also stimulates inflammatory responses and may also be involved in autoimmune hypersensitivity. Effector functions also include Fc receptor (FcR)-mediated effector functions, which can be triggered upon binding of the constant domain of an antibody to an Fc receptor (FcR). Binding of antibodies to Fc receptors on the cell surface results in phagocytosis and destruction of antibody-coated particles, clearance of immune complexes, and lysis of antibody-coated target cells by killer cells (antibody-dependent cell-mediated cytotoxicity). or ADCC), triggers many important and diverse biological responses, including the release of inflammatory mediators, placental passage, and control of immunoglobulin production. The effector function of an antibody can be modified by altering, eg, enhancing or reducing, the affinity of the antibody for effector molecules such as Fc receptors or complement components. Binding affinity is generally altered by modifying the effector molecule binding site, in which case it is appropriate to localize the site of interest and modify at least part of this site in a suitable manner. Although modification of the binding site in an antibody for an effector molecule need not substantially alter the overall binding affinity, the interaction geometry is such that the effector mechanism is disabled as in non-productive binding. It is also conceivable that the physical properties can be changed. It is further contemplated that effector function may be altered by modifying sites that are not directly involved in effector molecule binding, but are otherwise involved in the performance of effector function.
[0078] Epitope: An epitope or antigenic determinant is a portion of an antigen that is recognized by an antibody or other antigen binding moiety as described herein. Epitopes can be linear or conformational.
[0079] Fab: As used herein, "Fab" or "Fab region" refers to a polypeptide region that includes the VH, CH1, VL and CL immunoglobulin domains. These terms may refer to this region alone or in the context of an antigen binding molecule of the present disclosure.
[0080] The Fab domain is formed by the association of the CH1 domain, bound to the VH domain, with the CL domain, bound to the VL domain. The VH domain is paired with the VL domain to constitute the Fv region, and the CH1 domain is paired with the CL domain to further stabilize the binding module. Disulfide bonds between the two constant domains may further stabilize the Fab domain.
[0081] Fab regions can be generated by proteolytic cleavage of immunoglobulin molecules (eg, using enzymes such as papain) or recombinant expression. In natural immunoglobulin molecules, Fabs are formed by the association of two different polypeptide chains (eg, VH-CH1 on one chain with VL-CL on the other chain). Fab regions are typically expressed on two polypeptide chains, typically by recombinant techniques, although single chain Fabs are also contemplated herein.
[0082] Fc domain: The term "Fc domain" refers to a pair of associated Fc regions. These two Fc regions dimerize to create an Fc domain. The two Fc regions within an Fc domain can be the same (such Fc domains are referred to herein as "Fc homodimers") or different from each other (such Fc domains are referred to herein as "Fc homodimers"). (referred to herein as “Fc heterodimer”).
[0083] Fc region: As used herein, the term "Fc region" or "Fc chain" refers to a polypeptide that comprises the CH2-CH3 domain and, in some cases, the hinge of an IgG molecule. In the EU numbering for human IgG1, the CH2-CH3 domain contains amino acids 231-447 and the hinge is 216-230. Therefore, the definition of "Fc region" includes both amino acids 231-447 (CH2-CH3) or 216-447 (hinge-CH2-CH3) or a fragment thereof. "Fc fragments" in this context may contain fewer amino acids from either or both the N-terminus and C-terminus, but are generally analyzed by size-based standard methods (e.g., non-denaturing chromatography, size exclusion chromatography). It still retains the ability to form dimers with another Fc region, as can be detected using Fc-based imaging. A human IgG Fc region is particularly used in this disclosure and can be an Fc region from human IgG1, IgG2 or IgG4.
[0084] Fv: The term "Fv" refers to the smallest antibody fragment derivable from an immunoglobulin that contains complete target recognition and binding sites. This region consists of a dimer of one heavy chain variable domain and one light chain variable domain in tight non-covalent association (VH-VL dimer). It is in this configuration that the three CDRs of each variable domain interact to define a target binding site on the surface of the VH-VL dimer. These six CDRs often confer target-binding specificity to antibodies. However, in some instances, even a single variable domain (or half of an Fv containing only three target-specific CDRs) may have the ability to recognize and bind a target. The expression VH-VL dimer herein is not intended to convey any particular form. By way of example and without limitation, VH and VL may be taken together to form a half-antibody, taking any form described herein, or each may be present in separate half-antibodies, allowing them to The separate half-antibodies may together form an antigen-binding domain when associated, eg, a TBM of the present disclosure. When present on a single polypeptide chain (eg, scFv), it is N-terminal or C-terminal to VH and VL.
[0085] Half-antibody: The term "half-antibody" comprises at least one ABM or ABM chain, such as by disulfide bridges or molecular interactions (e.g., knob-in-hole interactions between Fc heterodimers). Refers to a molecule that can associate with another molecule, including an ABM chain. A half-antibody can be composed of one polypeptide chain or two or more polypeptide chains (eg, the two polypeptide chains of a Fab). In one embodiment, the half-antibody includes an Fc region.
[0086] An example of a half-antibody is a molecule that includes the heavy and light chains of an antibody (eg, an IgG antibody). Another example of a half-antibody is a molecule comprising a first polypeptide comprising a VL domain and a CL domain, and a second polypeptide comprising a VH domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; The VL and VH domains form the ABM. Yet another example of a half-antibody is a polypeptide that includes an scFv domain, a CH2 domain, and a CH3 domain.
[0087] A half-antibody may contain more than one ABM, eg, a half-antibody may contain (in order from N-terminus to C-terminus) an scFv domain, a CH2 domain, a CH3 domain and another scFv domain.
[0088] A half-antibody may also include an ABM chain that forms a complete ABM when associated with another ABM chain in another half-antibody.
[0089] Thus, an MBM may contain one, more typically two or even three or more half-antibodies, and a half-antibody may contain one or more ABMs or ABM chains.
[0090] In some MBMs, a first half-antibody associates with, eg, heterodimerizes with, a second half-antibody. In other MBMs, a first half-antibody is covalently linked to a second half-antibody, eg, by disulfide bridges or chemical cross-links. In still other MBMs, a first half-antibody associates with a second half-antibody through both covalent and non-covalent interactions, such as disulfide bridges and knob-in-hole interactions.
[0091] The term "half-antibody" is intended for descriptive purposes only and does not imply any particular form or method of manufacture. The descriptions of half antibodies such as "first" half antibody, "second" half antibody, "left" half antibody, "right" half antibody, etc. are for convenience and illustrative purposes only.
[0092] Hexavalent: The term "hexavalent" when used herein in reference to an antigen binding molecule (eg, TBM) refers to an antigen binding molecule having six antigen binding domains. The hexavalent TBMs of the present disclosure generally have three pairs of antigen-binding domains that each bind the same antigen, but in different morphologies (e.g., three antigen-binding domains that bind to CD19, bind to components of the TCR complex). two antigen-binding domains that bind to CD2 or TAA, and one antigen-binding domain that binds to CD2 or TAA, or three antigen-binding domains that bind to CD19, two antigen-binding domains that bind to CD2 or TAA, and bind to components of the TCR complex. one antigen binding domain) is within the scope of this disclosure. Examples of hexavalent TBMs are shown schematically in FIGS. 1U-1V.
[0093] Hole: In relation to knob-into-hole, the “hole” is recessed from the boundary of the first Fc strand and thus stabilizes the Fc heterodimer, thereby e.g. Refers to at least one amino acid side chain that is positionable in a complementary "knob" at the adjacent border of a second Fc chain to favor Fc heterodimer formation over Fc heterodimer formation.
[0094] Host cell or recombinant host cell: The term "host cell" or "recombinant host cell" refers to a cell that has been genetically modified, eg, by the introduction of a heterologous nucleic acid. It should be understood that such terms are intended to refer not only to the cells of a particular subject, but also to the progeny of such cells. As used herein, such progeny may not actually be identical to the parent cell, as certain modifications may be present in later generations, either due to mutations or environmental influences. still be included within the scope of the term "host cell" when used. A host cell may carry a heterologous nucleic acid either temporarily, eg, on an extrachromosomal heterologous expression vector, or stably, eg, by integration of the heterologous nucleic acid into the host cell genome. For the purpose of expressing antigen-binding molecules, host cells include monkey kidney cells (COS, e.g. COS-1, COS-7), HEK293, baby hamster kidney (BHK, e.g. BHK21), Chinese hamster ovary (CHO), NSO, PerC6, BSC-1, human hepatocellular carcinoma cells (e.g. Hep G2), SP2 / 0, HeLa, Madin Darby bovine kidney (MDBK), myeloma and lymphoma cells or derivatives and / or modified mutations thereof The cell line may be of mammalian origin or of mammalian-like characteristics, such as the human body. Modified variants include, for example, glycan profile modified and / or site-specific integration site derivatives.
[0095] Human antibody: As used herein, the term "human antibody" includes antibodies that have variable regions in which both the framework and CDR regions are derived from sequences of human origin. Furthermore, if the antibody comprises a constant region, the constant region may be a human sequence such as a human germline sequence or a mutant human germline sequence or, for example, Knappik et al., 2000, J Mol Biol 296,57- Antibody-containing consensus framework sequences derived from human framework sequence analysis are also derived, as described in 86. The structure and location of immunoglobulin variable domains, e.g. CDRs, can be defined using well-known numbering schemes such as the Kabat numbering scheme, the Chothia numbering scheme or a combination of Kabat and Chothia (e.g. Lazikani et al., 1997 ,J.Mol.Bio.273:927 948;Kabat et al.,1991,Sequences of Proteins of Immunological Interest,5th edit.,NIH Publication no.91-3242 U.S.Department of Health and Human Services;Chothia et al., 1987, J. Mol. Biol. 196:901-917; see Chothia et al., 1989, Nature 342:877-883).
[0096] Human antibodies contain amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or somatic mutagenesis in vivo or conservation to enhance stability or manufacture). substitutions). However, the term "human antibody" as used herein includes antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, are grafted onto human framework sequences. is not intended.
[0097] Humanized: The term "humanized" form of a non-human (eg, murine) antibody is a chimeric antibody that contains minimal sequences derived from non-human immunoglobulins. In general, humanized antibodies are those in which the hypervariable region residues of the recipient are derived from a non-human species (donor antibody), such as a mouse, rat, rabbit or non-human primate, with the desired specificity, affinity and potency. A human immunoglobulin (recipient antibody) in which hypervariable region residues have been replaced. In some instances, framework region (FR) residues of the human immunoglobulin are replaced with corresponding non-human residues. Additionally, humanized antibodies can contain residues that are not found in the recipient or donor antibody. These modifications are made to further refine antibody performance. Generally, a humanized antibody will contain substantially all of the variable domains of at least one, and typically two, where all or substantially all of the hypervariable loops are those of a non-human immunoglobulin. Correspondingly, all or substantially all of the FRs are of human immunoglobulin sequences. The humanized antibody will optionally also include at least a portion of an immunoglobulin constant region (Fc), typically of a human immunoglobulin. For further details see Jones et al., 1986, Nature 321:522-525; Riechmann et al., 1988, Nature 332:323-329; and Presta, 1992, Curr.Op.Struct.Biol.2:593. See -596. See also the following review articles and references cited therein: Vaswani and Hamilton, 1998, Ann. Allergy, Asthma & Immunol. 1:105-115; Harris, 1995, Biochem. Soc. Transactions 23: 1035-1038; Hurle and Gross, 1994, Curr. Op. Biotech. 5:428-433.
[0098] Knob: Related to knob-into-hole, a “knob” protrudes from the boundary of the first Fc strand and thus stabilizes Fc heterodimers, thereby favoring Fc heterodimer formation over, for example, Fc homodimer formation. Refers to at least one amino acid side chain that can be positioned in a complementary "hole" at the interface with the second Fc chain to favor merization.
[0099] Knob and hole (or knob-into-hole): One mechanism of Fc heterodimerization is known in the art as "knob and hole," or "knob-into-hole," or "knob-into-hole." ” is commonly called. These terms are described, for example, in Ridgway et al., 1996, Protein Engineering 9(7):617; Atwell et al., 1997, J. Mol. Biol. 270:26; and U.S. Pat. No. 8,216,805. refers to an amino acid mutation that produces a steric effect that favors the formation of Fc heterodimers over Fc homodimers, as described above. Knob-in-hole mutations can be combined with other techniques to improve heterodimerization, for example, as described in Section 7.2.2.1.6.
[0100] Monoclonal antibody: As used herein, the term "monoclonal antibody" refers to polypeptides, including antibodies, antibody fragments, molecules (including MBM), etc., derived from the same genetic source.
[0101] Monovalent: The term "monovalent" as used herein in relation to an antigen binding molecule refers to an antigen binding molecule having a single antigen binding domain.
[0102] Multispecific binding molecule: The term "multispecific binding molecule" or "MBM" refers to a molecule that specifically binds at least two antigens and that contains two or more antigen binding domains. The antigen binding domains can each independently be an antibody fragment (eg, scFv, Fab, Nanobody), a ligand, or a non-antibody-derived binding agent (eg, fibronectin, Fynomer, DARPin).
[0103] Mutation or modification: In relation to the primary amino acid sequence of a polypeptide, the terms "modification" and "mutation" refer to amino acid substitutions, insertions and / or deletions in the polypeptide sequence compared to a reference polypeptide. . Furthermore, the term "modification" further encompasses alterations to amino acid residues, for example, by chemical conjugation (eg, of a drug or polyethylene glycol moiety) or post-translational modification (eg, glycosylation).
[0104] Nucleic acid: The term "nucleic acid" is used herein interchangeably with the term "polynucleotide" and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single-stranded or double-stranded form. The term refers to nucleic acids that are synthetic, natural and non-natural and contain known nucleotide analogs or modified backbone residues or linkages that have similar binding properties and are metabolized similarly to the reference nucleotide. includes. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2-O-methylribonucleotides, and peptide-nucleic acids (PNAs).
[0105] Unless otherwise indicated, a particular nucleic acid sequence implicitly encompasses not only the explicitly stated sequence but also conservatively modified variations (e.g., degenerate codon substitutions) and complementary sequences of that nucleic acid sequence. . Specifically, as detailed below, a degenerate codon substitution is one in which the third position of one or more selected (or all) codons is replaced with a mixed base and / or a deoxyinosine residue. (Batzer et al., 1991, Nucleic Acid Res. 19:5081; Ohtsuka et al., 1985, J. Biol. Chem. 260:2605-2608; and Rossolini et al. .,1994,Mol.Cell.Probes 8:91-98).
[0106] Operaably linked: The term "operably linked" refers to a functional relationship between two or more peptide or polypeptide domains or nucleic acid (eg, DNA) segments. The term "operably linked" in the context of fusion proteins or other polypeptides means that two or more amino acid segments are linked to produce a functional polypeptide. For example, in the context of an antigen binding molecule, separate ABMs (or chains of ABMs) can be operably linked via a peptide linker sequence. In the context of nucleic acids encoding a fusion protein, such as a polypeptide chain of an antigen-binding molecule, "operably linked" means that the two nucleic acids are such that the amino acid sequences encoded by the two nucleic acids remain in frame. means to be combined so that In the context of transcriptional regulation, the term refers to the functional relationship of transcriptional regulatory sequences to transcribed sequences. For example, a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or regulates transcription of the coding sequence in a suitable host cell or other expression system.
[0107] Pentavalent: The term "pentavalent" when used herein in reference to an antigen binding molecule (eg, TBM) refers to an antigen binding molecule having five antigen binding domains. The pentavalent TBMs of the present disclosure generally include (a) two pairs of antigen-binding domains that each bind the same antigen and a single antigen-binding domain that binds a third antigen, or (b) a single antigen-binding domain that binds the same antigen. It has either three antigen binding domains and two antigen binding domains each binding a separate antigen. An example of a pentavalent TBM is schematically shown in Figure 1T.
[0108] Polypeptides and proteins: The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term encompasses amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding natural amino acid, as well as natural amino acid polymers and non-natural amino acid polymers. Additionally, the term includes, for example, synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, linkers to other molecules, proteins or protein domains. Includes amino acid polymers that are derivatized by fusion and addition of peptide tags or labels.
[0109] Recognize: As used herein, the term "recognize" refers to an ABM that finds and interacts with (eg, binds to) its epitope.
[0110] Sequence identity: Sequence identity between two similar sequences (e.g., antibody variable domains) is determined by Smith, T.F. & Waterman, M.S. (1981) “Comparison Of Biosequences”, Adv. Appl. Math. 2:482 Needleman, S.B. & Wunsch, CD. (1970) “A General Method Applicable To the Search For Similarities In Amino Acid Sequence Of Two Proteins”, J. Mol. Biol. 48:443 [Homology Alignment Algorithm] , Pearson, W.R. & Lipman, D.J. (1988) “Improved Tools For Biological Sequence Comparison”, Proc. Natl. Acad. Sci. (U.S.A.) 85:2444 [Similarity Search Method]; Measured by an algorithm such as that of “Basic Local Alignment Search Tool”, J.Mol.Biol.215:403-10, “BLAST” algorithm (see blast.ncbi.nlm.nih.gov / Blast.cgi) can be done. When using any of the above algorithms, default parameters (window length, gap penalty, etc.) are used. In one embodiment, sequence identity is determined using the BLAST algorithm using default parameters.
[0111] Optionally, identity spans a region of length of at least about 50 nucleotides (or in the case of a peptide or polypeptide, at least about 10 amino acids) or in some cases 100 to 500 or 1000 or more nucleotides (or 20 , 50, 200 or more amino acids) in length. In certain embodiments, identity is determined over a defined domain, eg, the VH or VL of the antibody. Unless otherwise specified, sequence identity between two sequences is determined over the entire length of the shorter of the two sequences.
[0112] Single Chain Fab or scFab: The terms "single chain Fab" and "scFab" refer to the antibody heavy chain variable domain (VH), antibody Refers to a polypeptide comprising constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker. In certain embodiments, the antibody domains and linkers are in one of the following orders from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL. The linker can be a polypeptide of at least 30 amino acids, such as 32-50 amino acids. Single-chain Fabs are stabilized by natural disulfide bonds between the CL and CH1 domains.
[0113] Single-chain Fv or scFv: The term "single-chain Fv" or "scFv" as used herein refers to an antibody fragment that comprises the VH and VL domains of an antibody; these domains are part of a single polypeptide. Exists in chains. The Fv polypeptide can further include a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. For a review of scFvs, see Plueckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., 1994, Springer-Verlag, New York, pp. 269-315.
[0114] Specifically (or selectively) binds: The term “specifically (or selectively) binds” to an antigen or epitope refers to refers to the binding reaction that determines the existence of This binding reaction may, but need not, be mediated by an antibody or antibody fragment, but by any type of ABM described in Section 7.2.1, such as a ligand, DARPin. ABM is typically less than 5 x 10-2M, less than 10-2M, less than 5 x 10-3M, less than 10-3M, less than 5 x 10-4M, less than 10-4M, less than 5 x 10-5M , less than 10-5M, less than 5 x 10-6M, less than 10-6M, less than 5 x 10-7M, less than 10-7M, less than 5 x 10-8M, less than 10-8M, less than 5 x 10-9M or 10 It also has a dissociation rate constant (KD) (koff / kon) of less than -9M and binds to a target antigen with an affinity that is at least two times higher than its affinity for binding non-specific antigens (eg, HSA). Binding affinity can be measured using Biacore, SPR or BLI assays. The term "specifically binds" does not exclude cross-species cross-reactivity. For example, an antigen-binding module (e.g., an antigen-binding fragment of an antibody) that "specifically binds" to an antigen from one species also "specifically binds" to that antigen in one or more other species. obtain. Therefore, such cross-species cross-reactivity in and of itself does not change the classification of the antigen-binding module as a "specific" binding agent. In certain embodiments, the antigen binding module that specifically binds human antigens is derived from one or more non-human mammalian species, such as primate species (Macaca fascicularis, Macaca mulatta, and Macaca nemestrina). ) or rodent species, such as Mus musculus. In other embodiments, the antigen binding module does not have cross-species cross-reactivity.
[0115] Subject: The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, mammals and non-mammals such as non-human primates, sheep, dogs, cows, chickens, amphibians and reptiles. Unless otherwise specified, the terms "patient" or "subject" are used interchangeably herein.
[0116] Tandem of VH domains: As used herein, the term "tandem of VH domains (or VH)" refers to a series of VH domains consisting of multiples of the same VH domain in an antibody. Each of the VH domains has its C-terminus linked to the N-terminus of another VH domain with or without a linker, except for the last one at the ends of the tandem. A tandem has at least two VH domains, and in certain embodiments of the antigen binding module has 3, 4, 5, 6, 7, 8, 9 or 10 VH domains. VH tandems can be created using recombinant methods (e.g., as described in Section 7.2.2.3) with or without linkers that allow them to be created as a single polypeptide chain. can be generated by combining the encoding nucleic acids for each VH domain in sequence. The N-terminus of the first VH domain of a tandem is defined as the N-terminus of the tandem, while the C-terminus of the last VH domain of a tandem is defined as the C-terminus of the tandem.
[0117] VL domain tandem: As used herein, the term "VL domain (or VL) tandem" refers to a series of VL domains consisting of multiples of the same VL domain in an antibody. Each of the VL domains has its C-terminus linked to the N-terminus of another VL with or without a linker, except for the last one at the ends of the tandem. A tandem has at least two VL domains, and in certain embodiments of the antigen binding module has 3, 4, 5, 6, 7, 8, 9 or 10 VL domains. VL tandems can be created using recombinant methods (e.g., as described in Section 7.2.2.3) with or without linkers that allow them to be created as a single polypeptide chain. can be generated by joining the encoding nucleic acids for each VL domain in sequence. The N-terminus of the first VL domain of a tandem is defined as the N-terminus of the tandem, while the C-terminus of the last VL domain of a tandem is defined as the C-terminus of the tandem.
[0118] Target antigen: As used herein, "target antigen" refers to a molecule that is non-covalently, reversibly and specifically bound by an antigen binding domain.
[0119] Tetravalent: The term "tetravalent" when used herein in reference to an antigen binding molecule (eg, BBM or TBM) refers to an antigen binding molecule that has four antigen binding domains. The quadrivalent TBMs of the present disclosure generally have two antigen-binding domains that bind the same antigen (e.g., CD19) and each bind a separate antigen (e.g., a component of the TCR complex and either CD2 or TAA). It has two antigen-binding domains. Examples of quadrivalent BBMs are schematically shown in FIGS. 1AA to 1AH, and examples of quadrivalent TBMs are schematically shown in FIGS. 2Q to 2S.
[0120] Therapeutically Effective Amount: A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time, necessary to achieve the desired therapeutic result.
[0121] Treat, treat, treat: As used herein, the terms "treat," "treatment," and "treating" refer to the progression, severity, or severity of a disease or disorder (e.g., B-cell malignancy). reduction in severity and / or duration or remission or progression of one or more symptoms (e.g., one or more discernible symptoms) of the disorder (e.g., CRS) resulting from administration of one or more anti-CD19 agents; Refers to remission in severity and / or duration. In certain embodiments, the terms "treat," "treatment," and "treating" refer to an improvement in at least one measurable physical parameter of a disease, such as tumor growth, not necessarily identified by the patient. In other embodiments, the terms "treat", "treatment" and "treating" refer to physically, e.g., by stabilization of an identifiable symptom, physiologically, e.g., by stabilization of a physical parameter, or Both refer to the inhibition of the progression of either disease. In some embodiments, the terms "treat," "treatment," and "treating" can refer to reducing or stabilizing tumor size or cancerous cell number.
[0122] Trispecific binding molecule: The term "trispecific binding molecule" or "TBM" refers to a molecule that specifically binds three antigens and that contains three or more antigen binding domains. The TBM of the present disclosure includes at least one antigen-binding domain specific for CD19, at least one antigen-binding domain specific for a component of the TCR complex, and at least one antigen-binding domain specific for CD2 or TAA. including. The antigen binding domains can each independently be an antibody fragment (eg, scFv, Fab, Nanobody), a ligand, or a non-antibody-derived binding agent (eg, fibronectin, Fynomer, DARPin). A typical TBM is illustrated in Figure 1. A TBM may contain 1, 2, 3, 4 or more polypeptide chains. For example, the TBM illustrated in Figure 1M comprises a single polypeptide chain, one single polypeptide chain comprising three scFvs connected by ABM linkers. The TBM illustrated in Figure 1K contains, inter alia, two polypeptide chains containing three scFvs linked by an Fc domain. The TBM illustrated in FIG. 1J comprises, inter alia, three polypeptide chains forming an scFv, a ligand and a Fab, linked by an Fc domain. The TBM illustrated in Figure 1C contains, inter alia, four polypeptide chains forming three Fabs, linked by Fc domains. The TBM illustrated in Figure 1U contains, inter alia, six polypeptide chains forming four Fabs and two scFvs, linked by Fc domains.
[0123] Trivalent: The term "trivalent" when used herein in reference to an antigen binding molecule (eg, MBM) refers to an antigen binding molecule having three antigen binding domains. MBMs of the present disclosure are typically bispecific or trispecific. Bispecific BBMs specifically bind to CD19 and components of the TCR complex. Trispecific TBMs specifically bind to CD19, a component of the TCR complex and CD2 or TAA. Thus, the trivalent BBM has three antigen binding domains, two of which bind CD19 and one of which binds a component of the TCR, or vice versa. TBM has three antigen-binding domains, each binding a different antigen. Examples of trivalent BBMs are shown schematically in FIGS. 1G to 1Z, and examples of trivalent TBMs are shown schematically in FIGS. 2B to 2V.
[0124] Tumor: The term "tumor" is used herein synonymously with the term "cancer," eg, both terms encompass fluid, eg, diffuse or circulating tumors.
[0125] Tumor-associated antigen: The term "tumor-associated antigen" or "TAA" refers to whole or fragment molecules (typically proteins, carbohydrates, lipids or some combination thereof) expressed on the surface of cancer cells (e.g. MHC / peptides). ) refers to any molecule useful for preferentially targeting pharmacological agents to cancer cells. In some embodiments, the TAA is a marker expressed on both normal and cancer cells, such as a lineage marker, such as CD19 on B cells. In some embodiments, the TAA is overexpressed in cancer cells compared to normal cells, such as 1-fold overexpression, 2-fold overexpression, 3-fold overexpression, or It is a cell surface molecule that is overexpressed. In some embodiments, the TAA is a cell surface molecule that is inappropriately synthesized in cancer cells, eg, a molecule that contains deletions, additions, or mutations compared to molecules expressed in normal cells. In some embodiments, the TAA will be expressed only on the cell surface of cancer cells, either whole or as fragments (e.g., MHC / peptides), and will not be synthesized or expressed on the surface of normal cells. . Accordingly, the term "TAA" encompasses antigens specific to cancer cells, sometimes referred to as tumor-specific antigens ("TSA"). Although CD19 has characteristics of a tumor-associated antigen, the terms "tumor-associated antigen" and "TAA" are used throughout this disclosure to refer to molecules other than CD19.
[0126] Variable region: As used herein, "variable region" or "variable domain" means Refers to a region of an immunoglobulin that substantially comprises one or more encoded Ig domains and contains CDRs that confer antigen specificity. A "variable heavy chain domain" may be paired with a "variable light chain domain" to form an antigen binding domain ("ABD") or an antigen binding module ("ABM"). Furthermore, each variable domain consists of three hypervariable regions (“complementarity determining regions”, “CDR ) (CDR-H1, CDR-H2, CDR-H3 for the variable heavy chain domain and CDR-L1, CDR-L2, CDR-L3 for the variable light chain domain) and four framework (FR) regions.
[0127] Vector: The term "vector" is intended to refer to a polynucleotide molecule capable of transporting another polynucleotide to which it is linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication within a host cell into which they are introduced (eg, bacterial vectors having bacterial origins of replication and episomal mammalian vectors). Other vectors (eg, non-episomal mammalian vectors) can be integrated into the host cell's genome upon introduction into the host cell, thereby replicating along with the host genome. Additionally, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). Generally, expression vectors useful in recombinant DNA technology are often in the form of plasmids. In this specification, "plasmid" and "vector" may be used interchangeably, as the plasmid is the most commonly used form of vector. However, this disclosure is intended to include such other forms of expression vectors such as viral vectors (eg, replication-defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.
[0128] VH: The term "VH" refers to the variable region of an immunoglobulin heavy chain of an antibody, including the heavy chain of an Fv, scFv, dsFv or Fab.
[0129] VL: The term "VL" refers to the variable region of an immunoglobulin light chain, including the light chain of an Fv, scFv, dsFv or Fab.
[0130] VH-VL or VH-VL pair: With reference to a VH-VL pair, whether on the same or different polypeptide chains, the terms "VH-VL" and "VH-VL pair" are used for convenience. , is not intended to indicate any particular orientation unless the context requires otherwise. Thus, an scFv comprising a "VH-VL" or "VH-VL pair" can have the VH and VL domains in any orientation, eg, VH N-terminus to VL or VL N-terminus to VH.
[0131] 7.2. Monospecific and multispecific CD19 binding molecules In some embodiments, the anti-CD19 agents used in the methods and combinations of the present disclosure are monospecific molecules that bind human CD19. For example, the monospecific binding molecule can be an antibody or an antigen-binding fragment thereof (e.g., an antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab')2 or single domain antibody (SDAB). In addition, the CD19 binding molecule can be a multispecific molecule, such as a bispecific or trispecific binding molecule.
[0132] In certain embodiments, the CD19 binding molecule is a chimeric or humanized monoclonal antibody. Chimeric and / or humanized antibodies can be engineered to minimize immune responses by human patients to antibodies produced in non-human subjects or obtained from expression of non-human antibody genes. Chimeric antibodies contain non-human animal antibody variable regions and human antibody constant regions. Such antibodies retain the epitope binding specificity of the original monoclonal antibody, but when administered to humans, may be less immunogenic and therefore more likely to be tolerated by patients. For example, one or all (e.g., one, two, or three) of the light chain variable regions of a murine antibody (e.g., a murine monoclonal antibody) and / or one or all of the heavy chain variable regions (e.g., one, two or three) can each be linked to a human constant region, such as, but not limited to, an IgG1 human constant region. Chimeric monoclonal antibodies can be produced by known recombinant DNA techniques. For example, genes encoding constant regions of non-human antibody molecules can be replaced with genes encoding human constant regions (Robinson et al., PCT Patent Publication No. PCT / US86 / 02269; Akira et al., European Patent Application No. 184,187). or European Patent Application No. 171,496 of Taniguchi, M.). Additionally, other suitable techniques that can be used to generate chimeric antibodies include, for example, U.S. Pat. No. 4,816,567; U.S. Pat. No. 4,978,775; U.S. Pat. It is described in.
[0133] Chimeric or humanized antibodies and antigen-binding fragments thereof can be prepared based on the sequences of murine monoclonal antibodies. DNA encoding heavy and light chain immunoglobulins can be obtained from mouse hybridomas of interest and engineered to include non-murine (eg, human) immunoglobulin sequences using standard molecular biology techniques. For example, to generate chimeric antibodies, murine variable regions can be linked to human constant regions using known methods (see, eg, US Pat. No. 4,816,567 to Cabilly et al.). To generate humanized antibodies, mouse CDR regions can be inserted into human frameworks using known methods. See, for example, U.S. Pat. No. 5,225,539 to Winter and U.S. Pat. No. 5,530,101 to Queen et al.; Please refer.
[0134] Humanized antibodies can be produced by CDR grafting (e.g., EP 239,400; WO 91 / 09967; and U.S. Pat. Nos. 5,225,539, 5,530,101 and 5,585,089). EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4). / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6): 805-814; (chain shuffling) (see e.g. U.S. Pat. No. 5,565,332) and e.g. Specification, US Patent No. 5,766,886, International Publication No. WO 9317105 pamphlet, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13 (5):353-60(2000), Morea et al.,Methods,20(3):267-79(2000),Baca et al.,J.Biol.Chem.,272(16):10678-84 (1997), Roguska et al., Protein Eng.,9(10):895-904(1996), Couto et al.,Cancer Res.,55(23 Supp):5973s-5977s(1995), Couto et al. .,Cancer Res.,55(8):1717-22(1995), Sandhu J S,Gene,150(2):409-10(1994) and Pedersen et al.,J.Mol.Biol.,235(3 ):959-73 (1994). In many cases, framework residues in the framework regions are substituted with corresponding residues from the CDR donor antibody to alter, eg, improve antigen binding. These framework substitutions, e.g. conservative substitutions, can be made by well-known methods, e.g. modeling of interactions between CDRs and framework residues to identify framework residues important for antigen binding and aberrations at specific positions. identified by sequence comparison to identify unique frameworks. (See, eg, Queen et al., US Pat. No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323).
[0135] As provided herein, a humanized antibody or antibody fragment may contain one or more CDR and framework regions from a non-human immunoglobulin molecule, wherein the amino acid residues comprising the framework are germlined. wholly or largely derived from Multiple techniques for humanization of antibodies or antibody fragments are well known, including the method of Winter and coworkers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332 :323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), replacing CDR sequences for rodent CDRs or the corresponding sequences of human antibodies, i.e., CDR grafting. (European Patent No. 239,400; PCT Publication No. WO 91 / 09967 pamphlet; and U.S. Patent No. 4,816,567; U.S. Patent No. 6,331,415; U.S. Patent No. 5,225,539; U.S. Patent No. 5,530,101 ; 5,585,089; 6,548,640). In such humanized antibodies and antibody fragments, substantially less than the intact human variable domain is replaced with corresponding sequences from a non-human species. Humanized antibodies are often human antibodies in which some CDR residues and optionally some framework (FR) residues are replaced with residues from similar sites in rodent antibodies. Humanization of antibodies and antibody fragments can be achieved by veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS, 91:969-973 (1994)) or by chain shuffling (U.S. Pat. No. 5,565,332). can also be achieved.
[0136] The selection of human variable domains, both light and heavy chains, used to generate humanized antibodies will reduce antigenicity. Following the so-called "best-fit" method, the sequences of rodent antibody variable domains are screened against an entire library of known human variable domain sequences. The human sequence closest to the rodent sequence is then accepted as the human framework (FR) for humanized antibodies (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (e.g. Nicholson et al.Mol.Immun.34(16-17):1157-1165(1997); Carter et al., Proc. Natl. See Acad.Sci.USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993). In some embodiments, all of the framework regions, e.g., the heavy chain variable region. The four framework regions of are derived from the VH4_4-59 germline sequence. In one embodiment, the framework regions are derived from, for example, 1, 2, 3, 4 or 5 modifications from amino acids in the corresponding murine sequence, For example, substitutions may be included, such as conservative substitutions. In one embodiment, the framework regions, such as all four framework regions of the light chain variable region, are derived from VK3_1.25 germline sequences. In one embodiment: The framework regions may contain, for example, 1, 2, 3, 4 or 5 modifications, eg substitutions, eg conservative substitutions, from amino acids in the corresponding murine sequence.
[0137] In certain embodiments, the CD19 binding molecule comprises a heavy chain variable region from a particular germline heavy chain immunoglobulin gene and / or a light chain variable region from a particular germline light chain immunoglobulin gene. For example, such an antibody may comprise or consist of a human antibody that includes a heavy or light chain variable region that is "a product of" or "derived from" a particular germline sequence. A human antibody that is a "product of" or "derived from" a germline immunoglobulin sequence is determined by comparing the amino acid sequence of the human antibody with the amino acid sequence of the germline immunoglobulin (using the methods outlined herein). The sequence can be identified by selecting the germline immunoglobulin sequence with the closest (ie, highest % identity) sequence to that of a human antibody (using a human antibody). A human antibody that is "the product of" or "derived from" a particular germline immunoglobulin sequence is a human antibody that is "the product of" or "derived from" a particular germline immunoglobulin sequence, for example, due to natural somatic mutations or the deliberate introduction of site-directed mutations. Comparisons may include amino acid differences. However, humanized antibodies typically have an amino acid sequence that is at least 90% identical to the amino acid sequence encoded by a germline immunoglobulin gene and that has germline immunoglobulin amino acid sequences of other species (e.g., mouse reproductive contains amino acid residues that identify the antibody as derived from human sequences when compared to the sequence sequence). In some cases, the humanized antibody has an amino acid sequence that is at least 95, 96, 97, 98 or 99%, or at least 96%, 97%, 98% or 99% the amino acid sequence encoded by a germline immunoglobulin gene. They can be the same. Typically, humanized antibodies derived from a particular germline sequence exhibit no more than 10 to 20 amino acid differences from the amino acid sequence encoded by the germline immunoglobulin gene (as defined herein, any skew). ), before the introduction of pI and ablation mutations; ie, the number of mutations is generally lower before the introduction of the mutations of the present disclosure). In some cases, the humanized antibody may exhibit no more than 5, or no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene (again, any distortion herein, prior to the introduction of pI and ablation mutations; ie, the number of mutations is generally lower prior to the introduction of the mutations of the present disclosure).
[0138] In one embodiment, the parent antibody is affinity matured. For example, structure-based methods can be used for humanization and affinity maturation, as described in US patent application Ser. No. 11 / 004,590. Wu et al.,1999,J.Mol.Biol.294:151-162;Baca et al.,1997,J.Biol.Chem.272(16):10678-10684;Rosok et al.,1996,J. Biol.Chem.271(37):22611-22618;Rader et al.,1998,Proc.Natl.Acad.Sci.USA 95:8910-8915;Krauss et al.,2003,Protein Engineering 16(10):753 Selection-based methods can be used to humanize and / or affinity mature antibody variable regions, including, but not limited to, those described in US Pat. The method described in U.S. Patent No. 09 / 810,510; Tan et al., 2002, J. Immunol. 169:1119-1125; Other humanization methods, including but not limited to, may involve grafting only a portion of the CDR.
[0139] In certain embodiments, the CD19 binding molecule comprises an ABM that is a Fab. Fab domains can be produced by proteolytic cleavage of immunoglobulin molecules using enzymes such as papain or by recombinant expression. Fab domains typically include a CH1 domain linked to a VH domain paired with a CL domain linked to a VL domain. In wild-type immunoglobulins, the VH domain pairs with the VL domain to constitute the Fv region, and the CH1 domain pairs with the CL domain to further stabilize the binding module. Disulfide bonds between the two constant domains may further stabilize the Fab domain.
[0140] In certain embodiments, the CD19 binding molecule comprises an ABM that is a scFab. In one embodiment, the antibody domains and linkers in the scFab fragment are in one of the following orders from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, or b) VL-CL-linker. -VH-CH1. In some cases, VL-CL-linker-VH-CH1 is used.
[0141] In another embodiment, the antibody domains and linkers in the scFab fragment are in one of the following order from N-terminus to C-terminus: a) VH-CL-linker-VL-CH1 or b) VL-CH1-linker. -Has VH-CL.
[0142] Optionally, in the scFab fragment, in addition to the natural disulfide bond between the CL-domain and the CH1 domain, the antibody heavy chain variable domain (VH) and the antibody light chain variable domain (VL) are located at the following positions: i ) heavy chain variable domain position 44 and light chain variable domain position 100, ii) heavy chain variable domain position 105 and light chain variable domain position 43, or iii) heavy chain variable domain position 101 and light chain variable domain position 100 (Kabat) Disulfide stabilization is also achieved by the introduction of disulfide bonds between (numbering according to the EU index).
[0143] Such further disulfide stabilization of scFab fragments is achieved by the introduction of disulfide bonds between the variable domains VH and VL of single chain Fab fragments. Techniques for introducing non-natural disulfide bridges for stabilization of single-chain Fv are described, for example, in WO 94 / 029350, Rajagopal et al., 1997, Prot. Engin. 10:1453-59; Kobayashi et al., 1998, Nuclear Medicine & Biology, 25:387-393; and Schmidt, et al., 1999, Oncogene 18:1711-1721. In one embodiment, the optional disulfide bond between the variable domains of the scFab fragment is between position 44 of the heavy chain variable domain and position 100 of the light chain variable domain. In one embodiment, the optional disulfide bond between the variable domains of the scFab fragment is between heavy chain variable domain position 105 and light chain variable domain position 43 (numbering according to Kabat's EU index).
[0144] In certain embodiments, the CD19 binding molecule comprises ABM, which is an scFv. Single-chain Fv antibody fragments contain the VH and VL domains of an antibody in a single polypeptide chain and can be expressed as a single-chain polypeptide and retain the specificity of the intact antibody from which it is derived. hold. Generally, scFv polypeptides further include a polypeptide linker between the VH and VL domains that allows the scFv to form the desired structure for target binding. Examples of suitable linkers for joining the VH and VL chains of the scFV are any of the ABM linkers specified in Section 7.2.2.3, such as the linkers designated as L1 to L58.
[0145] Unless otherwise specified, as used herein, an scFv can have the VL and VH variable regions in any order, e.g., with respect to the N-terminus and C-terminus of the polypeptide; It may contain a VH or it may contain a VH-linker-VL.
[0146] To generate scFv-encoding nucleic acids, the VH- and VL-encoding DNA fragments encode a linker, e.g. etc.), with the VL and VH regions joined by a flexible linker, such that the VH and VL sequences can be expressed as a continuous single-chain protein. (e.g., Bird et al., 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al., 1990, Nature 348 :552-554).
[0147] CD19 binding molecules can also include ABMs that are Fv, dsFv, (Fab')2, single domain antibodies (SDAB), VH or VL domains or camelid VHH domains (also called nanobodies).
[0148] CD19 binding molecules can include single domain antibodies composed of a single VH or VL domain that exhibits sufficient affinity for CD19. In one embodiment, the single domain antibody is a camelid VHH domain (see, eg, Riechmann, 1999, Journal of Immunological Methods 231:25-38; WO 94 / 04678).
[0149] Tables 1A-1C (collectively “Table 1”) list sequences of exemplary CD19 binding sequences that may be included in a CD19 binding molecule.
[0150] The sequences listed in Table 1A are based on the CD19 antibody NEG258.
[0151]
table 1
[0152] In some embodiments, the CD19 binding molecule comprises the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences of NEG258 listed in Table 1A. CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences include Kabat (SEQ ID NO: 17-19 and 4-6, respectively), Chothia (SEQ ID NO: 20-22 and 7, respectively). ~9), or IMGT (SEQ ID NOs: 23-25 and 10-12, respectively), or CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences of Chothia and Kabat combinations (SEQ ID NOs: 14-16 and 1-3, respectively). The CD19 binding molecule may also include the light chain variable sequence (SEQ ID NO: 26) and / or the heavy chain variable sequence (SEQ ID NO: 13) of the anti-CD19 antibody NEG258 described in Table 1A.
[0153] The sequences listed in Table 1B are based on the CD19 antibody NEG218.
[0154] [Table 2]
[0155] In some embodiments, the CD19 binding molecule comprises the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences of NEG218 listed in Table 1B. The CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences are Kabat (SEQ ID NOs: 43-45 and 30-32, respectively), Chothia (SEQ ID NOs: 46-48 and 33, respectively). ~35), or IMGT (SEQ ID NOs: 49-51 and 36-38, respectively), or CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences of Chothia and Kabat combinations (SEQ ID NOs: 40-42 and 27-29, respectively). The CD19 binding molecule may also include the light chain variable sequence (SEQ ID NO: 52) and / or the heavy chain variable sequence (SEQ ID NO: 39) of the anti-CD19 antibody NEG218 described in Table 1B.
[0156] Exemplary CD19 binding molecules having the CDR sequences listed in Tables 1A and 1B are provided in Tables 20A-1 through 20D.
[0157] Additionally, exemplary CDR and variable domain sequences that can be incorporated into CD19 binding molecules are listed in Table 1C.
[0158] [Table 3]
[0159] [Table 4]
[0160] [Table 5]
[0161] [Table 6]
[0162] In certain embodiments, the CD19 binding molecules have heavy chain CDRs having the amino acid sequences of CD19-H1, CD19-H2A, and CD19-H3 set forth in Table 1C and CD19-L1, CD19-L2, and CD19-L2 set forth in Table 1C. Contains a light chain CDR with the amino acid sequence of CD19-L3. In certain embodiments, the CD19 binding molecule comprises a heavy chain variable region having the amino acid sequence of VHA set forth in Table 1C and a light chain variable region having the amino acid sequence of VLA set forth in Table 1C.
[0163] In other embodiments, the CD19 binding molecules include heavy chain CDRs having the amino acid sequences of CD19-H1, CD19-H2B, and CD19-H3 set forth in Table 1C and CD19-L1, CD19-L2, and CD19-L2 set forth in Table 1C. Contains a light chain CDR with the amino acid sequence of CD19-L3. In certain embodiments, the CD19 binding molecule comprises a heavy chain variable region having the amino acid sequence of VHB set forth in Table 1C and a light chain variable region having the amino acid sequence of VLB set forth in Table 1C.
[0164] In a further aspect, the CD19 binding molecule comprises a heavy chain CDR having the amino acid sequences of CD19-H1, CD19-H2C and CD19-H3 as set forth in Table 1C and CD19-L1, CD19-L2 and CD19-L2 as set forth in Table 1C. Contains a light chain CDR with the amino acid sequence of CD19-L3. In certain embodiments, the CD19 binding molecule comprises a heavy chain variable region having the amino acid sequence of a VHC set forth in Table 1C and a light chain variable region having the amino acid sequence of a VLB set forth in Table 1C.
[0165] In a further embodiment, the CD19 binding molecule comprises a heavy chain CDR having the amino acid sequences of CD19-H1, CD19-H2D and CD19-H3 as set forth in Table 1C and CD19-L1, CD19-L2 and CD19-L2 as set forth in Table 1C. Contains a light chain CDR with the amino acid sequence of CD19-L3. In certain embodiments, the CD19 binding molecule comprises a heavy chain variable region having the amino acid sequence of a VHD set forth in Table 1C and a light chain variable region having the amino acid sequence of a VLB set forth in Table 1C.
[0166] In a further embodiment, the CD19 binding molecule is in the form of a scFV. An exemplary anti-CD19 scFv comprises the amino acid sequence of any one of CD19-scFv1-CD19-scFv12 listed in Table 1C.
[0167] Other CD19 binding molecules are mutated but have amino acids in the CDR region that have at least 80, 85, 90, 95, 96, 97, 98 or 99 percent identity with the CDR sequences listed in Table 1. including. In certain embodiments, such CD19 binding molecules have no more than 1, 2, 3, 4 or 5 amino acids mutated in the CDR region when compared to the CDR sequences listed in Table 1. , containing a mutant amino acid sequence.
[0168] Other CD19 binding molecules include VH and / or amino acid sequences that have at least 80, 85, 90, 95, 96, 97, 98 or 99 percent identity to the VH and / or VL sequences listed in Table 1. Contains VL domains. In certain embodiments, the CD19 binding molecule has 1, 2, 3, 4 or 5 or fewer amino acids present in the VH and / or sequences set forth in Table 1 while retaining substantially the same therapeutic activity. Contains VH and / or VL domains that are mutated when compared to VL domains.
[0169] Additional CD19 binding molecules can be generated by gene-shuffling, motif-shuffling, exon-shuffling and / or codon-shuffling (collectively referred to as "DNA shuffling") techniques. DNA shuffling can be used to modify the activity of molecules of the disclosure or fragments thereof (eg, molecules or fragments thereof with higher affinity and lower dissociation rate). See generally U.S. Pat. No. 5,605,793, U.S. Pat. No. 5,811,238, U.S. Pat. 8:724-33;Harayama,1998,Trends Biotechnol.16(2):76-82;Hansson et al.,1999,J.Mol.Biol.287:265-76;and Lorenzo and Blasco,1998,Biotechniques 24 (2):308-313. The CD19 binding molecules or fragments thereof described herein can be modified prior to recombination by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion, or other methods. A polynucleotide encoding a fragment of a CD19 binding molecule described herein can be recombined with one or more components, motifs, sections, moieties, domains, fragments, etc. of one or more heterologous molecules.
[0170] Additionally, CD19 binding molecules can be fused to marker sequences, such as peptides, to facilitate purification. In certain embodiments, the marker amino acid sequence is a hexahistidine peptide (SEQ ID NO: 1253), such as the tag provided in the pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others. Many of them are commercially available. For example, hexahistidine (SEQ ID NO: 1253) provides convenient purification of fusion proteins, as described in Gentz et al., 1989, Proc. Natl. Acad. Sci. USA 86:821-824. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin (“HA”) tag, which corresponds to an epitope derived from influenza hemagglutinin protein (Wilson et al., 1984, Cell 37:767). and "flag" tags.
[0171] A variety of other CD19 binding molecules, some of which are monospecific and some of which are multispecific, are known in the art and described in the present disclosure. It can also be used in methods and combinations. For example, WO 2014 / 031687 pamphlet; WO 2012 / 079000 pamphlet; WO 2014 / 153270 pamphlet; US Patent No. 7,741,465; Naddafi et al., 2015, Int J Mol Cell Med. 4(3):143-151; and Hammer, 2012, MAbs.4(5):571-577, the contents of which are incorporated herein by reference. In certain embodiments, the CD19 binding molecule is blinatumomab (Amgen), cortuximab brutansine (Immunogen), MOR208 (also known as XmAb-5574; Morphosys), MEDI-551 (MedImmune), denintuzumab mafodotin ( Also called SGN-CD19A; Seattle Genetics), DI-B4 (Merck Serono), tapritumomab paptox (National Cancer Institute), XmAb5871 (Xencor), MDX-1342 (Bristol-Myers Squibb), AFM11 (Affimed), MDX-1342 (BMS), roncastuximab tesirin (ADC Therapeutics) or GBR401 (Glenmark).
[0172] 7.2.1. Antigen binding module of multispecific binding molecules In some embodiments, one or more of the molecules used in the methods and combinations of the present disclosure are multispecific binding molecules. For example, a CD19 binding molecule, in some embodiments, can be a multispecific binding molecule (MBM), such as a bispecific binding molecule (BBM) or a trispecific binding molecule (TBM). Typically, one or more ABMs of an MBM include an immunoglobulin-based antigen binding domain, such as an antibody fragment sequence or derivative. These antibody fragments and derivatives typically include the CDRs of the antibody and may include larger fragments and derivatives thereof, such as Fabs, scFabs, Fvs and scFvs.
[0173] Immunoglobulin-based ABMs may include modifications to framework residues within the VH and / or VL, eg, to improve the properties of the MBM comprising the ABM. For example, framework modifications can be made to reduce the immunogenicity of MBM. One approach to making such framework modifications is to "backmutate" one or more framework residues of the ABM to the corresponding germline sequence. Such residues can be identified by comparing the framework sequence to the germline sequence from which the ABM is derived. To "match" framework region sequences to a desired germline configuration, residues can be "backmutated" to the corresponding germline sequence, eg, by site-directed mutagenesis. MBMs having such "backmutated" ABMs are intended to be encompassed by this disclosure.
[0174] Another type of framework modification involves mutating one or more residues within the framework region or even within one or more CDR regions to eliminate T cell epitopes, thereby potentially immunizing MBM. It involves reducing the primordial properties. This approach is also referred to as "deimmunization" and is described in more detail in US Patent Application Publication No. 20030153043 by Carr et al.
[0175] ABM may also be modified to exhibit altered glycosylation, which may be useful, for example, to increase the affinity of MBM for one or more of its antigens. Such carbohydrate modifications can be accomplished, for example, by altering one or more glycosylation sites within the ABM sequence. For example, one or more amino acid substitutions can be made that result in the elimination of one or more variable region framework glycosylation sites, thereby eliminating glycosylation at that site. Such deglycosylation may increase the affinity of MBM for antigen. Such techniques are described, for example, in Co et al., US Pat. No. 5,714,350 and US Pat. No. 6,350,861.
[0176] 7.2.1.1. Immunoglobulin-based ABM 7.2.1.1.1.Fab In certain embodiments, the ABM is a Fab domain.
[0177] For the MBMs of the present disclosure, it is advantageous to use a Fab heterodimerization approach to allow precise association of Fab domains belonging to the same ABM and minimize aberrant pairing of Fab domains belonging to different ABMs. It is. For example, the Fab heterodimerization approach shown in Table 2 below can be used.
[0178] [Table 7]
[0179] Thus, in certain embodiments, a suitable association between two polypeptides of a Fab is, for example, exchanging the VL and VH domains of the Fab with each other as described in WO 2009 / 080251, or Facilitated by exchanging the CH1 and CL domains with each other.
[0180] Suitable Fab pairings introduce one or more amino acid modifications into the CH1 domain and one or more amino acid modifications into the CL domain of the Fab, and / or one or more amino acid modifications into the VH domain. It may also be facilitated by introducing one or more amino acid modifications into the VL domain. The amino acids that are modified are typically part of the VH:VL and CH1:CL boundaries so that the Fab components pair preferentially with each other rather than with other Fab components.
[0181] In one embodiment, the one or more amino acid modifications are limited to conserved framework residues of the variable (VH, VL) and constant (CH1, CL) domains, as indicated by Kabat numbering of the residues. . Almagro, 2008, Frontiers In Bioscience 13:1619-1633 provides definitions of framework residues based on the Kabat, Chothia and IMGT numbering schemes.
[0182] In one embodiment, the modifications introduced in the VH and CH1 and / or VL and CL domains are complementary to each other. Complementarity at the heavy and light chain boundaries can be achieved based on steric and hydrophobic contacts, electrostatic / charge interactions or a combination of various interactions. Complementarity between protein surfaces has been widely described in the literature in terms of lock-and-key fits, knob-into-holes, protrusions and cavities, donors and acceptors, etc., all of which are suggests the nature of the structural and chemical match.
[0183] In one embodiment, the one or more introduced modifications introduce new hydrogen bonds across the boundaries of the Fab components. In one embodiment, the one or more introduced modifications introduce new salt bridges across the boundaries of the Fab components. Exemplary substitutions are described in WO 2014 / 150973 and WO 2014 / 082179.
[0184] In certain embodiments, the Fab domain comprises a 192E substitution in the CH1 domain and 114A and 137K substitutions in the CL domain, which introduces a salt bridge between the CH1 and CL domains (Golay et al., 2016, J Immunol 196:3199-211).
[0185] In certain embodiments, the Fab domain comprises 143Q and 188V substitutions in the CH1 domain and 113T and 176V substitutions in the CL domain, which serve to swap the hydrophobic and polar contact regions between the CH1 and CL domains ( (See Golay et al., 2016, J Immunol 196:3199-211).
[0186] In certain embodiments, the Fab domains may include modifications in some or all of the VH, CH1, VL, CL domains to introduce orthogonal Fab boundaries that promote proper assembly of the Fab domains (Lewis et al., 2014 Nature Biotechnology 32:191-198). In one embodiment, a 39K, 62E modification is introduced in the VH domain, a H172A, F174G modification is introduced in the CH1 domain, a 1R, 38D, (36F) modification is introduced in the VL domain, and a L135Y, S176W modification is introduced in the VL domain. Introduced into the CL domain. In another embodiment, a 39Y modification is introduced into the VH domain and a 38R modification is introduced into the VL domain.
[0187] Fab domains can also be modified to replace the native CH1:CL disulfide bond with a modified disulfide bond, thereby increasing the efficiency of Fab component pairing. For example, modified disulfide bonds can be introduced by introducing 126C into the CH1 domain and 121C into the CL domain (see Mazor et al., 2015, MAbs 7:377-89).
[0188] Fab domains can also be modified by replacing the CH1 and CL domains with another domain that promotes proper assembly. For example, Wu et al., 2015, MAbs 7:364-76 describes the replacement of the CH1 domain of the α T cell receptor with a constant domain and the replacement of the CL domain of the T cell receptor with a β domain, as well as 38D It has been described to combine further charge-charge interactions between the VL and VH domains with substitution of these domains by introducing modifications into the VL domain and 39K modifications into the VH domain.
[0189] ABM consists of single-chain Fab fragments, which are polypeptides consisting of antibody heavy chain variable domain (VH), antibody constant domain 1 (CH1), antibody light chain variable domain (VL), antibody light chain constant domain (CL), and a linker. may be included. In some embodiments, the antibody domain and linker have one of the following orders, from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker. -VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL. The linker can be a polypeptide of at least 30 amino acids, such as 32-50 amino acids. Single-chain Fab domains are stabilized by natural disulfide bonds between the CL and CH1 domains.
[0190] In certain embodiments, the antibody domain and linker of the single chain Fab fragment have one of the following orders in N-terminal to C-terminal orientation: a) VH-CH1-linker-VL-CL, or b) VL -CL-linker-VH-CH1. In some cases, VL-CL-linker-VH-CH1 is used.
[0191] In another embodiment, the antibody domain and linker of the single chain Fab fragment have one of the following orders in N-terminal to C-terminal orientation: a) VH-CL-linker-VL-CH1 or b) VL -CH1-linker-VH-CL.
[0192] Optionally in single chain Fab fragments, in addition to the natural disulfide bond between the CL-domain and the CH1 domain, the antibody heavy chain variable domain (VH) and antibody light chain variable domain (VL) ABM are located at the following positions: Disulfide stabilization is also achieved by the introduction of a disulfide bond between: i) heavy chain variable domain position 44 to light chain variable domain position 100, ii) heavy chain variable domain position 105 to light chain variable domain position 43, or iii) Heavy chain variable domain position 101 to light chain variable domain position 100 (numbering follows Kabat's EU index).
[0193] In one embodiment, the optional disulfide bond between the variable domains of the single chain Fab fragment is between position 44 of the heavy chain variable domain and position 100 of the light chain variable domain. In one embodiment, the optional disulfide bond between the variable domains of the single chain Fab fragment is between heavy chain variable domain position 105 and light chain variable domain position 43 (numbering according to Kabat's EU index).
[0194] 7.2.1.1.2.scFv In certain embodiments, the ABM is a single chain Fv or "scFv." Examples of linkers connecting the VH and VL chains of a scFV are any of the ABM linkers specified in Section 7.2.2.3, such as the linkers designated as L1-L54.
[0195] To create a nucleic acid encoding an scFv, a DNA fragment encoding VH and VL is combined with another fragment encoding a linker, such as one of the ABM linkers described in Section 7.2.2.3 (amino acid sequence (Gly4~Ser )3 (SEQ ID NO: 1174) or the like.
[0196] 7.2.1.1.3. Other immunoglobulin-based ABMs MBMs have immunoglobulin formats other than Fab or scFv, e.g. Fv, dsFv, (Fab')2, single domain antibodies (SDAB), VH or VL domains or camelid VHH domains (also called nanobodies). May also include ABM.
[0197] ABMs can be single domain antibodies composed of a single VH or VL domain that exhibits sufficient affinity for the target. In embodiments, the single domain antibody is a camelid VHH domain (see, eg, Riechmann, 1999, Journal of Immunological Methods 231:25-38; WO 94 / 04678).
[0198] 7.2.1.2. Non-immunoglobulin-based ABM In certain embodiments, the MBM comprises non-antibody scaffold proteins such as engineered ankyrin repeat proteins (DARPins), avimers (abbreviation for avidity multimers), anticalins / lipocalins, centrins, Kunitz domains, adnexins, affilins, affitins ( (also known as nanophytins), knottins, pronectins, versabodies, duocalins, and finomers), ligands, receptors, cytokines, or chemokines.
[0199] Non-immunoglobulin scaffolds that can be used in MBM include Tables 3 and 4 of Mintz and Crea, 2013, Bioprocess International 11(2):40-48; Vazquez-Lombardi et al., 2015, Drug Discovery Today 20(10) Examples include those listed in Figure 1, Table 1 and Figure I of :1271-83; Table 1 and Box 2 of Skrlec et al., 2015, Trends in Biotechnology 33(7):408-18. Tables 3 and 4 of Mintz and Crea, 2013, Bioprocess International 11(2):40-48; Figure 1, Table 1 and Figures of Vazquez-Lombardi et al., 2015, Drug Discovery Today 20(10):1271-83 I; Contents of Table 1 and Box 2 of Skrlec et al., 2015, Trends in Biotechnology 33(7):408-18 (collectively "Scaffold Disclosure"). In certain embodiments, the scaffold disclosures are incorporated by reference for what they disclose regarding adnexins. In another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding avimers. In another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding affibodies. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding anticalins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding DARPins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding Kunitz domains. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding knottin. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding pronectin. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding nanophytin. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding affilins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding Adnectins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding ABM. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding adhelons. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding affimers. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding alphabodies. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding armadillo repeat proteins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding atrimers / tetranectins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding the Obody / OB-fold. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding centrin. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding repbodies. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding anticalins. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding atrimers. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding bicyclic peptides. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding cys-knots. In yet another embodiment, the scaffold disclosures are incorporated by reference for what they disclose regarding Fn3 scaffolds (including Adnectin, Sentinin, Pronectin and Tn3).
[0200] In one embodiment, the ABM can be a designed ankyrin repeat protein (“DARPin”). DARPins are antibody mimetic proteins that typically exhibit highly specific and high affinity target protein binding. They are typically genetically engineered and derived from natural ankyrin proteins and consist of at least three, usually four or five, repeating motifs of these proteins. Their molecular weight is approximately 14 or 18 kDa (kilodaltons) for four or five repeat DARPins, respectively. Examples of DARPins can be found, for example, in US Pat. No. 7,417,130. Multispecific binding molecules comprising DARPin binding modules and immunoglobulin-based binding modules are disclosed, for example, in US Patent Application Publication No. 2015 / 0030596 A1.
[0201] In another embodiment, the ABM can be an affibody. Affibodies are well known and refer to affinity proteins based on a 58 amino acid residue protein domain derived from one of the IgG binding domains of staphylococcal protein A.
[0202] In another embodiment, the ABM can be anticalin. Anticalins are well known and refer to another antibody mimetic technology, the binding specificity of which is derived from lipocalins. Anticalins can also be formatted as dual targeting proteins called duocalins.
[0203] In another embodiment, the ABM can be a versabody. Versabodies are well known and refer to another antibody mimetic technology. They are small proteins of 3-5 kDa with >15% cysteines that form a high disulfide density scaffold that replaces the hydrophobic core of typical proteins.
[0204] Other non-immunoglobulin ABMs include "A" domain oligomers (also known as avimers) (e.g., U.S. Pat. / 017576), Fn3-based protein scaffolds (see, e.g., U.S. Patent Application Publication No. 2003 / 0170753), VASP polypeptide, avian pancreatic polypeptide (aPP), tetranectin (based on CTLD3), afilin (based on γB-crystallin / ubiquitin), knottin, SH3 domain, PDZ domain, tendamistat, neocardinostatin, protein A domain, lipocalin, transferrin or Kunitz domain. It will be done. In one embodiment, ABMs useful for constructing MBMs include fibronectin-based scaffolds as exemplified in WO 2011 / 130324.
[0205] Furthermore, in certain embodiments, the ABM comprises a ligand binding domain of a receptor or a receptor binding domain of a ligand.
[0206] 7.2.2. Connector It is contemplated that a CD19 binding molecule may in some cases comprise an ABM or a pair of ABM chains (e.g. the VH-CH1 or VL-CL components of a Fab) directly linked to each other, e.g. as a fusion protein without a linker. It will be done. For example, a CD19 binding molecule can include a connector moiety that joins individual ABMs or ABM chains. Use of a connector moiety may improve target binding, for example, by increasing the flexibility of the ABM within the CD19 binding molecule, thereby reducing steric hindrance. ABM or ABM chains can be linked to each other via, for example, Fc domains (each Fc domain represents a pair of associated Fc regions) and / or ABM linkers. The use of Fc domains typically requires the use of the hinge region as the ABM or ABM chain connector for optimal antigen binding. Accordingly, the term "connector" includes, but is not limited to, Fc regions, Fc domains, and hinge regions.
[0207] Connectors can be selected or modified to, for example, increase or decrease the biological half-life of the CD19 binding molecule. For example, to reduce biological half-life, the CD19-binding molecule containing the fragment has reduced Staphylococcyl protein A (SpA) binding compared to native Fc-hinge region SpA binding. One or more amino acid mutations can be introduced in the CH2-CH3 domain boundary region of the Fc-hinge fragment. This approach is described in further detail in Ward et al., US Pat. No. 6,165,745. Alternatively, a CD19 binding molecule can be modified to increase its biological half-life. For example, one or more of the following mutations can be introduced: T252L, T254S, T256F, as described in US Pat. No. 6,277,375 to Ward. Alternatively, to increase biological half-life, the CD19-binding molecule is linked to the CH2 domain of the Fc region of IgG, as described in Presta et al., US Pat. Nos. 5,869,046 and 6,121,022. can be modified within the CH1 or CL region to contain a salvage receptor binding epitope taken from the two loops of .
[0208] Examples of Fc domains (formed by the pairing of two Fc regions), hinge regions and ABM linkers are described in Sections 7.2.2.1, 7.2.2.2 and 7.2.2.3, respectively.
[0209] 7.2.2.1.Fc domain A CD19 binding molecule can include an Fc domain from any suitable species. In one embodiment, the Fc domain is derived from a human Fc domain.
[0210] The Fc domain may be derived from any suitable class of antibody, including IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3 and IgG4) and IgM. In one embodiment, the Fc domain is derived from IgG1, IgG2, IgG3 or IgG4. In one embodiment, the Fc domain is derived from IgG1. In one embodiment, the Fc domain is derived from IgG4.
[0211] The Fc domain contains two polypeptide chains, each called a heavy Fc region. These two heavy chain Fc regions dimerize to create an Fc domain. The two Fc regions within an Fc domain can be the same or different from each other. In natural antibodies, the Fc regions are typically identical, but for the purpose of generating multispecific binding molecules of the present disclosure, the Fc regions are as described in Section 7.2.2.1.5 below. may be advantageously different to allow heterodimerization.
[0212] Typically, each heavy chain Fc region comprises or consists of two or three heavy chain constant domains.
[0213] In natural antibodies, the heavy chain Fc regions of IgA, IgD, and IgG are composed of two heavy chain constant domains (CH2 and CH3), and the heavy chain Fc regions of IgE and IgM are composed of three heavy chain constant domains (CH2, CH3 and CH4). These dimerize to generate Fc domains.
[0214] In the present disclosure, a heavy chain Fc region may include heavy chain constant domains from one or more different classes of antibodies, such as one, two or three different classes.
[0215] In one embodiment, the heavy chain Fc region includes CH2 and CH3 domains derived from IgG1. An exemplary sequence of a heavy chain Fc region derived from human IgG1 is provided in SEQ ID NO: 1109. [ka] In some embodiments, the CD19 binding molecule comprises an Fc region whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 251 modified with one or more of the substitutions described in Section 7.2.2.1 and subsections thereof. include.
[0216] In one embodiment, the heavy chain Fc region includes CH2 and CH3 domains derived from IgG2.
[0217] In one embodiment, the heavy chain Fc region includes CH2 and CH3 domains derived from IgG3.
[0218] In one embodiment, the heavy chain Fc region includes CH2 and CH3 domains derived from IgG4.
[0219] In one embodiment, the heavy chain Fc region includes a CH4 domain derived from IgM. The IgM CH4 domain is typically located at the C-terminus of the CH3 domain.
[0220] In one embodiment, the heavy chain Fc region comprises CH2 and CH3 domains from IgG and CH4 domains from IgM.
[0221] It will be appreciated that heavy chain constant domains for use in generating heavy chain Fc regions for the CD19 binding molecules of the present disclosure may include variants of the natural constant domains described above. Such variants may contain one or more amino acid changes compared to the wild-type constant domain. In one example, the heavy chain Fc regions of the present disclosure include at least one constant domain that differs in sequence from a wild-type constant domain. It will be appreciated that variant constant domains may be longer or shorter than wild-type constant domains. For example, a variant constant domain is at least 60% identical or similar to a wild-type constant domain. In another example, variant constant domains are at least 70% identical or similar. In another example, variant constant domains are at least 75% identical or similar. In another example, variant constant domains are at least 80% identical or similar. In another example, variant constant domains are at least 85% identical or similar. In another example, variant constant domains are at least 90% identical or similar. In another example, variant constant domains are at least 95% identical or similar. In another example, variant constant domains are at least 99% identical or similar. Exemplary Fc variants are described in Sections 7.2.2.1.1-7.2.2.1.6 below.
[0222] IgM and IgA occur naturally in humans as covalent multimers of common H2L2 antibody units. IgM exists as a pentamer when it incorporates a J chain, or as a hexamer when it lacks a J chain. IgA exists as monomeric and dimeric forms. IgM and IgA heavy chains have an 18 amino acid extension to the C-terminal constant domain known as the tail. The tail contains cysteine residues that form disulfide bonds between heavy chains in the polymer and is thought to play an important role in polymerization. The tail also contains glycosylation sites. In certain embodiments, the CD19 binding molecules of the present disclosure do not include a tail.
[0223] The Fc domain incorporated into a CD19-binding molecule may have one or more functional properties that alter one or more functional properties of the protein, such as serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cytotoxicity. May include modifications. Additionally, the CD19 binding molecule can be chemically modified (e.g., one or more chemical moieties can be attached to the CD19 binding molecule) or to alter its glycosylation, as well as one of the CD19 binding molecules. Modifications may be made to alter the above functional properties.
[0224] Effector functions of antibody molecules include, for example, complement-mediated effector functions mediated by the binding of the C1 component of complement to the antibody. Activation of complement is important in opsonization and direct lysis of pathogens. Furthermore, it stimulates the inflammatory response by recruiting and activating phagocytes to the site of complement activation. Effector functions include Fc receptor (FcR)-mediated effector functions, which can be triggered upon binding of the constant domain of an antibody to an Fc receptor (FcR). Antigen-antibody complex-mediated cross-linking of Fc receptors on the effector cell surface results in phagocytosis and destruction of antibody-coated particles, clearance of immune complexes, and lysis of antibody-coated target cells by killer cells (antibody-coated particles). It elicits a number of important and diverse biological responses, including dependent cell-mediated cytotoxicity (referred to as ADCC), release of inflammatory mediators, placental passage, and control of immunoglobulin production.
[0225] The Fc region can be modified by replacing at least one amino acid residue with a different amino acid residue to alter effector function. For example, one or more amino acids can be substituted with a different amino acid residue such that the Fc region has altered affinity for effector ligands. The effector ligand for which the affinity is modified may be, for example, an Fc receptor or the C1 component of complement. This approach is described, for example, in US Pat. No. 5,624,821 and US Pat. No. 5,648,260, both by Winter et al. Modified Fc regions may also alter C1q binding and / or reduce or eliminate complement dependent cytotoxicity (CDC). This approach is described, for example, in US Pat. No. 6,194,551 by Idusogie et al. A modified Fc region may also alter the Fc region's ability to fix complement. This technique is described, for example, in PCT Publication No. WO 94 / 29351 by Bodmer et al. Allotypic amino acid residues include, but are not limited to, the constant regions of the heavy chains of the IgG1, IgG2 and IgG3 subclasses and the light of the kappa isotype, as described by Jefferis et al., 2009, MAbs, 1:332-338. and the constant region of the chain.
[0226] The Fc region can be used to "silence" effector functions, for example, to reduce or eliminate the ability of CD19-binding molecules to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP). ” may also be modified. This can be achieved, for example, by introducing mutations in the Fc region. Such mutations have been described in the art: LALA and N297A (Strohl, 2009, Curr. Opin. Biotechnol. 20(6):685-691); and D265A (Baudino et al., 2008, J. Immunol. 181:6664-69; Strohl, supra). Examples of silent Fc IgG1 antibodies include the so-called LALA mutant, which contains the L234A and L235A mutations in the IgG1 Fc amino acid sequence. Another example of a silent IgG1 antibody contains the D265A mutation. Another silent IgG1 antibody includes the so-called DAPA mutant, which contains the D265A and P329A mutations in the IgG1 Fc amino acid sequence. Another silent IgG1 antibody contains the N297A mutation, which results in a deglycosylated / non-glycosylated antibody.
[0227] The Fc region is modified with one or more amino acid residues, e.g., to increase the affinity of the CD19 binding molecule for active Fcγ receptors or to decrease the affinity of the CD19 binding molecule for inhibitory Fcγ receptors. can be modified to improve the ability of CD19 binding molecules containing an Fc region to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP). Human activating Fcγ receptors include FcγRIa, FcγRIIa, FcγRIIIa and FcγRIIIb, and human inhibitory Fcγ receptors include FcγRIIb. This technique is described, for example, in PCT Publication No. WO 00 / 42072 by Presta. Additionally, binding sites in human IgG1 for FcγRl, FcγRII, FcγRIII and FcRn have been mapped and variants with improved binding have been described (Shields et al., J. Biol. Chem. 276 :6591-6604,2001). Optimization of Fc-mediated effector functions of monoclonal antibodies, such as improving ADCC / ADCP function, has been described (see Strohl, 2009, Current Opinion in Biotechnology 20:685-691). Mutations that can improve ADCC / ADCP function include G236A, S239D, F243L, P247I, D280H, K290S, R292P, S298A, S298D, S298V, Y300L, V305I, A330L, I332E, E333A, K334A, A339D, A339Q, A339T and P396L (all positions according to EU numbering).
[0228] The Fc region can be used in ADCC and / or by, for example, modifying one or more amino acids to increase the affinity of the CD19 binding molecule for activating receptors that typically do not recognize parent CD19 binding molecules such as FcαRI. Alternatively, it can also be modified to improve the ability of CD19 binding molecules to mediate ADCP. This technique is described, for example, in Borrok et al., 2015, mAbs.7(4):743-751.
[0229] Thus, in certain embodiments, the CD19 binding molecule binds to an Fc-receptor, such as, but not limited to, FcRn or leukocyte receptor (e.g., as described above or in Section 7.2.2.1.1). , complement binding (e.g., as described above or in Section 7.2.2.1.2), modified disulfide-bonded structures (e.g., as described above or in Section 7.2.2.1.3), or It may include an Fc domain with altered effector function, such as an altered glycosylation pattern (eg, as described above or in Section 7.2.2.1.4). The Fc domain contains modifications that improve the possibility of producing asymmetric CD19 binding molecules, e.g., by allowing heterodimerization, the preferential pairing of non-identical Fc regions over identical Fc regions. It can also be modified as follows. Heterodimerization allows the generation of CD19 binding molecules in which different ABMs are linked to each other by Fc domains containing Fc regions that differ in sequence. Examples of heterodimerization techniques are illustrated in Section 7.2.2.1.5 (and subsections thereof).
[0230] Any of the modifications described in Sections 7.2.2.1.1 to 7.2.2.1.5 may be combined in any suitable manner to achieve the desired functional properties and / or combined with other modifications to improve CD19 binding. It will be appreciated that the properties of the molecule may be altered. In some embodiments, the CD19 binding molecules are 233, 234, 235, 236, 237, 239, 265, 266, 267, 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and Contains an IgG1 Fc domain with 1, 2, 3, 4, 5, 6, or more than 6 mutations at position 332 (EU numbering). For example, the CD19 binding molecule includes 1 at positions 233, 234, 235, 236, 237, 239, 265, 266, 267, 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and 332; It may include the IgG1 sequence of SEQ ID NO: 251 with 2, 3, 4, 5, 6 or more than 6 mutations.
[0231] In some embodiments, the CD19 binding molecule comprises a combination of the following substitutions: substitutions L234A, L235A and G237A (“LALAGA”); substitutions L234A, L235A, S267K and P329A (“LALASKPA”); substitutions D265A, P329A and S267K. (“DAPASK”); substitutions G237A, D265A and P329A (“GADAPA”); substitutions G237A, D265A, P329A and S267K (“GADAPASK”); substitutions L234A, L235A and P329G (“LALAPG”) and substitutions L234A, L235A and P329A (“LALAPA”), wherein the amino acid residues are numbered according to the EU numbering system. The terms "LALAGA", "LALASKPA", "DAPASK", "GADAPA", "GADAPASK", "LALAPG" and "LALAPA" do not refer to a contiguous amino acid sequence but to the various combinations of substitutions described in this paragraph. is understood to represent a shortened term representing .
[0232] In another embodiment, the CD19 binding molecule is a human IgG1 with an amino acid substitution selected from the substitutions L234A, L235A, S267K, P329A ("LALASKPA") or a combination of the substitutions G237A, D265A, P329A, S267K ("GADAPASK"). Amino acid residues, including the Fc region, are numbered according to the EU numbering system.
[0233] In a further embodiment, the CD19 binding molecule comprises an Fc region selected from FCV1-FCV7 (see Table A below).
[0234] In still further embodiments, the CD19 binding molecule comprises an Fc region that is FCV4 or FCV7.
[0235] In some embodiments, the CD19 binding molecule has a binding affinity for an Fcγ receptor or C1q, optionally measured by surface plasmon resonance using a Biacore T200 instrument, of a polypeptide comprising a wild-type human IgG1 Fc region. The Fcγ receptor is selected from the group consisting of FcγR1A, FcγRIIIaV158 mutant and FcγRIIIaF158 mutant, and the binding is reduced or undetectable compared to wild type, and the Fcγ receptor is , 90%, 95%, 98%, 99% decreased or undetectable.
[0236] In some embodiments, the CD19 binding molecule has reduced or undetectable effector function compared to a polypeptide comprising a wild-type human IgG1 Fc region.
[0237] In some embodiments, the CD19 binding molecule does not cause detectable antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC). Capable of binding antigens. In some embodiments, the effector function that is decreased or diminished is antibody-dependent cell-mediated cytotoxicity (ADCC) in the individual. In some embodiments, the effector function that is decreased or decreased is antibody-dependent cellular phagocytosis (ADCP) in the individual. In some embodiments, the effector function that is decreased or decreased is complement dependent cytotoxicity (CDC) in the individual. In some embodiments, the first and second Fc regions of the Fc domain have a nucleic acid sequence selected from the nucleic acid sequences listed in Table A below, or at least about 90%, 91% relative to this nucleic acid sequence, respectively. , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.
[0238] In one embodiment, the nucleic acid encoding the Fc region is at least about 90%, 91%, 92%, 93% relative to the FCV-7 nucleic acid sequence (see Table A below) or this nucleic acid sequence. Includes sequences with 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In one embodiment, the nucleic acid encoding the Fc region is at least about 90%, 91%, 92%, 93% relative to the FCV-4 nucleic acid sequence (see Table A below) or this nucleic acid sequence. Includes sequences with 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In some embodiments, the Fc domain comprises first and second Fc regions, each of which has an amino acid sequence selected from the amino acid sequences listed in Table A below, or at least about Includes any sequences with 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.
[0239] In one embodiment, the Fc domain is the amino acid sequence of FCV-7 (see Table A below) or at least about 90%, 91%, 92%, 93%, 94%, 95% relative to this amino acid sequence. %, 96%, 97%, 98%, 99% or 100% identity. In one embodiment, the Fc domain comprises the amino acid sequence of FCV-4 (see Table A below) or at least about 90%, 91%, 92%, 93%, 94%, 95% relative to this amino acid sequence. %, 96%, 97%, 98%, 99% or 100% identity.
[0240] Additionally, provided herein are vectors that include polynucleotides encoding CD19 binding molecules that include an Fc region selected from FCV1-FCV7 (see Table A below).
[0241] Also provided herein is a host cell comprising a vector or polynucleotide encoding and capable of expressing a CD19 binding molecule comprising an Fc region selected from FCV1-FCV7 (see Table A below). sea bream).
[0242] [Table 8]
[0243] [Table 9]
[0244] [Table 10]
[0245] [Table 11]
[0246] [Table 12]
[0247] [Table 13]
[0248] [Table 14]
[0249] [Table 15]
[0250] [Table 16]
[0251] [Table 17]
[0252] [Table 18]
[0253] [Table 19]
[0254] [Table 20]
[0255] [Table 21]
[0256] 7.2.2.1.1. Fc domains with modified FcR binding The Fc domain of a CD19 binding molecule may exhibit altered binding to one or more Fc-receptors (FcRs) compared to the corresponding native immunoglobulin. Binding to any particular Fc-receptor can be increased or decreased. In one embodiment, the Fc domain includes one or more modifications that alter its Fc-receptor binding profile.
[0257] Human cells can express several membrane-bound FcRs selected from FcαR, FcεR, FcγR, FcRn and glycan receptors. Some cells are also capable of expressing soluble (extracellular domain) FcR (Fridman et al., 1993, J Leukocyte Biology 54:504-512). FcγRs can be further divided by IgG binding affinity (high / low) and biological impact (activation / inhibition). Human FcγRI is widely considered to be the only "high affinity" receptor, while all others are considered to be of intermediate to low affinity. FcγRIIb is the only receptor with 'inhibitory' functionality due to its intracellular ITIM motif, whereas all others are 'activating' through ITAM motifs or pair with a common FcγR--γ chain. It is thought that then. Although FcγRIIIb is active, it is also unique in that it associates with cells via a GPI anchor. Overall, humans express six "canonical" FcγRs: FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb. In addition to these sequences, there are numerous sequence or allotypic variants spread across these families. Some of these are known to have important functional consequences and may therefore be considered receptor subtypes in their own right. Examples include FcγRIIaH134R, FcγRIIbI190T, FcγRIIIaF158V, FcγRIIIbNA1, FcγRIIIbNA2 and FcγRIIISH. Each receptor sequence has been shown to have different affinities for four subclasses: IgG: IgG1, IgG2, IgG3 and IgG4 (Bruhns, 1993, Blood 113:3716-3725). Other species have somewhat different numbers and functionality of FcγRs, with the mouse system being the best tested to date and containing four FcγRs, FcγRI FcγRIIb FcγRIII FcγRIV (Bruhns, 2012, Blood 119:5640-5649). Human FcγRI on cells is usually mediated by monomeric IgG in normal serum conditions due to its affinity for IgG1 / IgG3 / IgG4 (approximately 10-8 M) and the concentration of these IgGs in serum (approximately 10 mg / ml). It is considered to be "occupied." It is therefore believed that cells carrying FcγRI on their surface are capable of "screening" or "sampling" their antigenic environment surrogately by bound multispecific IgG. Other receptors with lower affinities for the IgG subclass (in the range of about 10-5 to 10-7 M) are usually considered "unoccupied." Therefore, low affinity receptors are inherently susceptible to detection and activation by antibody-mediated immune complexes. Increased Fc density in antibody immune complexes results in increased functional affinity of binding avidity to low affinity FcγRs. This was demonstrated in vitro using several methods (Shields et al., 2001, J Biol Chem 276(9):6591-6604; Lux et al., 2013, J Immunol 190:4315-4323) . It was also suggested to be one of the major modes of action in the use of anti-RhD to treat ITP in humans (Crow, 2008, Transfusion Medicine Reviews 22:103-116).
[0258] Many cell types express multiple types of FcγRs, and therefore binding of IgG or antibody immune complexes to FcγR-bearing cells can have multiple and complex consequences depending on the biological context. . Most simply, cells can receive either activation, inhibition or mixed signals. This may include phagocytosis (e.g. macrophages and neutrophils), antigen processing (e.g. dendritic cells), reduced IgG production (e.g. B cells) or degranulation (e.g. neutrophils, mast cells). can bring about events. There are data supporting that inhibitory signals from FcγRIIb can predominate over those of activating signals (Proulx, 2010, Clinical Immunology 135:422-429).
[0259] There are several useful Fc substitutions that can be made to alter binding to one or more FcγR receptors. Substitutions that result in increased binding as well as decreased binding may be useful. For example, increased binding to FcγRIIIa generally results in increased ADCC (antibody-dependent cell-mediated cytotoxicity; non-specific cytotoxic cells expressing FcγRs recognize bound antibodies on target cells and subsequently , a cell-mediated reaction that causes lysis of target cells). Similarly, reduced binding to FcγRIIb (inhibitory receptor) may be beneficial in certain situations as well. Amino acid substitutions utilized in the present disclosure include those described in US Patent Application Publication No. 2006 / 0024298 (particularly FIG. 41), US Patent Application Publication No. 2006 / 0121032, and US Patent Application Publication No. 2006 / 0235208. , US Patent Application Publication No. 2007 / 0148170, and US Patent Application Publication No. 2019 / 0100587. Specific variants utilized include, but are not limited to, 236A, 239D, 239E, 332E, 332D, 239D / 332E, 267D, 267E, 328F, 267E / 328F, 236A / 332E, 239D / 332E / 330Y, 239D , 332E / 330L, 243A, 243L, 264A, 264V, 299T, 265A / 297A / 329A, 265N / 297D / 329G and 265E / 297Q / 329S.
[0260] FcRn plays an important role in maintaining the long half-life of IgG in adult and pediatric serum. The receptor binds to IgG in acidified vesicles (pH<6.5), protecting the IgG molecule from degradation and then releasing it in the blood at a higher pH of 7.4.
[0261] FcRn differs from leukocyte Fc receptors and instead has structural similarities with MHC class I molecules. It is a heterodimer composed of a β2-microglobulin chain non-covalently linked to a membrane-bound chain containing three extracellular domains. One of these domains, containing the carbohydrate chain, interacts with β2-microglobulin at a site between the CH2 and CH3 domains of Fc. The interaction involves a salt bridge made to a positively charged histidine residue on the IgG at pH<6.5. At higher pH, His residues lose their positive charge, the FcRn-IgG interaction is weakened, and the IgG dissociates.
[0262] In one embodiment, the CD19 binding molecule comprises an Fc domain that binds human FcRn.
[0263] In one embodiment, the Fc domain has an Fc region (eg, one or two) that includes a histidine residue at position 310, and in some cases also at position 435. These histidine residues are important for human FcRn binding. In one embodiment, the histidine residues at positions 310 and 435 are natural residues, ie, positions 310 and 435 are unmodified. Alternatively, one or both of these histidine residues may be present as a result of modification.
[0264] A CD19 binding molecule can include one or more Fc regions that modify Fc binding to FcRn. Altered binding can be increased binding or decreased binding.
[0265] In one embodiment, the CD19 binding molecule comprises one or more modifications such that at least one (optionally both) Fc region binds to FcRn with higher affinity and avidity than the corresponding native immunoglobulin. Contains an Fc domain containing.
[0266] Fc substitutions that increase binding to FcRn receptors and increase serum half-life are described in U.S. Patent Application Publication No. 2009 / 0163699 and include 434S, 434A, 428L, 308F, 259I, 428L / 434S , 259I / 308F, 436I / 428L, 436I or V / 434S, 436V / 428L and 259I / 308F / 428L.
[0267] In one embodiment, the Fc region is modified by replacing the threonine residue at position 250 with a glutamine residue (T250Q).
[0268] In one embodiment, the Fc region is modified by replacing the methionine residue at position 252 with a tyrosine residue (M252Y).
[0269] In one embodiment, the Fc region is modified by replacing the serine residue at position 254 with a threonine residue (S254T).
[0270] In one embodiment, the Fc region is modified by replacing the threonine residue at position 256 with a glutamic acid residue (T256E).
[0271] In one embodiment, the Fc region is modified by replacing the threonine residue at position 307 with an alanine residue (T307A).
[0272] In one embodiment, the Fc region is modified by replacing the threonine residue at position 307 with a proline residue (T307P).
[0273] In one embodiment, the Fc region is modified by replacing the valine residue at position 308 with a cysteine residue (V308C).
[0274] In one embodiment, the Fc region is modified by replacing the valine residue at position 308 with a phenylalanine residue (V308F).
[0275] In one embodiment, the Fc region is modified by replacing the valine residue at position 308 with a proline residue (V308P).
[0276] In one embodiment, the Fc region is modified by replacing the glutamine residue at position 311 with an alanine residue (Q311A).
[0277] In one embodiment, the Fc region is modified by replacing the glutamine residue at position 311 with an arginine residue (Q311R).
[0278] In one embodiment, the Fc region is modified by replacing the methionine residue at position 428 with a leucine residue (M428L).
[0279] In one embodiment, the Fc region is modified by replacing the histidine residue at position 433 with a lysine residue (H433K).
[0280] In one embodiment, the Fc region is modified by replacing the asparagine residue at position 434 with a phenylalanine residue (N434F).
[0281] In one embodiment, the Fc region is modified by replacing the asparagine residue at position 434 with a tyrosine residue (N434Y).
[0282] In one embodiment, the Fc region comprises a methionine residue at position 252 with a tyrosine residue, a serine residue at position 254 with a threonine residue, and a threonine residue at position 256 with a glutamic acid residue (M252Y / S254T / T256E). ).
[0283] In one embodiment, the Fc region is modified by replacing the valine residue at position 308 with a proline residue and the asparagine residue at position 434 with a tyrosine residue (V308P / N434Y).
[0284] In one embodiment, the Fc region comprises a methionine residue at position 252 with a tyrosine residue, a serine residue at position 254 with a threonine residue, a threonine residue at position 256 with a glutamic acid residue, and a histidine residue at position 433. modified by replacing the group with a lysine residue and the asparagine residue at position 434 with a phenylalanine residue (M252Y / S254T / T256E / H433K / N434F).
[0285] It will be appreciated that any of the modifications listed above can be combined to alter FcRn binding.
[0286] In one embodiment, the CD19 binding molecule comprises an Fc domain in which one or both Fc regions include one or more modifications such that the Fc domain binds FcRn with lower affinity and avidity than the corresponding native immunoglobulin. include.
[0287] In one embodiment, the Fc region includes any amino acid residue other than histidine at position 310 and / or 435.
[0288] A CD19 binding molecule can include an Fc domain in which one or both Fc regions include one or more modifications that increase its binding to FcγRIIb. FcγRIIb is the only inhibitory receptor in humans and the only Fc receptor found on B cells.
[0289] In one embodiment, the Fc region is modified by replacing the proline residue at position 238 with an aspartic acid residue (P238D).
[0290] In one embodiment, the Fc region is modified by replacing the glutamic acid residue at position 258 with an alanine residue (E258A).
[0291] In one embodiment, the Fc region is modified by replacing the serine residue at position 267 with an alanine residue (S267A).
[0292] In one embodiment, the Fc region is modified by replacing the serine residue at position 267 with a glutamic acid residue (S267E).
[0293] In one embodiment, the Fc region is modified by replacing the leucine residue at position 328 with a phenylalanine residue (L328F).
[0294] In one embodiment, the Fc region is modified by replacing the glutamic acid residue at position 258 with an alanine residue and the serine residue at position 267 with an alanine residue (E258A / S267A).
[0295] In one embodiment, the Fc region is modified by replacing the serine residue at position 267 with a glutamic acid residue and the leucine residue at position 328 with a phenylalanine residue (S267E / L328F).
[0296] It will be appreciated that any of the modifications listed above can be combined to increase FcγRIIb binding.
[0297] In one embodiment, a CD19 binding molecule is provided that includes an Fc domain that exhibits reduced binding to FcγR.
[0298] In one embodiment, the CD19 binding molecule comprises an Fc domain in which one or both Fc regions include one or more modifications that reduce Fc binding to FcγRs.
[0299] Fc domains may be derived from IgG1.
[0300] In one embodiment, the Fc region is modified by replacing the leucine residue at position 234 with an alanine residue (L234A).
[0301] In one embodiment, the Fc region is modified by replacing the leucine residue at position 235 with an alanine residue (L235A).
[0302] In one embodiment, the Fc region is modified by replacing the glycine residue at position 236 with an arginine residue (G236R).
[0303] In one embodiment, the Fc region is modified by replacing the asparagine residue at position 297 with an alanine residue (N297A) or a glutamine residue (N297Q).
[0304] In one embodiment, the Fc region is modified by replacing the serine residue at position 298 with an alanine residue (S298A).
[0305] In one embodiment, the Fc region is modified by replacing the leucine residue at position 328 with an arginine residue (L328R).
[0306] In one embodiment, the Fc region is modified by replacing the leucine residue at position 234 with an alanine residue and the leucine residue at position 235 with an alanine residue (L234A / L235A).
[0307] In an embodiment, the Fc region is modified by replacing the phenylalanine residue at position 234 with an alanine residue and the leucine residue at position 235 with an alanine residue (F234A / L235A).
[0308] In one embodiment, the Fc region is modified by replacing the glycine residue at position 236 with an arginine residue and the leucine residue at position 328 with an arginine residue (G236R / L328R).
[0309] In one embodiment, the Fc region is prepared by replacing the aspartic acid residue at position 265 with an alanine residue, the asparagine residue at position 297 with an alanine residue, and the proline residue at position 329 with an alanine residue. Modified (D265A / N297A / P329A).
[0310] In one embodiment, the Fc region comprises replacing the aspartic acid residue at position 265 with an asparagine residue, the asparagine residue at position 297 with an aspartic acid residue, and the proline residue at position 329 with a glycine residue. Modified by (D265N / N297D / P329G).
[0311] In one embodiment, the Fc region is prepared by replacing the aspartic acid residue at position 265 with a glutamic acid residue, the asparagine residue at position 297 with a glutamine residue, and the proline residue at position 329 with a serine residue. Qualified (D265E / N297Q / P329S).
[0312] It will be appreciated that any of the modifications listed above can be combined to reduce FcγR binding.
[0313] In one embodiment, the CD19 binding molecule comprises an Fc domain in which one or both Fc regions include one or more modifications that reduce Fc binding to FcγRIIIa without affecting binding of Fc to FcγRII. .
[0314] In one embodiment, the Fc region is modified by replacing the serine residue at position 239 with an alanine residue (S239A).
[0315] In one embodiment, the Fc region is modified by replacing the glutamic acid residue at position 269 with an alanine residue (E269A).
[0316] In one embodiment, the Fc region is modified by replacing the glutamic acid residue at position 293 with an alanine residue (E293A).
[0317] In one embodiment, the Fc region is modified by replacing the tyrosine residue at position 296 with a phenylalanine residue (Y296F).
[0318] In one embodiment, the Fc region is modified by replacing the valine residue at position 303 with an alanine residue (V303A).
[0319] In one embodiment, the Fc region is modified by replacing the alanine residue at position 327 with a glycine residue (A327G).
[0320] In one embodiment, the Fc region is modified by replacing the lysine residue at position 338 with an alanine residue (K338A).
[0321] In one embodiment, the Fc region is modified by replacing the aspartate residue at position 376 with an alanine residue (D376A).
[0322] It will be appreciated that any of the modifications listed above can be combined to reduce FcγRIIIa binding.
[0323] Fc region mutations with reduced FcR binding may be referred to as "FcγR ablation mutations," "FcγR silencing mutations," or "Fc knockout (FcKO or KO)" mutations. In some therapeutic applications, the normal binding of the Fc domain to one or more or all of the Fcγ receptors (e.g., FcγR1, FcγRIIa, FcγRIIb, FcγRIIIa) is reduced or eliminated to avoid additional mechanisms of action. This is desirable. Thus, for example, in many embodiments, particularly in the use of MBM that monovalently binds CD3, it is generally desirable to eliminate FcγRIIIa binding to eliminate or substantially reduce ADCC activity. In certain embodiments, at least one of the Fc regions of the MBM described herein comprises one or more Fcγ receptor ablation mutations. In certain embodiments, the Fc regions both include one or more Fcγ receptor ablation mutations. These deletion mutations are shown in Table 3, each of which can be independently and optionally included or excluded, with certain embodiments including G236R / L328R, E233P / L234V / L235A / G236del / S239K, E233P / L234V / L235A / G236del / S267K, E233P / L234V / L235A / G236del / S239K / A327G, E233P / L234V / L235A / G236del / S267K / A327G, E233P / L234V / L235A / G2 36del, D265A / N297A / P329A, D265N / Deletion mutations selected from the group consisting of N297D / P329G and D265E / N297Q / P329S ("del" indicates deletion, eg G236del refers to deletion of glycine at position 236) are used. It should be noted that the deletion mutations referred to herein eliminate FcγR binding, but generally do not eliminate FcRn binding.
[0324] [Table 22]
[0325] In certain embodiments, the MBM of the present disclosure includes a first Fc region and a second Fc region. In certain embodiments, the first Fc region and / or the second Fc region may include the following mutations: E233P, L234V, L235A, G236del and S267K.
[0326] The Fc domain of human IgG1 has the highest binding to Fcγ receptors, so deletion mutations can be used when the constant domain (or Fc domain) in the backbone of the heterodimeric antibody is IgG1.
[0327] Alternatively or in addition to deletion mutations in the IgG1 background, mutations at glycosylation position 297, e.g. by replacing the asparagine residue at position 297 with an alanine residue (N297A) or a glutamine residue (N297Q), e.g. Binding to FcγRIIIa can be significantly eliminated. Human IgG2 and IgG4 have naturally reduced binding to Fcγ receptors, so their scaffolds can be used with or without ablation mutations.
[0328] 7.2.2.1.2. Fc domain with modified complement fixation A CD19 binding molecule can include an Fc domain in which one or both Fc regions include one or more modifications that alter Fc binding to complement. Altered complement fixation can be increased binding or decreased binding.
[0329] In one embodiment, the Fc region includes one or more modifications that reduce its binding to C1q. Initiation of the classical complement pathway begins with the binding of the hexameric C1q protein to the CH2 domain of antigen-bound IgG and IgM.
[0330] In one embodiment, the CD19 binding molecule comprises an Fc domain in which one or both Fc regions include one or more modifications that reduce Fc binding to C1q.
[0331] In one embodiment, the Fc region is modified by replacing the leucine residue at position 234 with an alanine residue (L234A).
[0332] In one embodiment, the Fc region is modified by replacing the leucine residue at position 235 with an alanine residue (L235A).
[0333] In one embodiment, the Fc region is modified by replacing the leucine residue at position 235 with a glutamic acid residue (L235E).
[0334] In one embodiment, the Fc region is modified by replacing the glycine residue at position 237 with an alanine residue (G237A).
[0335] In one embodiment, the Fc region is modified by replacing the lysine residue at position 322 with an alanine residue (K322A).
[0336] In one embodiment, the Fc region is modified by replacing the proline residue at position 331 with an alanine residue (P331A).
[0337] In one embodiment, the Fc region is modified by replacing the proline residue at position 331 with a serine residue (P331S).
[0338] In one embodiment, the CD19 binding molecule comprises an Fc domain derived from IgG4. IgG4 naturally has a lower complement activation profile than IgG1, as well as weaker binding of FcγRs. Thus, in one embodiment, the CD19 binding molecule comprises an IgG4 Fc domain and also comprises one or more modifications that increase FcγR binding.
[0339] It will be appreciated that any of the modifications listed above may be combined to reduce C1q binding.
[0340] 7.2.2.1.3. Fc domain with modified disulfide structure A CD19 binding molecule can include an Fc domain that includes one or more modifications to create and / or remove cysteine residues. Cysteine residues play an important role in the spontaneous assembly of Fc-based multispecific binding molecules by forming disulfide bridges between individual pairs of polypeptide monomers. Thus, by altering the number and / or position of cysteine residues, it is possible to modify the structure of CD19 binding molecules to produce proteins with improved therapeutic properties.
[0341] A CD19 binding molecule of the present disclosure can include an Fc domain in which one or both Fc regions, eg, both Fc regions, include a cysteine residue at position 309. In one embodiment, the cysteine residue at position 309 is generated by modification, e.g. in the case of an Fc domain derived from IgG1, the leucine residue at position 309 is replaced with a cysteine residue (L309C), and the Fc domain derived from IgG2 is replaced with a cysteine residue (L309C). In the case of the domain, the valine residue at position 309 is replaced with a cysteine residue (V309C).
[0342] In one embodiment, the Fc region is modified by replacing the valine residue at position 308 with a cysteine residue (V308C).
[0343] In one embodiment, two disulfide bonds in the hinge region are removed by mutating the core hinge sequence CPPC (SEQ ID NO: 1179) to SPPS (SEQ ID NO: 1180).
[0344] 7.2.2.1.4. Fc domains with altered glycosylation In certain embodiments, CD19 binding molecules with improved manufacturability are provided that contain fewer glycosylation sites than the corresponding immunoglobulin. These proteins have simpler post-translational glycosylation patterns and are therefore simpler and cheaper to produce.
[0345] In one embodiment, the glycosylation site in the CH2 domain is removed by replacing the asparagine residue at position 297 with an alanine residue (N297A) or a glutamine residue (N297Q). In addition to improved manufacturability, these glycosyl mutants also reduce FcγR binding as described herein above.
[0346] In certain embodiments, CD19 binding molecules are created that have an altered type of glycosylation, such as hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bipartite GlcNac structures. obtain. Such altered glycosylation patterns have been demonstrated to improve the ADCC capabilities of antibodies. Such carbohydrate modifications can be accomplished, for example, by expressing CD19 binding molecules in host cells with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells to internally express CD19 binding molecules and thereby produce CD19 binding molecules with altered glycosylation. obtain. For example, European Patent No. 1,176,195 by Hang et al. describes cell lines with a functionally disrupted FUT8 gene encoding fucosyltransferase, and antibodies expressed in such cell lines are It has come to show hypofucosylation. PCT Publication WO 03 / 035835 by Presta describes mutations that have a reduced ability to bind fucose to Asn(297)-linked carbohydrates and also result in hypofucosylation of antibodies expressed in the relevant host cells. A type CHO cell line, Lecl3 cells, has been described (see also Shields et al., 2002, J. Biol. Chem. 277:26733-26740). In PCT Publication WO 99 / 54342 by Umana et al. Cell lines have been described and antibodies expressed in engineered cell lines now exhibit increased bipartite GlcNac structures resulting in increased ADCC activity of the antibody (Umana et al., Nat.Biotech. 17:176-180, 1999).
[0347] 7.2.2.1.5.Fc heterodimerization Many multispecific molecular formats differ from natural immunoglobulins in that they contain two Fc regions that are operably linked to non-identical antigen-binding domains (or portions thereof, e.g., the VH or VH-CH1 of a Fab). Accompanied by embodiment. Insufficient heterodimerization of two Fc regions to form an Fc domain has always been an obstacle to increasing the yield of desired multispecific molecules and is a difficult problem for purification. Various techniques available in the art are described, for example, in European Patent Application Publication No. 1870459A1; US Patent No. 5,582,996; US Patent No. 5,731,168; US Patent No. 5,910,573; No. 5,932,448; US Patent No. 6,833,441; US Patent No. 7,183,076; US Patent Application Publication No. 2006204493A1; and PCT Publication No. WO 2009 / 089004A1 pamphlet. , can be used to promote dimerization of Fc regions that may be present in CD19 binding molecules (and particularly the MBMs of the present disclosure).
[0348] The present disclosure provides CD19 binding molecules that include Fc heterodimers, ie, Fc domains that include non-identical heterogeneous Fc regions. Heterodimerization techniques are used to promote dimerization of Fc regions operably linked to different ABMs (or portions thereof, e.g. VH or VH-CH1 of a Fab) and to the same ABM or portion thereof. Reduces dimerization of operably linked Fc regions. Typically, each Fc region in an Fc heterodimer comprises the CH3 domain of the antibody. The CH3 domain is derived from the constant region of an antibody of any isotype, class or subclass, in some cases the IgG (IgG1, IgG2, IgG3 and IgG4) class, as described in the previous section.
[0349] Typically, in addition to the CH3 domain, the MBM contains other antibody fragments such as CH1 domains, CH2 domains, hinge regions, VH domains, VL domains, CDRs and / or antigen-binding fragments as described herein. include. In certain embodiments, the two heteropolypeptides are two heavy chains forming a bispecific or multispecific molecule. Heterodimerization of two different heavy chains in the CH3 domain gives rise to the desired antibody or antibody-like molecule, whereas homodimerization of the same heavy chain reduces the yield of the desired antibody or molecule. let In an exemplary embodiment, the two or more heteropolypeptide chains include two chains that include a CH3 domain and form a molecule of any of the above-described multispecific molecular formats of this disclosure. In one embodiment, the two heteropolypeptide chains that include CH3 domains contain modifications that favor heterodimeric association of the polypeptides relative to the unmodified chains. Various examples of modification techniques are shown in Table 4 below and in subsections (a) to (g) of Section 7.2.2.1.5.1.
[0350] [Table 23]
[0351] [Table 24]
[0352] [Table 25]
[0353] [Table 26]
[0354] [Table 27]
[0355] [Table 28]
[0356] [Table 29]
[0357] [Table 30]
[0358] Exemplary pairs of non-identical heterologous Fc sequences that can pair to form Fc heterodimers and that can be included in CD19 binding molecules of the present disclosure include (i) SEQ ID NO: 252 and SEQ ID NO: 252; No. 253, and (ii) SEQ ID No. 252 and SEQ ID No. 254. [ka] An Fc region having an amino acid sequence of one of SEQ ID NOs: 252-254 may be modified to include one or more of the substitutions listed in Section 7.2.2.1 (including subparts thereof), e.g., deletions listed in Table 3. Can be modified to include one or more substitutions corresponding to the variant. In some embodiments, the CD19 binding molecules are 233, 234, 235, 236, 237, 239, 265, 266, 267, 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and Mutations in 1, 2, 3, 4, 5, 6 or more than 6 of position 332 (EU numbering), such as one or more of those listed in Section 7.2.2.1 (including its subparts) It contains an Fc region having one amino acid sequence of SEQ ID NOs: 252 to 254 with a mutation of . For example, the CD19 binding molecule includes 1 at positions 233, 234, 235, 236, 237, 239, 265, 266, 267, 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and 332; Fc region having the amino acid sequence of SEQ ID NO: 252 with 2, 3, 4, 5, 6 or more than 6 mutations and / or 233, 234, 235, 236, 237, 239, 265, 266, 267 , 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and 332 of SEQ ID NO: 253 with mutations at positions 1, 2, 3, 4, 5, 6 or more than 6. Fc region having the amino acid sequence and / or positions 233, 234, 235, 236, 237, 239, 265, 266, 267, 268, 269, 297, 299, 322, 327, 328, 329, 330, 331 and 332 It may include an Fc region having the amino acid sequence of SEQ ID NO: 254 with 1, 2, 3, 4, 5, 6, or more than 6 mutations.
[0359] (a)Stereomorphism A CD19 binding molecule may include one or more, eg, multiple modifications to one or more of the constant domains of the Fc domain, eg, to the CH3 domain. In one example, a CD19 binding molecule of the present disclosure comprises two polypeptides each comprising an antibody heavy chain constant domain, eg, a CH2 or CH3 domain. In one example, the two heavy chain constant domains of the CD19 binding molecule, eg, the CH2 or CH3 domains, contain one or more modifications that enable heterodimeric association between the two chains. In one embodiment, one or more modifications are placed on the CH2 domains of the two heavy chains. In one embodiment, the one or more modifications are placed on the CH3 domains of at least two polypeptides of the CD19 binding molecule.
[0360] One mechanism for Fc heterodimerization is commonly referred to as "knob and hole" or "knob-into-hole." These terms are described, for example, in Ridgway et al., 1996, Protein Engineering 9(7):617; Atwell et al., 1997, J. Mol. Biol. 270:26; U.S. Patent No. 8,216,805. refers to an amino acid mutation that produces a steric effect that favors the formation of Fc heterodimers over Fc homodimers. Knob-in-hole mutations can be combined with other techniques to improve heterodimerization.
[0361] In one embodiment, the one or more modifications to a first polypeptide of a CD19 binding molecule that includes a heavy chain constant domain can generate a "knob" and one or more modifications to a second polypeptide of a CD19 binding molecule that include a heavy chain constant domain. Modification of the ``hole'' generates a ``hole'' and heterodimerization of the polypeptide of the CD19-binding molecule containing the heavy chain constant domain causes the ``knob'' to associate with the ``hole'' (e.g., interact, e.g. the CH2 domain of the polypeptide interacts with the CH2 domain of the second polypeptide, or the CH3 domain of the first polypeptide interacts with the CH3 domain of the second polypeptide. The knob protrudes from the boundary of the first polypeptide of the CD19 binding molecule, which contains the heavy chain constant domain, thus stabilizing heteromultimers, thereby favoring, for example, heteromultimer formation over homomultimer formation. , can be positioned in a complementary "hole" at the interface with a second polypeptide of a CD19-binding molecule containing a heavy chain constant domain. The knob may be present on the original border or may be introduced synthetically (eg, by modifying the nucleic acid encoding the border). Import residues for knob formation are generally natural amino acid residues and may be selected from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W). In some cases tryptophan and tyrosine are selected. In embodiments, the original residues for the formation of protrusions have a small side chain capacity, such as alanine, asparagine, aspartic acid, glycine, serine, threonine or valine.
[0362] The "hole" is recessed from the border of the second polypeptide of the CD19 binding molecule containing the heavy chain constant domain, thus allowing for adjacent interactions of the first polypeptide of the CD19 binding molecule containing the heavy chain constant domain. Contains at least one amino acid side chain that fits into a corresponding knob on the surface. The hole may be present in the original border or may be introduced synthetically (eg, by modifying the nucleic acid encoding the border). Import residues for hole formation are typically natural amino acid residues, and in some embodiments are selected from alanine (A), serine (S), threonine (T), and valine (V). In one embodiment, the amino acid residue is serine, alanine or threonine. In another embodiment, the original residue for the formation of the hole has a large side chain capacity, such as tyrosine, arginine, phenylalanine or tryptophan.
[0363] In embodiments, the first CH3 domain is modified at residues 366, 405 or 407 to create either a "knob" or a "hole" (as described above), and the first CH3 domain is modified at residues 366, 405 or 407 to create a heterogeneous The second CH3 domain that dimerizes with residue 407 if residue 366 is modified in the first CH3 domain, residue 394 or the residue if residue 405 is modified in the first CH3 domain. When group 407 is modified in the first CH3 domain to create a "hole" or "knob" that is complementary to a "knob" or "hole" in the first CH3 domain, it is modified at residue 366.
[0364] In another embodiment, the first CH3 domain is modified at residue 366 and the second CH3 domain that heterodimerizes with the first CH3 domain is modified at residues 366, 368 and / or 407. to generate a "hole" or "knob" that is complementary to the "knob" or "hole" of the first CH3 domain. In one embodiment, the modification to the first CH3 domain introduces a tyrosine (Y) residue at position 366. In one embodiment, the first modification to CH3 is T366Y. In one embodiment, the modification to the first CH3 domain introduces a tryptophan (W) residue at position 366. In one embodiment, the first modification to CH3 is T366W. In certain embodiments, a modification to the second CH3 domain (e.g., a tyrosine (Y) or tryptophan (W) introduced at position 366) heterodimerizes with the first CH3 domain modified at position 366. (e.g., including the modification T366Y or T366W) includes a modification at position 366, a modification at position 368, and a modification at position 407. In certain embodiments, the modification at position 366 introduces a serine (S) residue, the modification at position 368 introduces an alanine (A), and the modification at position 407 introduces a valine (V). In certain embodiments, the modifications include T366S, L368A and Y407V. In one embodiment, the first CH3 domain of the multispecific molecule comprises the modification T366Y and the second CH3 domain that heterodimerizes with the first CH3 domain comprises the modifications T366S, L368A and Y407V. Or vice versa. In one embodiment, the first CH3 domain of the multispecific molecule comprises the modification T366W and the second CH3 domain that heterodimerizes with the first CH3 domain comprises the modifications T366S, L368A and Y407V. Or vice versa.
[0365] Further steric or "distortion" (e.g. knob-in-hole) modifications may be made using PCT Publication No. WO 2014 / 145806 (e.g. Figures 3, 4 and 12 of WO 2014 / 145806). ), PCT Publication No. International Publication No. 2014 / 110601 pamphlet and PCT Publication No. International Publication No. 2016 / 086186 pamphlet, International Publication No. 2016 / 086189 pamphlet, International Publication No. 2016 / 086196 pamphlet and International Publication No. 2016 / 182751 listed in the issue pamphlet. An example of a KIH variant includes a first constant chain containing L368D and K370S modifications paired with a second constant chain containing S364K and E357Q modifications.
[0366] Additional knob-in-hole modification pairs suitable for use in any of the CD19 binding molecules of the present disclosure include, for example, WO 1996 / 027011 and Merchant et al., 1998, Nat.Biotechnol., 16:677-681.
[0367] In further embodiments, the CH3 domain may be further modified to introduce a pair of cysteine residues. Without being bound by theory, the introduction of a pair of cysteine residues capable of forming disulfide bonds confers stability to a heterodimerized CD19-binding molecule containing paired CH3 domains, such as MBM. It is considered to be something that gives. In certain embodiments, the first CH3 domain includes a cysteine at position 354 and the second CH3 domain that heterodimerizes with the first CH3 domain includes a cysteine at position 349. In certain embodiments, the first CH3 domain comprises a cysteine (e.g., containing a modified S354C) at position 354 and a tyrosine (Y) at position 366 (e.g., containing a modified T366Y), and is heterozygous with the first CH3 domain. The second CH3 domain that dimerizes is cysteine at position 349 (e.g., containing a modified Y349C), serine at position 366 (e.g., containing a modified T366S), and alanine at position 368 (e.g., containing a modified L368A). and valine at position 407 (including, for example, the modification Y407V). In certain embodiments, the first CH3 domain comprises a cysteine at position 354 (e.g., containing a modified S354C) and a tryptophan (W) at position 366 (e.g., containing a modified T366W), and together with the first CH3 domain, a heterozygous The second CH3 domain that dimerizes is cysteine at position 349 (e.g., containing a modified Y349C), serine at position 366 (e.g., containing a modified T366S), and alanine at position 368 (e.g., containing a modified L368A). and valine at position 407 (including, for example, the modification Y407V).
[0368] A further mechanism utilized for the formation of heterodimers is called “electrostatic steering” as described in Gunasekaran et al., 2010, J. Biol. Chem. 285(25):19637. May be called. This is sometimes referred to herein as a "charge pair." In this embodiment, electrostatics are used to skew formation toward heterodimerization. As one skilled in the art will appreciate, this may also affect pI and therefore purification, and thus may be considered a pI mutation in some cases. However, because they were generated to promote heterodimerization and were not used as a purification tool, they are classified as "stereomutants." These include, but are not limited to, D221E / P228E / L368E paired with D221R / P228R / K409R and C220E / P228E / 368E paired with C220R / E224R / P228R / K409R.
[0369] Additional mutations may optionally be combined in any amount with other mutations such as the pI mutations outlined herein or other stereogenic mutations shown in Figure 37 of US Patent Application Publication No. 2012 / 0149876. and can be independently combined.
[0370] In certain embodiments, the stereomutations outlined herein optionally and independently modify any pI mutations (or other mutations, such as Fc mutations, FcRn mutations) in one or both Fc regions. and independently and optionally included or excluded from the CD19 binding molecules of the present disclosure.
[0371] A list of suitable distortion mutations is found in Table 5, which indicates some pairs that are particularly useful in many embodiments. Of particular use in many embodiments are S364K / E357Q:L368D / K370S;L368D / K370S:S364K;L368E / K370S:S364K;T411T / E360E / Q362E:D401K;L368D / K370S:S364K / E357L; and K370 S:S364K / A set of pairs including, but not limited to, E357Q. Regarding nomenclature, the pair "S364K / E357Q:L368D / K370S" means that one of the Fc regions has the double mutation set S364K / E357Q and the other has the double mutation set L368D / K370S.
[0372] [Table 31]
[0373] [Table 32]
[0374] [Table 33]
[0375] [Table 34]
[0376] In certain embodiments, the CD19 binding molecule includes a first Fc region and a second Fc region. In certain embodiments, the first Fc region includes the following mutations: L368D and K370S, and the second Fc region includes the following mutations: S364K and E357Q. In certain embodiments, the first Fc region includes the following mutations: S364K and E357Q, and the second Fc region includes the following mutations: L368D and K370S.
[0377] (b) Alternative knob and hole: IgG heterodimerization Heterodimerization of polypeptide chains of CD19 binding molecules containing paired CH3 domains can be increased by introducing one or more modifications in the CH3 domain from the IgG1 antibody class. In one embodiment, the modifications include a K409R modification on one CH3 domain paired with a F405L modification in a second CH3 domain. Further modifications may additionally or alternatively be at positions 366, 368, 370, 399, 405, 407 and 409. In some cases, heterodimerization of polypeptides containing such modifications is carried out under reducing conditions, e.g. at 25-37°C, e.g. 25°C or 37°C, for 1-10 hours, e.g. Perform with 10-100 mM 2-MEA (eg, 25, 50 or 100 mM 2-MEA) for 5 hours.
[0378] The amino acid substitutions described herein can be introduced into the CH3 domain using well-known techniques (e.g., McPherson, ed., 1991, Directed Mutagenesis: a Practical Approach; Adelman et al., 1983, DNA, 2:183).
[0379] IgG heterodimerization techniques are further described in, for example, WO 2008 / 119353, WO 2011 / 131746 and WO 2013 / 060867.
[0380] In any of the embodiments described in this section, the CH3 domain may be further modified to introduce a pair of cysteine residues, as described in Section 7.2.2.1.3.
[0381] (c) pI (isoelectric point) mutation Generally, as understood by those skilled in the art, there are two general categories of pI mutations: those that increase the pI of a protein (basic changes) and those that decrease the pI of a protein (acidic changes). As described herein, all combinations of these mutations can be made: one Fc region can be wild type or a mutant that does not exhibit a pI significantly different from the wild type; It can be either more basic or more acidic. Alternatively, each Fc region can be altered, one more basic and one more acidic.
[0382] Exemplary combinations of pI mutations are shown in Table 6. As outlined herein and shown in Table 6, these changes are shown relative to IgG1, but all isotypes can be modified in this way, as can isotype hybrids. If the heavy chain constant domain is derived from IgG2-4, R133E and R133Q may also be used.
[0383] [Table 35]
[0384] In one embodiment, for example in the format of Figures 1B-1W, Figures 1Y-1AH, Figures 2B-2L and Figures 2N-2V, the combination of pI mutations is one Fc containing the 208D / 295E / 384D / 418E / 421D mutation. region (negative Fab side) (N208D / Q295E / N384D / Q418E / N421D when compared to human IgG1) and a second Fc region (positive scFv side) containing a positively charged scFv linker, e.g. L36. (as described in Section 7.2.2.3). However, as will be understood by those skilled in the art, the first Fc region includes a CH1 domain that includes position 208. Therefore, in a construct that does not include a CH1 domain (e.g., for MBM that does not utilize a CH1 domain as one of the domains, e.g. in the format shown in Figure 2K), an exemplary negative pI mutant Fc set would be 295E / 384D / 418E / 421D mutations (Q295E / N384D / Q418E / N421D when compared to human IgG1).
[0385] In certain embodiments, the first Fc region has a set of substitutions from Table 6 and the second Fc region is linked to a charged linker (e.g., from those described in Section 7.2.2.3). selected).
[0386] In certain embodiments, a CD19 binding molecule of the present disclosure comprises a first Fc region and a second Fc region. In certain embodiments, the first Fc region includes the following mutations: N208D, Q295E, N384D, Q418E and N421D. In certain embodiments, the second Fc region includes the following mutations: N208D, Q295E, N384D, Q418E and N421D.
[0387] (d) Isotype variation Furthermore, many embodiments of the present disclosure rely on the "incorporation" of pI amino acids at specific positions from one IgG isotype to another, thus potentially introducing unwanted immunogenicity into the variant. reduce or eliminate gender. Some of these are shown in Figure 21 of US Patent Application Publication No. 2014 / 0370013. Thus, IgG1 is a common isotype of therapeutic antibodies for a variety of reasons, including high effector function. However, the heavy chain constant region of IgG1 has a higher pI than that of IgG2 (8.10 vs. 7.31). By introducing IgG2 residues into the IgG1 backbone at specific positions, the pI of the resulting Fc region is lowered (or increased) and also exhibits a longer serum half-life. For example, IgG1 has glycine (pI 5.97) at position 137, and IgG2 has glutamic acid (pI 3.22); incorporation of glutamate affects the pI of the resulting protein. As described below, several amino acid substitutions are generally required to significantly affect the pI of the mutant antibody. However, it should be noted that even changes in the IgG2 molecule allow for an increase in serum half-life, as discussed below.
[0388] In other embodiments, to reduce the overall charge state of the resulting protein (e.g., by changing from a higher pi amino acid to a lower pi amino acid) or for stability, as described further below. Non-isotypic amino acid changes are made to allow for structural adjustments.
[0389] Furthermore, by manipulating both the heavy and light chain constant domains of a CD19 binding molecule containing two half-antibodies with pI, significant changes in each half-antibody are seen. Having the pI of the two half antibodies differ by at least 0.5 may allow separation by ion exchange chromatography or isoelectric focusing or other methods sensitive to isoelectric points.
[0390] (e) Calculation of pI The pI of a half-antibody comprising the Fc region and ABM or ABM chain may depend on the pI of the mutant heavy chain constant domain and the pI of the entire half-antibody comprising the mutant heavy chain constant domain and ABM or ABM chain. Accordingly, in certain embodiments, the change in pI is calculated based on the variant heavy chain constant domain using the chart of FIG. 19 of US Patent Application Publication No. 2014 / 0370013. As described herein, which half-antibody to engineer is generally determined by the half-antibody's unique pI. Alternatively, the pI of each half-antibody can be compared.
[0391] (f) pI mutations that also confer good FcRn binding in vivo. If the pI mutation reduces the pI of the Fc region, it may have the additional benefit of improving serum retention in vivo.
[0392] The pI-mutated Fc region is thought to confer a longer half-life to antigen-binding molecules in vivo, as binding to FcRn at pH 6 in endosomes sequesters the Fc (Ghetie and Ward, 1997, Immunol Today. 18 (12):592-598). The endosomal compartment then recycles Fc to the cell surface. Once the compartment opens into the extracellular space, the higher pH of approximately 7.4 induces the release of Fc into the blood. In mice, Dall' Acqua et al. showed that Fc mutants with increased FcRn binding at pH 6 and pH 7.4 actually had reduced serum concentrations and the same half-life as wild-type Fc (Dall' Acqua et al. ' Acqua et al. 2002, J. Immunol. 169:5171-5180). The increased affinity of Fc for FcRn at pH 7.4 is thought to prevent release of Fc into the blood. Therefore, Fc mutations that increase the half-life of Fc in vivo ideally increase FcRn binding at lower pH while still allowing release of Fc at higher pH. The amino acid histidine changes its charge state in the pH range of 6.0-7.4. Therefore, it is not surprising to find His residues at key positions in the Fc / FcRn complex.
[0393] It has been suggested that antibodies with variable regions with lower isoelectric points may also have longer serum half-lives (Igawa et al., 2010, PEDS.23(5):385-392). However, the understanding of this mechanism remains inadequate. Furthermore, the variable regions differ from antibody to antibody. Constant region variants with reduced pI and extended half-lives, as described herein, may provide a more modular approach to improving the pharmacokinetic properties of CD19 binding molecules. Dew.
[0394] (g) Polar crosslinking Heterodimerization of polypeptide chains of CD19-binding molecules, e.g. MBM, containing Fc domains can be increased by introducing modifications based on the principle of "polar cross-linking", which Residues at the binding interface of two polypeptide chains interact with residues of similar (or complementary) physical properties in the heterodimeric form, while residues of different physical properties in the homodimeric form interact with. In particular, these modifications are designed such that polar residues interact with polar residues while hydrophobic residues interact with hydrophobic residues in heterodimer formation. In contrast, in homodimerization, residues are modified such that polar residues interact with hydrophobic residues. Favorable interactions in the heterodimeric form and unfavorable interactions in the homodimeric form work together to make the Fc region more likely to form heterodimers than to form homodimers. Do it like this.
[0395] In an exemplary embodiment, the above modifications are made at one or more of residues 364, 368, 399, 405, 409, and 411 of the CH3 domain.
[0396] In certain embodiments, one or more modifications selected from the group consisting of S364L, T366V, L368Q, N399K, F405S, K409F and R411K are introduced into one of the two CH3 domains. One or more modifications selected from the group consisting of Y407F, K409Q and T411N may be introduced into the second CH3 domain.
[0397] In another embodiment, one or more modifications selected from the group consisting of S364L, T366V, L368Q, D399K, F405S, K409F and T411K are introduced into one CH3 domain, while consisting of Y407F, K409Q and T411D. One or more modifications selected from the group are introduced into the second CH3 domain.
[0398] In one exemplary embodiment, the original residue of threonine at position 366 of one CH3 domain is replaced with valine, while the original residue of tyrosine at position 407 of the other CH3 domain is replaced with phenylalanine. .
[0399] In another exemplary embodiment, the original residue of serine at position 364 of one CH3 domain is replaced with leucine, while the original residue of leucine at position 368 of the same CH3 domain is replaced with glutamine. .
[0400] In yet another exemplary embodiment, the original residue of phenylalanine at position 405 of one CH3 domain is replaced with serine, while the original residue of lysine at position 409 of this CH3 domain is replaced with phenylalanine. , the original residue of lysine at position 409 of the other CH3 domain is replaced with glutamine.
[0401] In yet another exemplary embodiment, the original residue of aspartic acid at position 399 of one CH3 domain is replaced with lysine and the original residue of threonine at position 411 of the same CH3 domain is replaced with lysine. Meanwhile, the original residue of threonine at position 411 of the other CH3 domain is replaced with aspartic acid.
[0402] The amino acid substitutions described herein can be introduced into the CH3 domain using well-known techniques (e.g., McPherson, ed., 1991, Directed Mutagenesis: a Practical Approach; Adelman et al., 1983, DNA, 2:183). Polar crosslinking techniques are described, for example, in WO 2006 / 106905 pamphlet, WO 2009 / 089004 pamphlet and Gunasekaran, et al., 2010, JBC 285:19637-19646.
[0403] Further polar cross-linking modifications are described, for example, in PCT Publication No. WO 2014 / 145806 (e.g. Figure 6 of WO 2014 / 145806), PCT Publication No. WO 2014 / 110601 and PCT Publication No. Numbers are listed in International Publication No. 2016 / 086186 pamphlet, International Publication No. 2016 / 086189 pamphlet, International Publication No. 2016 / 086196 pamphlet, and International Publication No. 2016 / 182751 pamphlet. Examples of polar bridge variants include constant chains containing N208D, Q295E, N384D, Q418E and N421D modifications.
[0404] In any of the embodiments described herein, the CH3 domain may be further modified to introduce a pair of cysteine residues, as described in Section 7.2.2.1.3.
[0405] Further methods for promoting heterodimerization are available, for example, in WO 2016 / 105450, WO 2016 / 086186, WO 2016 / 086189, and WO 2016 / 086196. No. pamphlet, International Publication No. 2016 / 141378 pamphlet, International Publication No. 2014 / 145806 pamphlet, and International Publication No. 2014 / 110601 pamphlet. Any of these approaches can be used with the CD19 binding molecules described herein.
[0406] 7.2.2.1.6. Combinations of heterodimerization mutations and other Fc mutations As will be understood by those skilled in the art, all of the listed heterodimerization mutations (including distortions and / or pI mutations) are useful as long as the Fc region of the Fc domain retains their ability to dimerize. , optionally and independently, may be combined in any manner. Furthermore, all of these mutations can be combined in any heterodimerization format.
[0407] In the case of pI mutations, the embodiments specifically used are shown in Table 6, but the basic rule is to vary the pI difference between the two Fc regions in the Fc heterodimer to facilitate purification. Accordingly, other combinations may be generated.
[0408] Additionally, any of the heterodimerization mutations, distortions, and pI may be independently and optionally combined with Fc ablation mutations, Fc mutations, FcRn mutations, as generally outlined herein.
[0409] In certain embodiments, the particular combination of distortions and pI mutations utilized in this disclosure is T366S / L368A / Y407V:T366W (optionally including a bridging disulfide). ), one Fc region containing Q295E / N384D / Q418E / N481D and the other containing a positively charged scFv linker (if the format includes a scFv domain). As understood by those skilled in the art, "knob-in-hole" mutations do not change pI and therefore can be used in either of the Fc regions in an Fc heterodimer.
[0410] In certain embodiments, the first and second Fc regions utilized in this disclosure include the amino acid substitutions S364K / E357Q:L368D / K370S, and the first and / or second Fc regions include the deletion variant substitution 233P. / L234V / L235A / G236del / S267K, and the first and / or second Fc region contains the pI variant substitution N208D / Q295E / N384D / Q418E / N421D(pl_(-)_isosteric_A).
[0411] 7.2.2.2. Hinge area A CD19 binding molecule may also include, for example, a hinge region that connects the antigen binding domain to the Fc region. The hinge region can be a natural or modified hinge region. The hinge region is typically found at the N-terminus of the Fc region.
[0412] The native hinge region is the hinge region that can normally be found between the Fab and Fc domains in natural antibodies. A modified hinge region is any hinge that differs in length and / or composition from the natural hinge region. Such hinges may include hinge regions from other species, such as human, mouse, rat, rabbit, shark, pig, hamster, camel, llama or goat hinge regions. Other modified hinge regions may include complete hinge regions derived from antibodies of a different class or subclass than that of the heavy chain Fc region. Alternatively, the modified hinge region may include portions of the native hinge or repeating units in which each unit in the repeat is derived from the native hinge region. In further alternatives, the native hinge region converts one or more cysteines or other residues to neutral residues such as serine or alanine, or converts suitably positioned residues to cysteine residues. It can be modified by By such means, the number of cysteine residues in the hinge region can be increased or decreased. This approach is further described in US Pat. No. 5,677,425 by Bodmer et al. Altering the number of cysteine residues in the hinge region can, for example, promote assembly of light and heavy chains or increase or decrease the stability of the CD19 binding molecule. Other modified hinge regions can be entirely synthetic and designed to have desired properties, such as length, cysteine composition, and flexibility.
[0413] Some modified hinge regions are described, for example, in U.S. Pat. and described in International Publication No. 2005003171 pamphlet.
[0414] Examples of suitable hinge arrangements are shown in Table 7.
[0415] [Table 36]
[0416] In one embodiment, the heavy chain Fc region has an intact hinge region at its N-terminus.
[0417] In one embodiment, the heavy chain Fc region and hinge region are derived from IgG4, and the hinge region includes the modified sequence CPPC (SEQ ID NO: 1179). The core hinge region of human IgG4 contains the sequence CPSC (SEQ ID NO: 1189) compared to IgG1 which contains the sequence CPPC (SEQ ID NO: 1179). The serine residues present in the IgG4 sequence result in increased flexibility in this region, and therefore parts of the molecule rather than cross-linking to other heavy chains in the IgG molecule to form interchain disulfides. Form disulfide bonds within the same protein chain (intrachain disulfides). (Angel et al., 1993, Mol lmmunol 30(1):105-108). Changing serine residues to prolines to obtain the same core sequence as IgG1 allows complete formation of interchain disulfides in the IgG4 hinge region, thus reducing the heterogeneity of the purified product. This modified isotype is called IgG4P.
[0418] 7.2.2.3.ABM Linker In certain embodiments, the present disclosure provides CD19 binding molecules that include two or more components of an ABM (e.g., the VH and VL of a scFv), two or more ABMs, or an ABM and a non-ABM domain (e.g., an Fc region). (dimerization domains such as) are connected to each other by a peptide linker. Such linkers are referred to herein as "ABM linkers."
[0419] Peptide linkers can range from 2 amino acids to 60 or more amino acids; in certain embodiments, peptide linkers range from 3 amino acids to 50 amino acids, from 4 to 30 amino acids, from 5 to 25 amino acids. of amino acids, 10 to 25 amino acids, or 12 to 20 amino acids. In certain embodiments, the peptide linker comprises 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids, 30 amino acids, 31 amino acids, 32 amino acids, 33 amino acids, 34 amino acids, 35 amino acids, 36 amino acids, 37 amino acids, 38 amino acids, 39 amino acids, 40 amino acids, 41 amino acids, 42 amino acids, 43 amino acids, 44 amino acids, 45 amino acids, 46 amino acids, 47 amino acids, 48 amino acids, 49 amino acids or It is 50 amino acids long.
[0420] Charged and / or flexible linkers may be used.
[0421] Examples of flexible ABM linkers that can be used in CD19 binding molecules include Chen et al., 2013, Adv Drug Deliv Rev.65(10):1357-1369 and Klein et al., 2014, Protein Engineering, Design & Selection 27 (10):325-330. A particularly useful flexible linker is (GGGGS)n (also referred to as (G4S)n) (SEQ ID NO: 1171). In certain embodiments, n is any number from 1 to 10, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 or any two bounded by any two of the above numbers. For example, 1 to 5, 2 to 5, 3 to 6, 2 to 4, 1 to 4, etc., and others.
[0422] Other examples of ABM linkers suitable for use in the CD19 binding molecules of the present disclosure are shown in Table 8 below.
[0423] [Table 37]
[0424] [Table 38]
[0425] [Table 39]
[0426] In various embodiments, the disclosure provides CD19 binding molecules that include one or more ABM linkers. Each of the ABM linkers is optionally between 2 and 60 amino acids selected from Table 8 above, such as 4-30 amino acids, 5-25 amino acids, 10-25 amino acids. or may range in length from 12 to 20 amino acids. In certain embodiments, the CD19 binding molecule comprises 2, 3, 4, 5 or 6 ABM linkers. ABM linkers can be on one, two, three, four or even more polypeptide chains of the CD19 binding molecule.
[0427] 7.2.3. Bispecific binding molecular forms An exemplary BBM configuration is shown in FIG. 1. FIG. 1A shows the components of the BBM configuration shown in FIGS. 1B-1AH. scFvs, Fabs, scFabs, non-immunoglobulin-based ABMs and Fc domains may have the properties described for these components in Sections 7.2.1 and 7.2.2, respectively. The components of the BBM morphology shown in Figure 1 can be assembled by any of the means described in Sections 7.2.1 and 7.2.2 (e.g., by direct binding, ABM linker, disulfide bond, knob-in-hole interaction). may be associated with each other (such as by modified Fc domains). The orientation and association of the various components shown in FIG. 1 is exemplary only; other orientations and associations may be suitable, as will be understood by those skilled in the art (e.g., Section 7.2). 1 and as described in Sections 7.2.2).
[0428] BBM is not limited to the form shown in FIG. Other forms that can be used are known to those skilled in the art. For example, WO 2014 / 145806 pamphlet; WO 2017 / 124002 pamphlet; Liu et al.,2017,Front Immunol.8:38;Brinkmann&Kontermann,2017,mAbs 9:2,182-212;US Patent Application Publication No. See 2016 / 0355600; Klein et al., 2016, MAbs 8(6):1010-20; and US Patent Application Publication No. 2017 / 0145116.
[0429] 7.2.3.1. Exemplary Bivalent BBM BBMs can be bivalent, i.e. they have two antigen binding domains, one that binds CD19 (ABM1) and one that binds a second target antigen (ABM2), e.g. Binds to components of the TCR complex.
[0430] Exemplary bivalent BBM configurations are shown in FIGS. 1B-1F.
[0431] As shown in Figures 1B-1D, the BBM can include two half-antibodies, one containing one ABM and the other containing one ABM, where the two half-antibodies pair via the Fc domain. has been done.
[0432] In the embodiment of FIG. 1B, the first (or left) half-antibody includes Fab and Fc regions and the second (or right) half-antibody includes Fab and Fc regions. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0433] In the embodiment of FIG. 1C, the first (or left) half-antibody includes a Fab and Fc region, and the second (or right) half-antibody includes an scFv and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0434] In the embodiment of Figure ID, the first (or left) half-antibody includes a scFv and an Fc region, and the second (or right) half-antibody includes a scFab and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0435] As shown in FIGS. 1E-1F, a bivalent BBM can include two ABMs attached to one Fc region of an Fc domain.
[0436] In the embodiment of FIG. 1E, the BBM includes a Fab, scFv and Fc domain, where the scFv is located between the Fab and Fc domain.
[0437] In the embodiment of Figure IF, the BBM (in the form of a "one-arm scFv-mAb") comprises a Fab, a scFv and an Fc domain, where the Fab is located between the scFv and the Fc domain.
[0438] In the forms shown in FIGS. 1B to 1F, each of X and Y represents either ABM1 or ABM2, provided that BBM includes one ABM1 and one ABM2. Accordingly, the present disclosure discloses that 2 such as the one shown in any one of FIGS. 1B-1F, where Provide value BBM. The present disclosure describes a bivalent BBM such as that shown in any one of FIGS. 1B-1F, where X is ABM2 and Y is ABM1 (this form of ABM is referred to as "B2" for convenience). Also provided.
[0439] 7.2.3.2. Exemplary trivalent BBM A BBM can be trivalent, i.e. it has three antigen binding domains, one or two of which bind CD19 (ABM1) and one or two of which bind a second target antigen. (ABM2), e.g., to components of the TCR complex.
[0440] Exemplary trivalent BBM configurations are shown in FIGS. 1G-1Z.
[0441] As shown in Figures 1G to 1N, Figures 1Q to 1W, and Figures 1Y to 1Z, the BBM contains two half-antibodies, one containing two ABMs and the other containing one ABM, and these The two half-antibodies are paired through their Fc domains.
[0442] In the embodiment of FIG. 1G, the first (or left) half-antibody includes a Fab and Fc region, and the second (or right) half-antibody includes an scFab, Fab and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0443] In the embodiment of FIG. 1H, the first (or left) half-antibody includes Fab and Fc regions, and the second (or right) half-antibody includes Fab, scFv, and Fc regions. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0444] In the embodiment of FIG. 1I, the first (or left) half-antibody includes a scFv and an Fc region, and the second (or right) half-antibody includes two Fab and Fc regions. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0445] In the embodiment of FIG. 1J, the first (or left) half-antibody includes two Fav and Fc regions, and the second (or right) half-antibody includes Fab and Fc regions. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0446] In the embodiment of FIG. 1K, the first (or left) half-antibody includes an scFv and an Fc region, and the second (or right) half-antibody includes two scFvs and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0447] In the embodiment of FIG. 1L, the first (or left) half-antibody includes a scFv and an Fc region, and the second (or right) half-antibody includes a scFv, Fab, and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0448] In the embodiment of FIG. 1M, the first (or left) half-antibody comprises a scFv and Fc region, and the second (or right) half-antibody comprises Fab, scFv and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0449] In the embodiment of FIG. 1N, the first (or left) half-antibody includes a diabody-type binding domain and an Fc region, and the second (or right) half-antibody includes a Fab and an Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0450] In the embodiment of FIG. 1Q, the first (or left) half-antibody includes a Fab and Fc region, and the second (or right) half-antibody includes a Fab, an Fc region, and an scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0451] In the embodiment of FIG. 1R, the first (or left) half-antibody includes an scFv and an Fc region, and the second (or right) half-antibody includes a Fab, an Fc region, and a scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0452] In the embodiment of FIG. 1S, the first (or left) half-antibody includes an scFv and an Fc region, and the second (or right) half-antibody includes an scFv, an Fc region, and a second scFv. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0453] In the embodiment of FIG. 1T, the first (or left) half-antibody includes a scFv, an Fc region and a Fab, and the second (or right) half-antibody includes a Fab and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0454] In the embodiment of FIG. 1U, the first (or left) half-antibody includes two Fab and Fc regions, and the second (or right) half-antibody includes a non-immunoglobulin-based ABM and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0455] In the embodiment of FIG. 1V, the first (or left) half-antibody includes a Fab, scFv and Fc region, and the second (or right) half-antibody includes a non-immunoglobulin-based ABM and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0456] In the embodiment of FIG. 1W, the first (or left) half-antibody includes a Fab and Fc region, and the second (or right) half-antibody includes an scFv, non-immunoglobulin-based ABM and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0457] In the embodiment of FIG. 1Y, the first (or left) half-antibody includes a scFv and Fc region, and the second (or right) half-antibody includes Fab, scFv, and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0458] In the embodiment of FIG. 1Z, the first (or left) half-antibody includes a Fab, an Fc region and a scFab, and the second (or right) half-antibody includes a Fab and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0459] Instead, as shown in Figures 1O and 1P, the trivalent BBM consists of one complete ABM (Fab in Figures 1O and 1P) and a portion of another ABM (one VH and the other VL). may include two half-antibodies, each comprising: These two half-antibodies pair through the Fc domain, where the VH and VL associate to form a complete antigen-binding Fv domain.
[0460] BBM can be single chain, as shown in Figure 1X. The BBM in Figure 1X contains three scFv domains connected via linkers.
[0461] In the forms shown in FIGS. 1G to 1Z, each of X, Y, and A represents either ABM1 or ABM2, provided that BBM includes at least ABM1 and at least one ABM2. Therefore, a trivalent MBM will contain one or two ABM1 and one or two ABM2. In some embodiments, the trivalent BBM comprises two ABM1 and one ABM2. In other embodiments, the trivalent BBM of the present disclosure includes one ABM1 and two ABM2.
[0462] Accordingly, in this disclosure, any one of FIGS. 1G to 1Z wherein Provides a trivalent BBM as shown in
[0463] The present disclosure is illustrated in any one of FIGS. 1G-1Z, where X is ABM1, Y is ABM2, and A is ABM1 (this form of ABM is referred to as "T2" for convenience). We will further provide trivalent BBM such that
[0464] The present disclosure is illustrated in any one of FIGS. 1G-1Z, where X is ABM2, Y is ABM1, and A is ABM1 (this form of ABM is referred to as "T3" for convenience). We will further provide trivalent BBM such that
[0465] The present disclosure is illustrated in any one of FIGS. 1G-1Z, where X is ABM1, Y is ABM2, and A is ABM2 (this form of ABM is referred to as "T4" for convenience). We will further provide trivalent BBM such that
[0466] The present disclosure is illustrated in any one of FIGS. 1G-1Z, where X is ABM2, Y is ABM1, and A is ABM2 (this form of ABM is referred to as "T5" for convenience). We will further provide trivalent BBM such that
[0467] The present disclosure is illustrated in any one of FIGS. 1G-1Z, where X is ABM2, Y is ABM2, and A is ABM1 (this form of ABM is referred to as "T6" for convenience). We will further provide trivalent BBM such that
[0468] 7.2.3.3. Exemplary quadrivalent BBM A BBM can be tetravalent, i.e. it has four antigen-binding domains, one, two or three of which bind CD19 (ABM1) and one, two or three of which bind CD19 (ABM1) and which bind CD19 (ABM1); One binds to a second target antigen (ABM2), for example to a component of the TCR complex.
[0469] Exemplary quadrivalent BBM morphologies are shown in Figures 1AA-1AH.
[0470] As shown in Figures 1AA-1AH, a quadrivalent BBM can contain two half-antibodies, each containing two complete ABMs, and these two half-antibodies pair through the Fc domain. are doing.
[0471] In the embodiment of FIG. 1AA, the first (or left) half-antibody includes a Fab, an Fc region, and a scFab, and the second (or right) half-antibody includes a Fab, an Fc region, and a scFab. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0472] In the embodiment of FIG. 1AB, the first (or left) half-antibody includes a Fab, scFv and Fc region, and the second (or right) half-antibody includes a Fab, scFv and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0473] In the embodiment of FIG. 1AC, the first (or left) half-antibody comprises a scFv, Fab and Fc region, and the second (or right) half-antibody comprises a scFv, Fab and Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain.
[0474] In the embodiment of Figure 1AD, the first (or left) half-antibody comprises a Fab, an Fc region and a second Fab, and the second (or right) half-antibody comprises a Fab, an Fc region and a second Fab. including. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0475] In the embodiment of Figure 1AE, the first (or left) half-antibody comprises a scFv, a second scFv and an Fc region, and the second (or right) half-antibody comprises a scFv, a second scFv and an Fc region. including. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0476] In the embodiment of FIG. 1AF, the first (or left) half-antibody includes a Fab, scFv and Fc region, and the second (or right) half-antibody includes a Fab, scFv and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0477] In the embodiment of FIG. 1AG, the first (or left) half-antibody includes a Fab, an Fc region, and an scFv, and the second (or right) half-antibody includes an scFv, an Fc region, and a Fab. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0478] In the embodiment of FIG. 1AH, the first (or left) half-antibody comprises a scFv, Fc region and Fab, and the second (or right) half-antibody comprises a scFv, Fc region and Fab. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0479] In the forms shown in FIGS. 1AA to 1AH, each of X, Y, A, and B represents ABM1 or ABM2, although the order is not essential; however, BBM may include at least one ABM1 and at least one ABM2. shall be included. Therefore, a quadrivalent ABM will contain one, two or three ABM1 and one, two or ABM2. In some embodiments, the quadrivalent BBM comprises three ABM1s and one ABM2. In other embodiments, the quadrivalent BBM comprises two ABM1 and two ABM2. In yet other embodiments, the quadrivalent BBM comprises one ABM1 and three ABM2.
[0480] Accordingly, in the present disclosure, X is ABM1 and each of Y, A and B comprises ABM2 (this form of ABM is referred to as "Tv 1" for convenience). Provides a quadrivalent BBM as shown in
[0481] The present disclosure relates to any one of FIGS. 1AA-1AH, where Y is ABM1 and each of Further providing a tetravalent BBM as shown.
[0482] The present disclosure relates to any one of FIGS. 1AA-1AH, where A is ABM1 and each of Further providing a tetravalent BBM as shown.
[0483] The present disclosure relates to any one of FIGS. 1AA-1AH, where B is ABM1 and each of Further providing a tetravalent BBM as shown.
[0484] The present disclosure provides that any one of FIGS. It further provides a quadrivalent BBM as shown in .
[0485] The present disclosure provides that any one of FIGS. It further provides a quadrivalent BBM as shown in .
[0486] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where X and B are both ABM1 and Y and A are both ABM2 (this form of ABM is designated as “Tv 7” for convenience).
[0487] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AG, where Y and A are both ABM1 and X and B are both ABM2 (this form of ABM). is designated as “Tv 8” for convenience).
[0488] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where Y and B are both ABM1 and X and A are both ABM2 (this form of ABM is designated as “Tv 9” for convenience).
[0489] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where A and B are both ABM1 and X and Y are both ABM2 (this form of ABM). is designated as “Tv 10” for convenience).
[0490] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where each of X, Y, and A is ABM1 and B is ABM2 (this form of ABM is For convenience, it is designated as "Tv 11").
[0491] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where each of X, Y, and B is ABM1 and A is ABM2 (this form of ABM is For convenience, it is designated as "Tv 12").
[0492] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where each of X, A and B is ABM1 and Y is ABM2 (this form of ABM is For convenience, it is designated as "Tv 13").
[0493] The present disclosure further provides a quadrivalent BBM as shown in any one of FIGS. 1AA-1AH, where each of Y, A, and B is ABM1 and X is ABM2 (this form of ABM is For convenience, it is designated as "Tv 14").
[0494] 7.2.4.Trispecific binding molecular morphology An exemplary TBM configuration is shown in Figure 2. FIG. 2A shows the components of the TBM configuration shown in FIGS. 2B to 1V. scFv, Fab, non-immunoglobulin-based ABM and Fc can each have the characteristics described for these components in Sections 7.2.1 and 7.2.2. Components of the TBM form shown in Figure 2 can be assembled by any of the means described in Sections 7.2.1 and 7.2.2 (e.g., direct linkage, ABM linker, disulfide bond, knob-in-hole may be associated with each other (such as by interaction-modified Fc domains). The orientations and associations of the various components shown in FIG. (as described in ) may be suitable.
[0495] The TBM is not limited to the form shown in FIG. Other forms that can be used are known to those skilled in the art. For example, WO 2014 / 145806 pamphlet; WO 2017 / 124002 pamphlet; Liu et al.,2017,Front Immunol.8:38;Brinkmann&Kontermann,2017,mAbs 9:2,182-212;US Patent Application Publication No. See 2016 / 0355600; Klein et al., 2016, MAbs 8(6):1010-20; and US Patent Application Publication No. 2017 / 0145116.
[0496] 7.2.4.1. Exemplary trivalent TBM A TBM can be trivalent, i.e., it has three antigen-binding domains, one of which binds CD19, one of which binds a component of the TCR complex, and one of which binds to CD2 or bind to either TAA.
[0497] Exemplary trivalent TBM configurations are shown in FIGS. 2B-2P.
[0498] As shown in Figures 2B-2K and 2N-2P, the TBM can include two half antibodies, one containing two ABMs and the other one containing one ABM, and these two halves Antibodies are paired through their Fc domains.
[0499] In the embodiment of FIG. 2B, the first (or left) half-antibody includes a scFv and Fc region, and the second (or right) half-antibody includes Fab, scFv and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0500] In the embodiment of Figure 2C, the first (or left) half-antibody includes two Fab and Fc regions, and the second (or right) half-antibody includes Fab and Fc regions. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0501] In the embodiment of Figure 2D, the first (or left) half-antibody includes Fab, scFv and Fc regions, and the second (or right) half-antibody includes Fab and Fc regions. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0502] In the embodiment of FIG. 2E, the first (or left) half-antibody includes a scFv and an Fc region, and the second (or right) half-antibody includes two Fab and Fc regions. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0503] In the embodiment of Figure 2F, the first (or left) half-antibody comprises an scFv, Fc region and Fab, and the second (or right) half-antibody comprises a Fab and an Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0504] In the embodiment of FIG. 2G, the first (or left) half-antibody includes an scFv and an Fc region, and the second (or right) half-antibody includes a Fab Fc region and an scFV. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0505] In the embodiment of FIG. 2H, the first (or left) half-antibody includes two Fab and Fc regions, and the second (or right) half-antibody includes a non-immunoglobulin-based ABM and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0506] In the embodiment of FIG. 2I, the first (or left) half-antibody includes a Fab, scFv and Fc region, and the second (or right) half-antibody includes a non-immunoglobulin-based ABM and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0507] In the embodiment of FIG. 2J, the first (or left) half-antibody includes a Fab and Fc region, and the second (or right) half-antibody includes an scFv, non-immunoglobulin-based ABM and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0508] In the embodiment of FIG. 2K, the first (or left) half-antibody includes an scFv and an Fc region, and the second (or right) half-antibody includes an scFv, an Fc region, and a second scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0509] In the embodiment of FIG. 2N, the first (or left) half-antibody includes a Fab, an Fc region, and an scFv, and the second (or right) half-antibody includes a Fab and an Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0510] In the embodiment of Figure 2O, the first (or left) half-antibody includes a Fab, an Fc region and a scFab, and the second (or right) half-antibody includes a Fab and an Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0511] In the embodiment of Figure 2P, the first (or left) half-antibody comprises a Fab, non-immunoglobulin-based ABM and Fc region, and the second (or right) half-antibody comprises an scFv and Fc region. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0512] Alternatively, as shown in Figure 2L, a trivalent TBM can contain two half-antibodies, each comprising one complete ABM and a portion of another ABM, one VH and the other VL. These two half-antibodies pair through the Fc domain, where the VH and VL associate to form the complete antigen-binding Fv domain.
[0513] TBM can be single chain, as shown in Figure 2M. The TBM in Figure 2M contains three scFv domains connected via linkers.
[0514] In each of the configurations shown in FIGS. 2B-2P, each of the domains referred to as X, Y, and Z represents ABM1, ABM2, or ABM3, although not necessarily in this order. In other words, It shall contain one ABM3.
[0515] Accordingly, in this disclosure, any one of FIGS. 2B-2P, where X is ABM1, Y is ABM3, and Z is ABM2 (this form of ABM is referred to as "T1" for convenience) Provides trivalent TBM as shown in
[0516] The present disclosure is illustrated in any one of FIGS. 2B-2P, where X is ABM1, Y is ABM2, and Z is ABM3 (this form of ABM is conveniently referred to as "T2"). We also offer trivalent TBM that can
[0517] The present disclosure is illustrated in any one of FIGS. 2B-2P, where X is ABM3, Y is ABM1, and Z is ABM2 (this form of ABM is referred to as "T3" for convenience). We will further provide trivalent TBM that can
[0518] The present disclosure still provides that any one of FIGS. 2B-2P, where X is ABM3, Y is ABM2, and Z is ABM1 (this form of ABM is referred to as "T4" for convenience) Further provides a trivalent TBM as shown in .
[0519] The present disclosure still provides that any one of FIGS. 2B-2P, where X is ABM2, Y is ABM1, and Z is ABM3 (this form of ABM is referred to as "T5" for convenience) Further provides a trivalent TBM as shown in .
[0520] The present disclosure still provides that any one of FIGS. 2B-2P, where X is ABM2, Y is ABM3, and Z is ABM1 (this form of ABM is referred to as "T6" for convenience) Further provides a trivalent TBM as shown in .
[0521] 7.2.4.2. Exemplary quadrivalent TBM The TBM of the present disclosure can be tetravalent, i.e., the TBM has four antigen-binding domains, one or two of which bind CD19 and one or two of which are components of the TCR complex. and one or two of which bind to CD2 or TAA.
[0522] Exemplary quadrivalent TBM configurations are shown in Figures 2Q-2S.
[0523] As shown in Figures 2Q to 2S, a quadrivalent TBM can contain two half-antibodies, each containing two complete ABMs, and these two half-antibodies pair through the Fc domain. are doing.
[0524] In the embodiment of Figure 2Q, the first (or left) half-antibody comprises a Fab, an Fc region and a second Fab, and the second (or right) half-antibody comprises a Fab, an Fc region and a second Fab. including. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0525] In the embodiment of FIG. 2R, the first (or left) half-antibody includes a Fab, an Fc region, and a scFv, and the second (or right) half-antibody includes a Fab, an Fc region, and a scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0526] In the embodiment of Figure 2S, the first (or left) half-antibody comprises a Fab, an Fc region and an scFv, and the second (or right) half-antibody comprises an scFv, an Fc region and a Fab. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0527] In the forms shown in FIGS. 2Q to 2S, each of X, Y, Z, and A represents ABM1, ABM2, or ABM3, although not necessarily in this order, provided that TBM includes at least one ABM1 and It shall include at least one ABM2 and at least one ABM3. Thus, a quadrivalent ABM would contain two ABMs for CD19, a component of the TCR complex and one for CD2 or TAA. In some cases, a quadrivalent TBM has two CD19 ABMs.
[0528] 7.2.4.3. Exemplary pentavalent TBM The TBM of the present disclosure can be pentavalent, i.e., the TBM has five antigen binding domains, one, two or three of which bind CD19 and one, two or three of which bind CD19. One binds to a component of the TCR complex, and one, two or three bind to CD2 or TAA.
[0529] An exemplary pentavalent TBM morphology is shown in Figure 2T.
[0530] As shown in Figure 2T, a pentavalent TBM can contain two half-antibodies, one of which contains two complete ABMs and the other one containing one full ABM, and these two half-antibodies are paired via the Fc domain.
[0531] In the embodiment of Figure 2T, the first (or left) half-antibody comprises a Fab, scFv and Fc region, and the second (or right) half-antibody comprises a Fab, an Fc region and a scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0532] In the form shown in Figure 2T, each of X, Y, Z, A and B represents ABM1, ABM2 or ABM3, although not necessarily in this order, provided that TBM represents at least one ABM1, one shall include ABM2 and one ABM3. Thus, a pentavalent TBM may include two ABMs for CD19, a member of the TCR complex and two for CD2 or TAA or three ABMs for CD19, a member of the TCR complex and one for CD2 or TAA. In some cases, the pentavalent TBM has two or three CD19 ABMs. In some embodiments, the pentavalent TBM has 3 ABM1, 1 ABM2 and 1 ABM3.
[0533] 7.2.4.4. Exemplary hexavalent TBM The TBM of the present disclosure can be hexavalent, i.e., the TBM has six antigen binding domains, of which 1, 2, 3 or 4 bind CD19, and of which 1, 2, 3 or 4 One binds to a component of the TCR complex, and one, two, three or four bind to CD2 or TAA.
[0534] Exemplary hexavalent TBM configurations are shown in Figures 2U-2V.
[0535] As shown in Figures 2U to 2V, a pentavalent TBM can contain two half-antibodies, one containing two complete ABMs and the other containing one complete ABM, and these two The two half-antibodies are paired via their Fc domains.
[0536] In the embodiment of Figure 2U, the first (or left) half-antibody comprises a Fab, a second Fab, an Fc region and a scFv, and the second (or right) half-antibody comprises a Fab, a second Fab, Contains Fc region and scFv. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0537] In the embodiment of Figure 2V, the first (or left) half-antibody comprises a first Fv, a second Fv, a third Fv and an Fc region, and the second (or right) half-antibody comprises a first Fv, a second Fv, a third Fv and an Fc region; 1 Fv, 2nd Fv, 3rd Fv and Fc regions. The first and second half-antibodies are associated by the Fc regions forming an Fc domain.
[0538] In the configurations shown in FIGS. 2U to 2V, each of X, Y, Z, A, B, and C represents ABM1, ABM2, or ABM3, although not necessarily in this order, provided that TBM is at least one shall include one ABM1, one ABM2 and one ABM3. Therefore, a hexavalent TBM consists of (i) two ABMs for each of CD19, a component of the TCR complex and CD2 or TAA, (ii) three ABMs for each of CD19, a component of the TCR complex and CD2 or TAA. ABM, or (iii) four ABMs for one of CD19, a member of the TCR complex and CD2 or TAA. For example, a hexavalent ABM may include three ABMs for CD19, two ABMs for CD2 or TAA, and one ABM for components of the TCR complex. As another example, a hexavalent ABM may include three ABMs for CD19, two ABMs for components of the TCR complex, and one ABM for CD2 or TAA. In some cases, the hexavalent TBM has 2, 3 or 4 CD19 ABMs. In some embodiments, the hexavalent TBM has three CD19 ABMs. In other embodiments, the hexavalent TBM has four CD19 ABMs.
[0539] 7.2.5.TCR ABM The MBM of the present disclosure includes an ABM that specifically binds to CD19 and an ABM2 that is specific for a different antigen. In the BBM, type 1 TBM and type 2 TBM of the present disclosure, ABM2 can bind to components of the TCR complex. The TCR is a disulfide-bonded, membrane-anchored, heterodimeric protein that usually consists of hypervariable alpha (α) and beta (β) chains expressed as part of a complex with an invariant CD3 chain molecule. be. T cells that express this receptor are called α:β (or αβ) T cells, but a minority of T cells express another receptor, which has variable gamma (γ) and delta (δ) chains. These are called γδ T cells.
[0540] In certain embodiments, the MBM comprises an ABM that specifically binds CD3.
[0541] 7.2.5.1.CD3 ABM MBM can include ABM that specifically binds CD3. The term "CD3" refers to the T cell receptor cluster of differentiation 3 coreceptor (or coreceptor complex or polypeptide chain of a coreceptor complex). The amino acid sequence of the polypeptide chain of human CD3 is provided in NCBI accession numbers P04234, P07766 and P09693. CD3 protein can also include mutant forms. CD3 protein can also include fragments. The CD3 protein may also include post-translational modifications of the CD3 amino acid sequence. Post-translational modifications include, but are not limited to, N-linked and O-linked glycosylation.
[0542] In some embodiments, the MBM is an MBM (e.g., U.S. Pat. may include an anti-CD3 antibody (as described in the brochure) or its antigen-binding domain, ABM. Exemplary anti-CD3 VH, VL and scFV sequences that can be used in MBM are provided in Table 9A. Furthermore, exemplary anti-CD3 VH sequences, VL sequences, and scFv sequences that can be used in MBM are listed in WO 2019 / 104075, WO 2019 / 195535, and WO 2020 / 052692. , the contents of which are incorporated herein by reference in their entirety.
[0543] [Table 40]
[0544] The CDR sequences of CD3hi, CD3med and CD3lo as defined by the Kabat numbering scheme (Kabat et al, 1991, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.) are: Provided in Table 9B.
[0545] [Table 41]
[0546] In some embodiments, the MBM can include a CD3 ABM that includes any of the CD3hi, CD3med, or CD3lo CDRs listed in Table 9B.
[0547] In some embodiments, the MBM comprises a CD3 ABM that includes the VH and VL sequences of CD3hi. In some embodiments, the MBM comprises a CD3 ABM that includes the VH and VL sequences of CD3med. In some embodiments, the MBM comprises a CD3 ABM that includes the VH and VL sequences of CD3lo.
[0548] In addition to the CDR sets listed in Table 9B (ie, the six CDR sets for each of CD3hi, CD3med, and CD3lo), this disclosure provides variant CDR sets. In one embodiment, the set of six CDRs is such that the CD3 ABM is still present when measured by at least one of Biacore, surface plasmon resonance (SPR) and / or BLI (biolayer interferometry, e.g. Octet assay) assays. It may have 1, 2, 3, 4 or 5 amino acid changes compared to the CDR set listed in Table 9B, as long as it is capable of binding the target antigen.
[0549] In addition to the variable heavy and light chain domains disclosed in Table 9A that form the ABM for CD3, this disclosure provides variant VH and VL domains. In one embodiment, the variant VH and VL domains each have an ABM as measured by at least one of Biacore, surface plasmon resonance (SPR) and / or BLI (biolayer interferometry, e.g. Octet assay) assays. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids compared to the VH and VL domains listed in Table 9A, as long as the VH and VL domains are still capable of binding the target antigen. may have variations. In another embodiment, the mutant VH and VL are such that the ABM still remains as measured by at least one of Biacore, surface plasmon resonance (SPR) and / or BLI (biolayer interferometry, e.g. Octet assay) assays. At least 90, 95, 97, 98 or 99% identical to the respective VH or VL disclosed in Table 9A, as long as it is capable of binding the target antigen.
[0550] VH and VL sequences (amino acid sequences and nucleotide sequences encoding amino acid sequences) can be "mixed and matched" to create other CD3 ABMs. Such "mix and match" CD3 ABMs can be tested using binding assays known in the art (eg, FACS assays). When selecting and combining chains, the VH sequences from a particular VH / VL pair must be replaced by structurally similar VH sequences. The VL sequence from a particular VH / VL pair must be replaced with a structurally similar VL sequence.
[0551] In some embodiments, the antigen binding domain that specifically binds human CD3 is non-immunoglobulin-based and is instead a non-antibody scaffold protein, such as one of the non-antibody scaffold proteins described in Section 7.2.1.2. It originates from. In certain embodiments, the antigen binding domain that specifically binds human CD3 comprises Affilin-144160, which is described in WO 2017 / 013136. Affilin-144160 has the following amino acid sequence. [ka]
[0552] 7.2.5.2.TCR-α / β ABM MBMs can include ABMs that specifically bind to TCR-α chains, TCR-β chains or TCR-αβ dimers. Exemplary anti-TCR-α / β antibodies are known (e.g., U.S. Patent Application Publication No. 2012 / 0034221; Borst et al., 1990, Hum Immunol. 29(3):175-88) (Please refer to ). The VH, VL and Kabat CDR sequences of antibody BMA031 are provided in Table 10.
[0553] [Table 42]
[0554] In certain embodiments, the TCR ABM may include CDR sequences of antibody BMA031. In other embodiments, the TCR ABM may include the VH and VL sequences of antibody BMA031.
[0555] 7.2.5.3.TCR-γ / δ ABM MBMs can include ABMs that specifically bind to TCR-γ chains, TCR-δ chains or TCR-γδ dimers. Exemplary anti-TCR-γ / δ antibodies are known (e.g., U.S. Pat. No. 5,980,892, which describes δTCS1, produced by a hybridoma deposited with the ATCC under accession number HB 9578). Please refer).
[0556] 7.2.6.CD2 ABM 7.2.6.1. Immunoglobulin-based CD2 ABM Type 1 TBM may include an anti-CD2 antibody or its antigen binding domain, ABM. Exemplary anti-CD2 antibodies are known (e.g., US Patent No. 6,849,258, China Patent Application No. 102827281A, US Patent Application No. 2003 / 0139579 A1 and US Patent No. 5,795,572). Please refer to the book). Table 11 provides exemplary CDR, VH and VL sequences that can be included in an anti-CD2 antibody or antigen binding fragment thereof for use in the MBM of the present disclosure.
[0557] [Table 43]
[0558] In some embodiments, the CD2 ABM comprises the CDR sequence of CD2-1 (SEQ ID NO:). In some embodiments, the CD2 ABM comprises the heavy and light chain variable sequences (SEQ ID NO: and each) of CD2-1. In some embodiments, the CD2 ABM comprises the heavy and light chain variable sequences (SEQ ID NO: and each) of hu1CD2-1. In some embodiments, the CD2 ABM comprises the heavy and light chain variable sequences (SEQ ID NO: and each) of hu2CD2-1.
[0559] In other embodiments, the CD2 ABM is produced by a hybridoma described in Chinese Patent Application Publication No. 102827281A deposited with the Chinese Culture Collection Committee General Microbiology Center on May 16, 2012 under accession number CGMCC 6132. may contain the CDR sequences of antibody 9D1 which has been described. In other embodiments, the CD2 ABM is produced by a hybridoma deposited with the American Type Culture Collection on June 22, 1999 under accession number PTA-802; It may contain the CDR sequences of the antibody LO-CD2b described. In yet other embodiments, the CD2 ABM is produced by expression of a construct cloned into recombinant E. coli, deposited with the ATCC on April 9, 1993 under accession number 69277, as described in U.S. Pat. It may contain the CDR sequences of CD2 SFv-Ig as described in US Pat. No. 5,795,572.
[0560] In other embodiments, the CD2 ABM may include the VH and VL sequences of antibody 9D1. In other embodiments, the CD2 ABM may include the VH and VL sequences of antibody LO-CD2b. In yet other embodiments, the CD2 ABM may include the VH and VL sequences of CD2 SFv-Ig produced by expression of a construct cloned into recombinant E. coli having ATCC Accession No. 69277.
[0561] 7.2.6.2.CD58-based CD2 ABM In certain embodiments, the present disclosure provides type 1 TBMs that include the ligand CD2 ABM. The CD2 ABM specifically binds human CD2, and the natural ligand for human CD2 is CD58, also known as LFA-3. The CD58 / LFA-3 protein is a glycoprotein expressed on the surface of various cell types (Dustin et al., 1991, Annu. Rev. Immunol. 9:27), which allows T cells to interact with APCs in an antigen-dependent manner and It plays a role in mediating interactions in both an antigen-independent manner (Wallner et al., 1987, J. Exp. Med. 166:923). Thus, in certain embodiments, the CD2 ABM is a CD58 moiety. As used herein, a CD58 portion has at least 70% sequence identity with the CD2 binding portion of CD58, such as at least 70%, 71%, 72%, 73%, 74%, with the CD2 binding portion of CD58, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity. The sequence of human CD58 has Uniprot identification number P19256 (www.uniprot.org / uniprot / P19256). It has been established that a CD58 fragment containing amino acid residues 30-123 of full-length CD58 (ie, the sequence referred to as CD58-6 in Table 12 below) is sufficient for binding to CD2. Wang et al., 1999, Cell 97:791-803. Thus, in certain embodiments, the CD58 portion has at least 70% sequence identity with amino acids 30-123 of CD58, e.g., at least 70%, 71%, 72%, 73%, with the amino acid sequence designated as CD58-6, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
[0562] The interaction between CD58 and CD2 has been mapped using X-ray crystallography and molecular modeling. Substitution of residues E25, K29, K30, K32, D33, K34, E37, D84 and K87 (numbering is relative to that of the mature polypeptide) reduces binding to CD2. Ikemizu et al., 1999, Proc. Natl. Acad. Sci. USA 96:4289-94. Thus, in some embodiments, the CD58 portion retains wild type residues at E25, K29, K30, K32, D33, K34, E37, D84 and K87.
[0563] In contrast, the following substitutions (numbering is based on the full-length polypeptide) did not affect binding to CD2: F29S; V37K; V49Q; V86K; T113S; and L121G. Thus, the CD58 moiety can include 1, 2, 3, 4, 5 or all 6 of the aforementioned substitutions.
[0564] In some embodiments, the CD58 portion is engineered to contain a pair of cysteine substitutions that create a disulfide bridge upon recombinant expression. Exemplary amino acid pairs (numbering is based on the full-length polypeptide) that can be substituted for cysteine to cause it to form a disulfide bridge upon expression are (a) V45C substitution and M105C substitution; (b) V54C substitution and G88C substitution; (c) V45C substitution and M114C substitution; and (d) W56C substitution and L90C substitution.
[0565] Exemplary CD58 portions are provided in Table 12 below.
[0566] [Table 44]
[0567] [Table 45]
[0568] 7.2.6.3.CD48-based CD2 ABM In certain embodiments, the present disclosure provides MBMs that include CD2 ABMs that are CD48 moieties. As used herein, a CD48 portion has at least 70% sequence identity with the CD2 binding portion of CD48, such as at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity. The sequence of human CD48 has Uniprot identification number P09326 (www.uniprot.org / uniprot / P09326) and includes a signal peptide (amino acids 1-26) and a GPI anchor (amino acids 221-243). In certain embodiments, the CD48 portion has at least 70% sequence identity (e.g., at least 70%, 71%, 72%, 73%, 74%, 75 %, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity). Human CD48 has an Ig-like C2-I type domain (amino acids 29-127 of Uniprot identification number P09326) and an Ig-like C2 type 2 domain (amino acids 132-212 of Uniprot identification number P09326). Thus, in some embodiments, the CD48 moiety comprises amino acids 29-212 of Uniprot identification number P09326, a C2-I type domain (amino acids 29-127 of Uniprot identification number P09326), and / or an Ig-like C2 type 2 domain (amino acids 29-127 of Uniprot identification number P09326). at least 70% sequence identity (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78 %, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity). The CD48 portion, in some embodiments, may include one or more natural variants compared to the sequence of Uniprot identification number P09326. For example, the CD48 portion can include the E102Q substitution. As another example, the CD48 moiety can include an amino acid sequence corresponding to a CD-48 isoform or a CD2 binding portion thereof, such as an isoform having Uniprot identification number P09326-2 or a CD2 binding portion thereof.
[0569] 7.2.7. Tumor-associated antigen ABM Type 2 TBM may include ABMs that specifically bind tumor-associated antigens (TAAs). In some embodiments, the TAA is a human TAA. This antigen may or may not be present on normal cells. In certain embodiments, TAAs are preferentially expressed or upregulated in tumor cells compared to normal cells. In other embodiments, the TAA is a lineage marker.
[0570] In certain embodiments, TAAs are expressed or upregulated in cancerous B cells compared to normal B cells. In other embodiments, the TAA is a B cell lineage marker.
[0571] It is anticipated that the MBMs of the present disclosure may target any type of B cell malignancy. Exemplary types of B cell malignancies that may be targeted include Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), and multiple myeloma. Examples of NHL include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and marginal zone lymphoma. Lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), hairy cell leukemia, splenic marginal zone B-cell lymphoma, MALT extranodal marginal zone B-cell lymphoma, nodal margin Includes band B-cell lymphoma and primary effusion lymphoma.
[0572] Examples of TAAs that can be targeted by CD19-binding MBM (e.g., TBM) include BCMA, CD20, CD22, CD123, CD33, CLL1, CD138 (also known as syndecan-1, SDC1), CS1, CD38, CD133, FLT3, CD52, TNFRSF13C (TNF receptor superfamily member 13C, also referred to in the art as BAFFR: B cell activating factor receptor), TNFRSF13B (TNF receptor superfamily member 13B, also referred to in the art as TACI: transmembrane activating factor receptor) CXCR4 (C-X-C motif chemokine receptor 4), PD-L1 (programmed death-ligand 1), LY9 (lymphocyte antigen 9, also referred to in the art as CD229), Includes CD200, FCGR2B (Fc fragment of IgG receptor IIb, also referred to in the art as CD32b), CD21, CD23, CD24, CD40L, CD72, CD79a and CD79b. In some embodiments, the TAA is BCMA. In some embodiments, the TAA is CD20. In some embodiments, the TAA is CD22. In some embodiments, the TAA is CD123. In some embodiments, the TAA is CD33. In some embodiments, the TAA is CLL1. In some embodiments, the TAA is CD138. In some embodiments, the TAA is CS1. In some embodiments, the TAA is CD38. In some embodiments, the TAA is CD133. In some embodiments, the TAA is FLT3. In some embodiments, the TAA is CD52. In some embodiments, the TAA is TNFRSF13C. In some embodiments, the TAA is TNFRSF13B. In some embodiments, the TAA is CXCR4. In some embodiments, the TAA is PD-L1. In some embodiments, the TAA is LY9. In some embodiments, the TAA is CD200. In some embodiments, the TAA is CD21. In some embodiments, the TAA is CD23. In some embodiments, the TAA is CD24. In some embodiments, the TAA is CD40L. In some embodiments, the TAA is CD72. In some embodiments, the TAA is CD79a. In some embodiments, the TAA is CD79b.
[0573] A TAA-binding ABM can include, for example, an anti-TAA antibody or antigen-binding fragment thereof. The anti-TAA antibody or antigen-binding fragment can include, for example, the CDR sequences of antibodies listed in Table 15. In some embodiments, the anti-TAA antibody or antigen binding domain thereof has the antibody heavy and light chain variable region sequences set forth in Table 15.
[0574] [Table 46]
[0575] [Table 47]
[0576] In certain embodiments, the TAA is selected from BCMA and CD20. In some embodiments, the TAA is BCMA. "BCMA" refers to B cell maturation antigen. BCMA (also known as TNFRSF17, BCM or CD269) is a member of the tumor necrosis receptor (TNFR) family and is primarily expressed on terminally differentiated B cells, such as memory B cells and plasma cells. Its ligands include B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL). The protein BCMA is encoded by the gene TNFRSF17. An exemplary BCMA sequence is available in the Uniprot database under accession number Q02223.
[0577] In certain embodiments, the type 2 TBM comprises an ABM3 that specifically binds BCMA, such as an anti-BCMA antibody or antigen binding domain thereof. The anti-BCMA antibody or its antigen-binding domain may have, for example, the CDR sequences, VH, and the like listed in Tables 11A to 11G of WO 2019 / 195535 (the contents of which are incorporated herein by reference in their entirety). sequence, VL sequence or scFV sequence.
[0578] 7.2.8. Nucleic acids and host cells The CD19 binding molecules described herein can be encoded by a single nucleic acid, or alternatively can be encoded by multiple (eg, 2, 3, 4 or more) nucleic acids.
[0579] A single nucleic acid can encode a CD19 binding molecule comprising a single polypeptide chain, a CD19 binding molecule comprising two or more polypeptide chains, or a portion of a CD19 binding molecule comprising three or more polypeptide chains. (e.g., a single nucleic acid can bind two polypeptide chains of a CD19 binding molecule containing three, four or more polypeptide chains or three polypeptide chains of a CD19 binding molecule containing four or more polypeptide chains) code). For separate control of expression, open reading frames encoding two or more polypeptide chains can be under the control of separate transcriptional regulatory elements (eg, promoters and / or enhancers). Open reading frames encoding two or more polypeptides may also be controlled by the same transcriptional regulatory elements and separated by internal ribosome entry site (IRES) sequences to allow translation into separate polypeptides.
[0580] In certain embodiments, a CD19 binding molecule that includes two or more polypeptide chains is encoded by two or more nucleic acids. The number of nucleic acids encoding a CD19 binding molecule can be less than or equal to the number of polypeptide chains in the CD19 binding molecule (eg, when two or more polypeptide chains are encoded by a single nucleic acid).
[0581] Nucleic acids can be DNA or RNA (eg, mRNA).
[0582] A host cell can be genetically modified to contain one or more nucleic acids encoding a CD19 binding molecule. In one embodiment, the host cell is genetically modified by using an expression cassette. The phrase "expression cassette" refers to a nucleotide sequence capable of effecting the expression of a gene in a host compatible with such sequence. Such a cassette may include a promoter, an open reading frame in the presence or absence of introns, and a termination signal. Additional elements necessary or useful to effectuate expression may also be used, such as inducible promoters. The cell can be, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell or a human cell. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells, and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells.
[0583] 7.3.CAR molecule In some embodiments, the anti-CD19 agents used in the methods and combinations of the present disclosure are a population of cells that express chimeric antigen receptor (CAR) molecules that bind CD19. As used herein, the term "CAR molecule" encompasses both contiguous and non-contiguous polypeptide CARs. Typically, CAR treatment involves administration of a population of cells expressing CD19 CAR molecules.
[0584] In certain embodiments, the CAR molecule comprises an extracellular antigen binding domain, a transmembrane domain and a functional signaling domain derived from a stimulatory molecule, and optionally one or more functional signaling domains derived from one or more costimulatory molecules. chimeric fusion proteins that contain intracellular signaling domains that contain intracellular signaling domains. For example, a CAR molecule may contain an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain that includes two functional signaling domains from one or more costimulatory molecules and a functional signaling domain from a stimulatory molecule. chimeric fusion proteins that include. Extracellular antigen-binding domains, transmembrane domains, and intracellular signaling domains are described in Sections 7.3.1, 7.3.2, and 7.3.3, respectively, and exemplary CAR sequences are described in Section 7.3. Described in Section .4.
[0585] In some cases, the transmembrane domain can be linked via a hinge to the extracellular region of the CAR, such as the antigen binding domain of the CAR. Exemplary hinge arrangements are described in Section 7.3.2.
[0586] The CAR may also include an optional leader sequence, if present, at the amino terminus (N-ter) of the CAR fusion protein, typically located at the N-terminus of the extracellular antigen binding domain. The leader sequence may be cleaved from the antigen binding domain (eg, scFv) during cellular processing and localization of the CAR to the cell membrane, so the CAR composition administered to a subject may lack the leader sequence. Leader sequences useful in the CAR molecules of the present disclosure are described in Section 7.3.1.
[0587] Additional embodiments of CAR molecules useful in the methods and combinations of the present disclosure are described below.
[0588] 7.3.1.CD19 Binding Domain and Optional Leader The portion of the CAR that includes an antibody or an antibody fragment thereof may have an antigen-binding domain that is linked to an adjacent polypeptide, including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv), a humanized antibody, or a bispecific antibody. When expressed as part of a peptide chain, it can exist in a variety of forms (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In:Antibodies:A Laboratory Manual,Cold Spring Harbor,New York;Houston et al.,1988,Proc.Natl.Acad.Sci.USA 85:5879-5883;Bird et al.,1988,Science 242:423-426 ). In one embodiment, the antigen binding domain of the CAR comprises an antibody fragment. In a further embodiment, the CAR comprises an antibody fragment comprising an scFv.
[0589] In one embodiment, the portion of the CAR that includes an antigen binding domain includes an antigen binding domain that targets CD19. In one embodiment, the antigen binding domain targets human CD19. In one aspect, the antigen binding domain of the CAR has the same or similar binding specificity as the FMC63 scFv fragment described in Nicholson et al., 1997, Mol. Immun. 34(16-17):1157-1165, or Including it. In one embodiment, the portion of the CAR that includes an antigen binding domain includes an antigen binding domain that targets a B cell antigen, such as a human B cell antigen. The CD19 antibody molecule can be, for example, an antibody molecule described in WO 2014 / 153270 (eg, a humanized anti-CD19 antibody molecule), which is incorporated herein by reference in its entirety. WO 2014 / 153270 also describes methods for assaying the binding and efficacy of various CART constructs.
[0590] In some embodiments, the CD19 CAR comprises an antigen binding domain derived from an anti-CD19 antibody (e.g., an anti-CD19 mono- or bispecific antibody) or a fragment or conjugate thereof (e.g., comprising an amino acid sequence thereof). ). In one embodiment, the anti-CD19 antibody is a humanized antigen-binding antibody as described in WO 2014 / 153270 (e.g., Table 1 of WO 2014 / 153270), which is incorporated herein by reference. domain or a conjugate thereof. Other exemplary anti-CD19 antibodies or fragments or conjugates thereof include, but are not limited to, bispecific T cell engagers that target CD19 (e.g., blinatumomab), SAR3419 (Sanofi), MEDI-551 (MedImmune LLC), Combotox, DT2219ARL (Masonic Cancer Center), MOR-208 (also known as XmAb-5574; MorphoSys), XmAb-5871 (Xencor), MDX-1342 (Bristol-Myers Squibb), SGN-CD19A (Seattle Genetics) and AFM11 (Affimed Therapeutics) is an example. For example, see Hammer.MAbs.4.5(2012):571-77. Blinatumomab is a bispecific antibody consisting of two scFvs, one that binds CD19 and one that binds CD3. Blinatumomab induces T cells to attack cancer cells. See, eg, Hammer et al.; Clinical Trial Identifier No. NCT00274742 and NCT01209286. MEDI-551 is a humanized anti-CD19 antibody with an engineered Fc to have enhanced antibody-dependent cellular cytotoxicity (ADCC). See, eg, Hammer et al.; and Clinical Trial Identifier No. NCT01957579. Combotox is a mixture of immunotoxins that binds to CD19 and CD22. The immunotoxin is composed of an scFv antibody fragment fused to a deglycosylated ricin A chain. See, e.g., Hammer et al.; and Herrera et al. J. Pediatr. Hematol. Oncol. 31.12 (2009): 936-41; Schindler et al. sea bream. DT2219ARL is a bispecific immunotoxin that targets CD19 and CD22, containing two scFvs and a truncated diphtheria toxin. See, eg, Hammer et al.; and Clinical Trial Identifier No. NCT00889408. SGN-CD19A is an antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody linked to the synthetic cytotoxic cell-killing agent monomethyl auristatin F (MMAF). See, eg, Hammer et al.; and Clinical Trial Identifier Nos. NCT01786096 and NCT01786135. SAR3419 is an anti-CD19 antibody-drug conjugate (ADC) comprising an anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivative via a cleavable linker. For example, Younes et al.J.Clin.Oncol.30.2(2012):2776-82;Hammer et al.;Clinical Trial Identifier No.NCT00549185; Please refer. XmAb-5871 is an Fc-engineered humanized anti-CD19 antibody. See, eg, Hammer et al. MDX-1342 is a human Fc-engineered anti-CD19 antibody with enhanced ADCC. See, eg, Hammer et al. In some embodiments, the antibody molecule is a bispecific anti-CD19 and anti-CD3 molecule. For example, AFM11 is a bispecific antibody that targets CD19 and CD3. See, eg, Hammer et al.; and Clinical Trial Identifier No. NCT02106091.
[0591] In certain embodiments, the CAR molecules used in the methods and combinations of the present disclosure are monospecific, having specificity exclusively for CD19, and the CD19 binding domain is a monospecific antibody or a multispecific antibody. It is irrelevant which of the sources it originates from.
[0592] In one embodiment, the antigen-binding domain for CD19 is an antigen-binding portion, eg, a CDR, of an antigen-binding domain as described in the Tables herein, eg, Table 1, or Section 7.3 thereof (including subparts thereof). In one embodiment, the CD19 antigen binding domain can be derived from any CD19 CAR, such as LG-740; US Patent No. 8,399,645; US Patent No. 7,446,190; Xu et al., 2013, Leuk Lymphoma .54(2):255-260(2012);Cruz et al.,2013,Blood 122(17):2965-2973;Brentjens et al.,2011,Blood,118(18):4817-4828;Kochenderfer et al. al.,2010,Blood 116(20):4099-102;Kochenderfer et al.,2013,Blood 122(25):4129-39;and 16th Annu Meet Am Soc Gen Cell Ther(ASGCT)(May15-18,Salt Lake City) 2013, Abst 10 (each of which is incorporated herein by reference in its entirety).
[0593] In one embodiment, the anti-CD19 protein binding portion of the CAR is an scFv antibody fragment. In one aspect, such antibody fragments are functional in that they retain comparable binding affinity, eg, bind the same antigen with an equivalent affinity as the IgG antibody from which they are derived. In one aspect, such antibody fragments are capable of activating an immune response, inhibiting the initiation of signal transduction from its target antigen, inhibiting kinase activity, etc., as will be understood by those skilled in the art. functional in that it provides a biological response that may involve In one embodiment, the anti-CD19 antigen binding domain of the CAR is an scFv antibody fragment that is humanized compared to the murine sequence of the scFv from which it is derived. In one aspect, the parent mouse scFv sequence is the CAR19 construct provided in PCT publication WO 2012 / 079000 and provided herein as SEQ ID NO: 149. In one embodiment, the anti-CD19 binding domain is the scFv described in WO 2012 / 079000 and provided by SEQ ID NO: 149, or a sequence at least 95%, e.g. 95-99% identical thereto. . In certain embodiments, the anti-CD19 binding domain is part of or at least 95% of the CAR construct provided in PCT Publication No. WO 2012 / 079000 and provided herein as SEQ ID NO: 148, e.g. The sequences are 95% to 99% identical. In certain embodiments, the anti-CD19 binding domain comprises at least one (eg, 2, 3, 4, 5, or 6) CDRs selected from Table 14 and / or Table 15.
[0594] [Table 48]
[0595] [Table 49]
[0596] In one aspect, the CAR comprises the polypeptide sequence provided as SEQ ID NO: 12 in PCT Publication No. WO 2012 / 079000 and provided herein as SEQ ID NO: 149, and the scFv domain comprises the polypeptide sequence provided as SEQ ID NO: 12 in PCT publication no. Replaced with one or more sequences selected from 96-107. In one embodiment, the scFv domains of SEQ ID NO: 96-107 are humanized variants of the scFv domain of SEQ ID NO: 149, which is an scFv fragment of murine origin that specifically binds human CD19. Humanization of this murine scFv is useful if mouse-specific residues are capable of inducing human anti-mouse antigen (HAMA) responses in subjects undergoing CART19 therapy, e.g. treatment with T cells transduced with a CAR19 construct. In clinical situations, it may be desirable.
[0597] In one embodiment, the CD19 CAR comprises the amino acid sequence provided as SEQ ID NO: 12 in PCT publication WO 2012 / 079000. In embodiments, the amino acid sequence is [ka] or a sequence substantially homologous thereto. It is.
[0598] In another embodiment, the amino acid sequence is [ka] or a sequence substantially homologous thereto. It is.
[0599] In one embodiment, the humanized CAR19 comprises the scFv portion provided in SEQ ID NO:96. In one embodiment, the humanized CAR19 comprises the scFv portion provided in SEQ ID NO:97. In one embodiment, the humanized CAR19 comprises the scFv portion provided in SEQ ID NO:98. In one embodiment, the humanized CAR19 comprises the scFv portion provided in SEQ ID NO:99. In one embodiment, the humanized CAR19 comprises the scFv...
Claims
1. (a) a CD19 binding molecule; (b) a BAFF receptor-binding molecule; A combination comprising: The CD19 binding molecule comprises: (i) an antigen binding module 1 (ABM1) that specifically binds to CD19 and is a Fab comprising a VH having the amino acid sequence of SEQ ID NO: 13 and a VL having the amino acid sequence of SEQ ID NO: 26; (ii) an antigen-binding module 2 (ABM2) that specifically binds to CD3 and comprises the amino acid sequence of the scFv of SEQ ID NO: 1281; (iii) an antigen binding module 3 (ABM3) that specifically binds to human CD2 and comprises the amino acid sequence of SEQ ID NO: 1315; and (iv) Fc domain and a trispecific binding molecule (TBM) comprising: The BAFF receptor binding molecule is an antibody or an antigen-binding domain thereof, and comprises CDR sequences of CDR-H1, CDR-H2, CDR-H3 having the amino acid sequences of SEQ ID NOs: 53, 54, and 55, respectively, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NOs: 56, 57, and 58, respectively; Combination.
2. The combination described in claim 1, wherein the CD19 binding molecule comprises an Fc domain that is an Fc heterodimer.
3. The Fc domain of the CD19 binding molecule (a) a first CH3 domain comprising the modification T366W; and (b) a second CH3 domain that forms a heterodimer with the first CH3 domain and includes the modifications T366S, L368A and Y407V. The combination according to claim 2, wherein the Fc domain is a human IgG1 Fc domain comprising:
4. The Fc domain of the CD19 binding molecule (a) a first CH3 domain comprising the modification S354C; and (b) a second CH3 domain comprising the modification Y349C. The combination according to claim 2 or 3, wherein the Fc domain is a human IgG1 Fc domain comprising: [0014] Claim 5: The CD19 binding molecule comprises: (a) a first half-antibody comprising an antigen-binding module 1 (ABM1) that specifically binds to CD19; (b) an antigen-binding module 2 (ABM2) that specifically binds to CD3; and (d) an Fc region; and (c) a second half-antibody comprising an antigen-binding module 3 (ABM3) and (d) an Fc region; the Fc region of the first half antibody and the Fc region of the second half antibody form an Fc heterodimer; A combination according to any one of claims 2 to 4.
6. The CD19 binding molecule comprises: (a) a first half antibody heavy chain, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:63 and an Fc sequence; (b) a first half antibody light chain, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:64; (c) a second half antibody, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:65 and an Fc sequence. The combination of claim 5 comprising:
7. The CD19 binding molecule comprises: (a) a first polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:74; (b) a second polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:64; and (c) a third polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO:75 or SEQ ID NO:
86. The combination of claim 5 comprising:
8. The CD19 binding molecule comprises: (a) a first polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 1127; (b) a second polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 1129; and (c) a third polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 1110. The combination of claim 5 comprising:
9. The combination according to any one of claims 1 to 8, wherein the BAFF receptor binding molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the VH and VL sequences of SEQ ID NOs: 59 and 60, respectively.
10. The combination of claim 1, wherein the BAFF receptor binding molecule comprises a heavy chain sequence of SEQ ID NO:61 and a light chain sequence of SEQ ID NO:
62.
11. The combination of claim 9 or 10, wherein the BAFF receptor binding molecule is ianalumab.
12. A combination according to any one of claims 1 to 11, further comprising one or more additional drugs.
13. 13. The combination of claim 12, wherein the one or more additional agents comprise a corticosteroid, and optionally, the corticosteroid is dexamethasone.
14. A combination according to any one of claims 1 to 13 for use in a method for treating a subject with a B-cell malignancy.
15. 15. The combination for use of claim 14, wherein the method comprises administering the B cell targeting agent to the subject one or more times prior to a first administration of the anti-CD19 agent to the subject.
16. 16. The combination for use according to claim 14 or 15, wherein the method comprises administering a single dose of the B cell targeting agent to the subject prior to a first administration of the anti-CD19 agent to the subject.
17. 16. The combination for use of claim 14 or 15, wherein the method comprises administering the B cell targeting agent to the subject two or more times prior to a first administration of the anti-CD19 agent to the subject.
18. 15. The combination for use of claim 14, wherein the method comprises administering the B cell targeting agent and the anti-CD19 agent to the subject simultaneously.
19. The combination for use according to any one of claims 14 to 18, wherein the disease or disorder is selected from the group consisting of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), relapsed and / or refractory DLBCL, acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and Burkitt's lymphoma.
20. 15. The combination for use according to claim 14, wherein the method comprises administering the B cell targeting agent prior to administering the anti-CD19 agent to the subject.
